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CHAPTER 1
INTRODUCTION AND OUTLINE OF THE THESIS
1. The virus
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Bovine herpesvirus 4 (BHV4) is a member of the family of Herpesviridae, subfamily
Gammaherpesvirinae (Roizman et al., 1992). Epstein-Barr virus and herpesvirus saimiri are other
members of this subfamily (Bublot et al., 1992); BHV4 is more closely related to herpesvirus saimiri
than to Epstein-Barr virus (Lomonte et al., 1996). Bovine herpesvirus 4 has an enveloped icosahedral
nucleocapsid, with a diameter of 100 nm, while the overall diameter of the virus particle is
approximately 150 nm. The BHV4 virion contains a double-stranded DNA of 144 ± 6 kb, and the
genome possesses a coding sequence (L-DNA) of approximately 108 kb. The L-DNA is flanked by a
(G+C)-rich tandem repeat region, called polyrepetitive DNA (pr-DNA), which are sequentialcopies of
a 1.5 – 3 kb region (Broll et al., 1999). The number of copies of pr-DNA at each end of the linear
genome varies, but the average number per genome is approximately 15 (Ehlers et al., 1985). Based
on restriction endonuclease patterns, BHV4 can be classified mainly in two groups, as differences
between BHV4 isolates can be detected both in the unique L-DNA and in the pr-DNA fragments.
Restriction analyses show that almost all American strains belong to the DN-599 group, whereas the
Movar 33/63 group comprises the European strains (Bublot et al., 1990). In addition, the restriction
patterns of some strains do not fit completely with those belonging to the DN-599 or the Movar 33/63
group, e.g. the LVR140 strain, which has been called the Belgian reference strain (Wellemans et al.,
1983; Thiry et al., 1992), and the recently described Taiwan strain which was isolated from bovine
vascular endothelial cells (Lin et al., 1999). Cloning and mapping studies indicate further that the size
of the pr-DNA of BHV4 varies among isolates, and therefore, restriction endonuclease analyses can be
used to differentiate between BHV4 isolates. In addition, BHV4 restriction patterns are sharply
different from those of other herpesviruses.
All BHV4 strains are antigenically closely related (Osorio et al., 1985; Castrucci et al., 1986),
and indistinguishable by FAT and by neutralisation with a specific antiserum (reviewed by Thiry
et al., 1989). The use of a panel of monoclonal antibodies confirmed the close antigenic
relationship between BHV4 strains, and only slight antigenic differences were found (Dubuisson et
al., 1989a; Duboisson et al., 1989b). There is no antigenic relationship with other bovine
herpesviruses (Bartha et al., 1987).
2. Viral replication and host range
The replication cycle of BHV4 in infected cells is slow (McCoy et al., 1985), and expression of viral
genes was shown to be dependent on the cell cycle. Vanderplasschen et al. (1995) reported that BHV4
needs dividing cells for effective virus replication, as the S-phase of the cell cycle increased viralDNA
replication and protein expression. In contrast to other animal herpesviruses, BHV4 was able to
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replicate in human embryonic lung cells and giant-cell glioblastoma cell cultures (Egyed, 1998). The
virus has been isolated from different ruminant species, e.g. cattle, sheep (VanOpdenbosch et al.,
1988), but also from non-ruminants like cats suffering from urolithiasis (Fabricant 1977; Kruger et al.,
2000). It is uncommon that a herpesvirus of ruminants is also able to infect carnivorous species
(Egyed, 2000).
3. Clinical signs
Bovine herpesvirus 4 was first isolated and characterised in Hungary in 1963 from calves with
respiratory disease and keratoconjunctivitis (Bartha et al., 1966). Bovine herpesvirus 4 was later
isolated in the United States by Mohanty et al. (1971) from a steer with signs of respiratory disease.
The virus has been isolated from cattle with various clinical signs such as conjunctivitis, pneumonia
and inflammations of the upper respiratory tract (Mohanty et al., 1971; Smith et al., 1972), skin lesions
(House et al., 1990), mammary dermatitis (Cavirani et al., 1990; Reed et al., 1977), enteritis (Eugster,
1979), postpartum metritis (Parks and Kendrick 1973), and chronic metritis (Wellemans et al., 1983;
Wellemans et al., 1984; VanOpdenbosch et al., 1984). An association of BHV4 with abortion has been
reported (Czaplicki et al., 1998), and in addition, BHV4, in combination with BVDV, has been
recovered from aborted foetuses (Reed et al., 1979). Kendrick et al. (1976) inoculated a strain, isolated
from a cow with metritis, into foetuses at various gestational stages. Inoculations were made in 16
cows of gestational ages ranging from 3 – 9 months. The inoculation resulted in the death of some
foetuses in the 3rd and 4th month, and all older than 4 months were alive and normal at the time of
delivery. One foetus was aborted in an autolysed condition and one foetus was mummified.
Pathological changes observed in the foetuses at 3 – 4 months of gestation were confined mostly to
lymphoreticular activation. Virus was reisolated from 4 out of 12 examined foetuses.
Studies have implicated BHV4 in orchitis with potential of virus spread in semen (Dubuisson et al.,
1987). Reproduction of orchitis and azoospermia was attempted in bulls by using the V-test isolate of
BHV4, but no clinical signs were apparent except that a few bulls showed temporaryazoospermia and
conjunctivitis (Dubuisson et al., 1989c).
Whether BHV4 was the causative agent of the above mentioned clinical signs is not clear, as the virus
has also been detected in apparently healthy animals (Luther et al., 1971). Experimental infection
failed to elicit any severe or moderate clinical signs in cattle and sheep (Bartha et al., 1966), but
induced only mild clinical signs in cattle (reviewed by Thiry et al., 1989). In experimentally infected
rabbits BHV4 may accelerate the atherosclerotic process (Lin et al., 2000). This study suggests that
rabbits experimentally infected with BHV4 may be a useful model for atherosclerosis. The rabbit may
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also be suitable as a model for studying the reproductive tract pathogenesis of BHV4 (Naeem et al.,
1991a; Naeem et al., 1991b). After intrauterine inoculation of rabbits with BHV4 some isolates caused
abortion, reabsorption and mummification. Infection of the foetus after an intravenous inoculation of
rabbits with BHV4 indicates transplacental transfer. Intraurethral inoculation of cats with BHV4,
which were given immunosuppressive doses of methylprednisolone-acetate prior to the inoculation of
the urinary bladder with BHV4, resulted in dysuria and gross haematuria in one of the 18 inoculated
cats. However BHV4 infections in cats may also remain clinically inapparent (Kruger et al., 1990).
4. Epidemiology
BHV4 is distributed worldwide. BHV4 infections have been diagnosed in the United States (Mohanty
et al., 1971; Naeem et al., 1989), in several countries of Europe, and also in different countries of
Africa. A serological survey study revealed that 70% of the examined cattle in Zaire were BHV4
seropositive (reviewed by Thiry et al., 1989). The BHV4 seroprevalence in cattle has also been
determined in many European countries, including the countries surrounding the Netherlands (Metzler
and Wyler, 1986). However, no information concerning the seroprevalence of BHV4 in Dutch cattle
has been published until yet. In the northern part of Belgium 15%, and in Wallony (Belgium) 29%, of
the cattle older than 1 year were BHV4 seropositive (Van Malderen et al., 1987). In the former West
Germany, the BHV4 seroprevalence in cattle was 18.4%, while 38% of the bulls used for artificial
insemination had BHV4 antibodies (Truman et al., 1986). BHV4 antibodies have alsobeen detected in
cats (Kruger et al., 2000), but the epidemiological distribution of BHV4 in cats is unknown.
5. Pathogenesis
Transmission experiments with BHV4 are very scarce. It has been suggested that the natural route of
infection may be through the respiratory and alimentary tracts, by inspired air, and recently it has been
suggested that cattle may be infected by virus-infected-cells in milk (Donofrio et al., 2000). After
infection, BHV4 replicates in the epithelial cells of the upper respiratory tract and of the intestines. The
virus may also replicate in peripheral blood leukocytes and may spread throughout the body by these
infected cells. At that time BHV4 can be isolated from various tissues and organs, and the association
of BHV4 with peripheral blood leukocytes could explain the diversity of tissues and organs from
which the virus has been isolated (Egyed et al., 1996; Osorio et al., 1985).
BHV4 establishes latency after experimental and natural infection. At 48 days post-inoculation (pi),
BHV4 DNA has been detected in several organs of experimentally infected cattle e.g. in the nasal
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mucosa, trachea, lung and spleen, and in a low amount in lymph nodes, kidneys, tonsils and thymus
(Egyed and Bartha, 1998; Egyed et al., 1996).
Several cells and tissues have been considered to be sites of viral latency. Splenic mononuclear cells
(macrophages), and mononuclear blood cells (Osorio and Reed, 1983; Lopez et al., 1996) have been
shown to be sites of BHV4 latency. The ability to infect a bovine macrophage cell line with BHV4
supports the likely site of virus latency in cells of the monocyte-macrophage lineage (Donofrio and
Van Santen, 2001). The fact that BHV4 can persist in a latent form in cells involved in the immune
system suggests that BHV4 may induce immunosuppressive effects in the host, but clear evidence has
not been reported so far (Wellemans et al., 1984; VanOpdenbosch et al., 1984). Besides splenic
macrophages and mononuclear blood cells also the nervous system has been shown to be a possible
site of BHV4 latency (Naeem et al., 1991b; Egyed and Bartha, 1998). Recently, BHV4 has been
isolated from the spinal cord of a cow with astasia. This finding supports the theory that the nervous
system is one of the sites for viral latency in natural infection (Yamamoto et al., 2000).
BHV4 can be reactivated from the latent state (Castrucci et al., 1987). Stress and dexamethasone
(glucocorticoids) have been reported to reactivate BHV4 in cattle (Thiry et al., 1986). In addition,
BHV4 has been isolated from cows showing signs of metritis after parturition (Wellemans et al.,
1986), which suggests that parturition may also be a trigger for BHV4 reactivation.
6. Diagnosis
BHV4 infections can be detected by virus isolation. But, despite the tropism of BHV4 for many cell
types the virus is relatively difficult to isolate in cell cultures, e.g. Madin Darby bovine kidney
(MDBK) cells, which is still the commonly used cell type for BHV4 isolation. After isolation,
restriction endonuclease analyses is one of the best ways to differentiate between BHV4 strains
(Bublot et al., 1990; Thiry et al., 1992).
For the detection of BHV4 DNA in organs and tissues, DNA hybridisation techniques might be
used, but this has not been routinely used as a diagnostic tool (Galik et al., 1992). Recently the
complete genome of BHV4 strain 66-p-347, and the thymidine kinase (Lomonte et al., 1992), the
glycoprotein B (Goltz et al., 1994), the early genes, and the pr-DNA of some other BHV4 strains,
have been sequenced (Broll et al., 1999; Zimmermann et al., 2001). This information offers
opportunities for the development of molecular biological tools such as PCR and micro-array.
BHV4 specific antibodies have been demonstrated by complement fixation (Guo et al., 1988), dot
immunobinding assay, AGIDT, indirect-FAT (Sass et al., 1974), and iELISA (Edwards and Newman,
1985). Natural and experimental infections do not induce high levels of neutralising antibodies; they
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may even remain undetectable (reviewed by Thiry et al., 1989; Thiry et al., 1990). Therefore, the virus
neutralisation test (VNT) is not a suitable method for BHV4 antibody detection. The iELISA and the
indirect-FAT are the best standardised serological tools for the detection of BHV4 antibodies, but
these test are not commercially available and the indirect-FAT is laborious (Edwards and Newman,
1985). Therefore, highly sensitive, specific, rapid and reliable tests are still required for the detection
of BHV4 antibodies.
7. Outline of this thesis
The research described in this thesis started with an investigation on the possible role of viruses in the
aetiology of bovine mastitis. When we found that BHV4 might be involved in the aetiology of bovine
mastitis, the first part of this research mainly concentrated on the development and validation of new
tools to detect BHV4 and its antibodies. These newly developed tools were used in the studies that
were undertaken to gain further insight into the role of BHV4 in bovine mastitis.
Not many tests are available for the detection of BHV4, its DNA or antibodies in fluids and tissues
of infected animals, and in addition, most of these tests have not been validated thoroughly according
to modern principles. The detection of BHV4 infections by virus isolation is often difficult due to its
slow replication cycle on many cell culture systems routinely used. Therefore, the value of a non-
conventional cell type in the isolation of bovine herpesviruses, including BHV4, has been examined
and will be discussed in Chapter 2. In Chapter 3, the evaluation and validation of a newly developed
immunoperoxidase monolayer assay (IPMA) for the detection of BHV4 antibodies in bovine serum
samples is described, and this newly developed IPMA was used to estimate the BHV4 seroprevalence
in Dutch cattle at different age categories. Molecular diagnostic tools were developed and validated for
the rapid and reliable detection of BHV4 glycoprotein-B and thymidine kinase DNA in bovine milk
samples (Chapter 4).
Due to the high percentage of unknown causes of bovine clinical mastitis, still 20 – 35% of the
clinical cases of bovine mastitis have an unknown aetiology (Miltenburg et al., 1996; Barkema et al.,
1998), we performed a case-control study to examine the role of viruses in the aetiology of bovine
clinical mastitis. Newly developed assays for the detection of viral antibodies and genomic sequences,
in combination with new ideas concerning the isolation of viruses on non-conventional cell types,
might provide new insights in the role of viruses in bovine mastitis. In a first case-control study
(Chapter 5), non-conventional cell types, including bovine umbilical cord endothelial (BUE) cells,
were used for the detection of viruses in milk from cows with clinical mastitis and in their controls. A
second case-control study was performed to extend the first study and to attempt to confirm the results
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of the first case-control study (Chapter 6). A simultaneous intramammaryand intranasal inoculation of
lactating cows with BHV4 was performed to examine whether the virus would induce clinicalmastitis
under experimental conditions (Chapter 7).
In Chapter 8, the in vitro susceptibility of BHV4 was evaluated to a variety of antivirals. This in
vitro study was performed to examine whether antivirals might offer opportunities for the development
of pharmaceutical drugs to inhibit the replication of BHV4.
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Abstract
The purpose of this study was to determine the susceptibility of bovine umbilical cord endothelial
(BUE) cells to bovine herpesvirus (BHV) 1, BHV2, BHV4, and BHV5, and to pseudocowpox virus.
Detection limits and growth curves of these viruses in BUE cells were compared with those in Veroor
Madin Darby bovine kidney (MDBK) cells. Detection limits were determined by inoculating cell
cultures with serial 10-fold dilutions of above-mentioned viruses, and growth curves by titration of
virus, harvested at various times after infecting cells at a multiplicity of infection of 0.1. The detection
limits of BHV2 and BHV4 were lower in BUE cells than in Vero and MDBK cells, and cytopathic
effects were observed earlier in BUE cells. In addition, BHV2 and BHV4 grew to higher titres in BUE
cells than in Vero and MDBK cells. BUE cells appeared to be equally susceptible to BHV5, and less
susceptible to BHV1.1 and BHV1.2 than MDBK cells. This study shows that the BUE cells are highly
susceptible to BHV2 and BHV4, and the use of BUE cells can improve the laboratory diagnosis of
these viruses. The use of BUE cells can also improve the isolation and growth of pseudocowpox virus.
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1. Introduction
Virus isolation is the most conventional method to detect the presence of the virus in clinical samples.
This method is still commonly used, despite the introduction of new advanced molecular biological
techniques, such as the polymerase chain reaction. Many studies on the susceptibility of different cell
culture systems to human herpesviruses have been reported (Landry et al., 1982; Mayo et al., 1985),
but similar studies with animal herpesviruses are scarce. The development of new cell lines, highly
susceptible to animal viruses, could improve the detection limits of viruses, and thereby facilitate the
diagnosis of virus infections. This development may also lead to higher yields of animal viruses, e.g.
vaccine viruses.
Bovine endothelial cells are seldom applied in veterinary virology, and the number of studies on the
susceptibility of bovine endothelial cells to bovine viruses is very low. Recently, BHV4 has been
isolated from milk samples from cattle with clinical mastitis. BHV4 was isolated on bovine umbilical
cord endothelial (BUE) cells, whereas it was not detected on three other cell types (Wellenberg et al.,
2000). This report indicated that BUE cells are susceptible to BHV4, but information regarding the
replication of BHV4 in BUE cells, or the susceptibility of BUE cells to other bovine herpesviruses
have not been published before. Although, the susceptibility of bovine endothelial cells to BHV4 has
been described (Lin et al., 1997), these cells were derived from bovine carotid arteries, and the
replication cycle and total yields of viruses may vary for different types of endothelial cells used.
We determined the detection limits of BHV1.1, BHV1.2, BHV2, BHV4, and BHV5 on BUE cells,
and the susceptibility of these cells to above-mentioned viruses by growth curve analysis. These data
were compared with those obtained with commonly used cell cultures.
Pseudocowpox virus was included in this study, because this virus is usually isolated on primary
cells, of which the growth is more laborious, e.g. primary foetal lung cells and secondary cells
(Thomas et al., 1980; Mayr and Büttner, 1990). Virus isolation has sometimes been unsuccessfuleven
though virus-like particles were observed in lesions (Inoshima et al., 2000). The use of cells that can be
maintained for many passages would facilitate the diagnosis of pseudocowpox virus infections.
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2. Materials and methods
2.1 Reagents
Cells were grown and maintained in Eagle’s minimal essential medium (EMEM) supplemented with
2% normal calf serum (NCS) and 0.5% antibiotic mix (stock mix containing: 10,000 IU penicillin,
11.25 mg streptomycin, 10 mg kanamycin and 5,000 IU nystatin per ml). NCS showed to be free of
antibodies against BHV1, BHV2, BHV4, and BHV5. Cell monolayers were washed with Hanks
minimal essential medium (HMEM). Rabbit antibodies against Von Willebrand factor (factor VIII)
were obtained from Dakopatts, Denmark. All chemicals were of high grade and commercially
available.
2.2 Cells
Bovine endothelial cells from the umbilical cord were isolated as described (Van der Wielet al., 1989;
Jongejan, 1991). These cells were pestivirus-free, as determined by virus isolation, and mycoplasma-
free, as determined by isolation technique and by using the Mycoplasma Detection kit (Roche
Diagnostics GmbH, Mannheim, Germany) and the Immu-Mark Myco-test (ICN Biomedicals, Inc.,
Ohio, USA). The cells from the umbilical cord were identified as endothelial cells by immunostaining
with rabbit antibodies against Von Willebrand factor, and by cell morphology. The endothelial cells
appeared as typical “cobblestone” patterned monolayers. Madin Darby bovine kidney (MDBK) cells
and African green monkey kidney (Vero) cells, are commonly used cells for virus propagation. Bovine
foetal diploid lung (BFDL) cells and embryonic bovine trachea cells are used for the isolation of
various viruses, e.g. bovine respiratory syncytial virus. Cells of passages 21 – 32 (BUE), 17 – 42
(MDBK), 214 (Vero), and 15 (BFDL) were used in the experiments.
2.3 Viruses
The BHV1.1 reference strain Cooper (“IBR-like”) and the Dutch field isolate BHV1.2 strain LAB
(“IPV-like”) (Metzler et al., 1985; Kaashoek et al., 1995) were used. Virus stocks were prepared and
titrated on embryonic bovine trachea cells. The BHV2 used was kindly provided by K. Borchers
(Institut für Virologie der Freie Universität Berlin, Berlin, Germany). This virus has been isolated from
teat lesions (strain BMV; B. Roizman, Chicago, USA). The American BHV4 reference strain DN-599
(Cat. no.: VR 631) was obtained from the American Type Culture Collection, Rockville, USA. The
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BHV5 Australian encephalitic strain N569, which is recognised as the prototype BHV5 strain, was
kindly provided by M.J. Studdert. The pseudocowpox virus has been isolated from a Dutch cow with
teat lesions.
The susceptibility of BUE cells to BHV1, BHV4 and BHV5 was compared with that in MDBK cells,
to BHV2 was compared with Vero cells, and to pseudocowpox virus was compared with BFDL cells.
2.4 Detection limit
Serial 10-fold dilutions were prepared from each viral strain, ranging from 100 – 0.01 TCID50/ml, in
EMEM culture medium. A volume of 1 ml of each dilution was added in triplicate to a 70-80% semi-
confluent monolayer of BUE cells, MDBK, BFDL or Vero cells grown on 6-wells cell culture plates
(Costar, The Netherlands), followed by an incubation step at 37°C (5% CO2) for one hour. Thereafter,
cells were washed twice with HMEM and a volume of 5 ml of this medium was added to each well.
The cell cultures were incubated at 37°C (5% CO2) for 7 days and examined daily for the presence of
cytopathic effect (cpe). After this incubation period the plates were stored at –70°C.
Wells without cpe were checked for the presence of virus by a second inoculation. Therefore, 1 ml of
freeze/thawed cell-virus suspension from the first inoculation was added into a new 6-well cell culture
plate with a 70-80% semi-confluent monolayer of BUE cells, MDBK, Vero or BFDLcells. Cells were
washed after one hour of incubation, and incubated as described above. Cells were inoculated again
for 7 days and checked daily for the presence of virus by cpe. Semi-confluent cells, with only EMEM
(supplemented with 2% NCS and 0.5% antibiotics) maintenance medium, were used as negative
control cells. Negative control cells were washed, incubated and evaluated as described above.
2.5 Growth curves
For growth curve analysis and growth kinetics, cells were plated in 6-wells (35 mm diameter) tissue
culture plates and incubated at 37°C (5% CO2). BUE cells, and other commonly used cell types, were
routinely maintained as described before (Wellenberg et al., 2000). Prior to infection, semi-confluent
(70-80%) monolayers were counted in duplicate, and the mean number of cells was calculated. Cell
culture medium was discarded from the remaining wells that contained semi-confluent monolayers.
Bovine herpesviruses and pseudocowpox virus were inoculated onto cell cultures at a multiplicity of
infection (m.o.i.) of 0.1, followed by an incubation step at 37°C (5% CO2) for one hour. Thereafter,
cells were washed twice with HMEM to remove non-adsorbed viruses. To each well, 5 ml of EMEM
(supplemented with 2% NCS and 0.5% antibiotics) maintenance medium was added, and the cell
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cultures were incubated at 37°C (5% CO2). At various times thereafter, cells with supernatant were
harvested, namely on: 0 (directly after washing and the addition of 5 ml of fresh EMEM), 6, 12, 18,
24, 48 and 72 hours post-infection (pi.), and frozen at –70°C. The titre of infectious virus, harvested
on various times after infection of cells, was determined to create growth curves. Data of the growth
curves were also used to obtain information about the growth kinetics, i.e. the eclipse period, in which
the main processes of viral replication are initiated, and the total yield of infectious bovine
herpesviruses and pseudocowpox virus on BUE cells.
2.6 Virus titration
The total amount of infectious virus at any given time point (sum of extracellular and intracellular
virus) was determined by median tissue culture infectious dose (TCID50) assays in 96-wells cell culture
plates (Costar, The Netherlands). Therefore, serial 10-fold dilutions of virus were prepared in EMEM
maintenance medium. Cells, in suspensions of 150 µl, were inoculated with 50 µl of diluted virus
aliquots in 24-fold, and incubated for 7 days at 37°C (5% CO2). Cell cultures were observed for cpe,
and titres were determined according to the method of Reed and Muench and expressed as log10
TCID50/ml. Growth curves were obtained by plotting the titres as a function of time.
The influence of cell types on virus titres was first determined by titration of infectious BHV1.2,
grown in BUE cells and grown in MDBK cells, on BUE cells and MDBK cells as well. Titration of
infectious BHV1.1, BHV2, BHV4, BHV5 and pseudocowpox virus was further performed on the cell
type analogous to the cell type used for primary infection, i.e. viruses grown on BUE cells were
quantified on BUE cells, and viruses grown on MDBK were quantified on MDBK cells.
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3. Results
3.1 Detection limit
The detection limits of BHV1.1 and BHV5 in BUE cells and MDBK cells were comparable, but BUE
cells inoculated with BHV5 displayed cpe earlier than MDBK cells (Table I). Lower quantities of
BHV1.2 were detectable in MDBK cells (up to 0.01 TCID50/ml) than in BUE cells (up to 0.1
TCID50/ml), although in both cell types cpe was rapidly observed. In contrast to the BHV1 and BHV5
strains, the detection limits of BHV2 and BHV4 were lower in BUE cells than in Vero and MDBK
cells, respectively. Although, BUE cells appeared to be slightly more susceptible in detecting low
amounts of BHV2 than Vero cells, cpe was more rapidly observed in BUE cells. After inoculating the
cells with 10 TCID50 BHV2, cpe was observed in BUE cells on day 1 pi., whereas no cpe was
detectable in Vero cells within 7 days pi. In BUE cells, even 10-100 lower levels of BHV4 were
detectable than in MDBK cells, and cpe occurred more rapidly in BUE cells than in MDBK. BUE
cells, that were inoculated with BHV4, displayed cpe 3-4 days pi., whereas no cpe was detectable in
MDBK cells within 7 days pi. The detection limits of pseudocowpox virus in BUE cells and BFDL
cells, and the appearance of cpe in both cell cultures, were comparable. None of the negative control
cells showed cpe.
3.2 Growth curves
Fig 1. Growth curves of BHV1.2 in BUE cells and in MDBK cells at an m.o.i. of 0.1. Titration of BHV1.2,
harvested on various times pi, was performed for both cell types on BUE cells and on MDBK cells.
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The growth curve of BHV1.2 propagated in BUE cells was similar when titrated either on BUE cells
or on MDBK cells (Figure 1), and a similar growth curve was also recorded of BHV1.2 propagated in
MDBK cells and titrated on MDBK cells or on BUE cells. Because of this finding, the titres of the
other virus harvests, harvested at various times pi., were determined on the same cells that were used
to propagate the virus. The eclipse period for BHV1.1, BHV1.2, and BHV5 in BUE cells and in
MDBK cell was between 6 and 12 hours pi. (Figures 1 - 2). Thereafter, virus progeny was produced at
a steady rate and production reached a plateau at approximately 48 hours pi. The totalyield of BHV1.1
and BHV1.2 was approximately 10 times lower in BUE cells than in MDBK cells, whereas the growth
curve of BHV5 in BUE cells was comparable to that in MDBK cells (Figure 2).
Fig 2. Growth curves of bovine herpesviruses; (A) BHV1.1, (B) BHV2, (C) BHV4, and (D) BHV5 in BUE
cells and in MDBK cells or in Vero cells (BHV2) at an m.o.i. of 0.1.
Production of infectious BHV2 in BUE cells was detectable after 12 hours pi., and in Vero cells after
18 hours pi. (Figure 2). A plateau in both growth curves occurred between 48 and 72 hours pi., but at
72 hours pi., the BHV2 titre was approximately 5 times higher in BUE cells than in Vero cells. The
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growth curves of BHV4 showed that replication of BHV4 in BUE cells and MDBK cells did not occur
within 12 hours pi. Thereafter, virus production increased more rapidly in MDBK cells than in BUE
cells. A plateau in the production of BHV4 was reached in MDBK cells around 48 hours pi, whereas
this did not occur in BUE cells before 72 hours pi. At 72 hours pi., the BHV4 titre was, however,
approximately 100 times higher than in MDBK cells.
The growth curves of pseudocowpox virus in BUE cells and BFDL cells were similar (Figure 3).
The eclipse period in both cells was between 6 and 12 hours pi., and thereafter, the titres of
pseudocowpox virus increased at a steady rate, but more slowly compared to bovine herpesviruses.
The total yields of pseudocowpox virus in BUE cells and in BFDL cells were comparable at 72 hours
pi., but no plateau was observed.
Fig 3. Growth curve of pseudocowpox virus in BUE cells and in BFDL cells at an m.o.i. of 0.1.
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Table 1. Detection limits of bovine herpesviruses and pseudocowpoxvirus inoculated in triplicate on BUE cell
cultures, and MDBK, Vero or BFDL, as determined by cytopathic effect (cpe)
BUE cells MDBK, Vero or BFDL
cells
Virus TCID50/ml
No. wells Cpe first No. wells Cpe first
with cpe appeared with cpe appeared
on day pi on day pi
BHV1.1 100 3/3 2 3/3 (a) 2
10 3/3 3 3/3 3
1 0/3 1/3 4
0.1 , 0.01 0/3 0/3
BHV1.2 100 , 1 3/3 1 3/3 (a) 1
0.1 1/3 2 3/3 4
0.01 0/3 2/3 > 7(d)
BHV2 100 3/3 1 3/3 (b) 2
10 3/3 1 1/3 > 7
1 , 0.01 0/3 0/3
BHV4 100 3/3 3 3/3 (a) > 7
10 3/3 3 0/3
1 1/3 4 0/3
0.1 , 0.01 0/3 0/3
BHV5 100 , 10 3/3 1 3/3 (a) 3
1 , 0.01 0/3 0/3
Pseudocowpox 100 3/3 4 3/3 (c) 3
virus 10 1/3 4 0/3
1 , 0.01 0/3 0/3
(a) : grown in MDBK cells; (b) : grown in Vero cells; (c) : grown in BFDL cells; > 7(d) : cpe observed first at the second
passage
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4. Discussion
This study demonstrates that BUE cells are susceptible to bovine herpesviruses and pseudocowpox
virus, and therefore, these cells may be used to improve the laboratory diagnosis and/or the in vitro
growth of these viruses. So far, it has only been reported that bovine arterial endothelial cells can be
used for the detection and quantitation of BHV4 (Lin et al., 1997), and that BHV4 has been
successfully isolated on BUE cells inoculated with milk samples from cows with clinical mastitis
(Wellenberg et al., 2000), indicating that BUE cells might be susceptible to BHV4. Isolation of BHV4
on conventional cells, e.g. MDBK is difficult (Naeem et al., 1991), and therefore BUE cells were used
in this preceding study, which was undertaken to gain more insight into the possible role of viruses in
bovine clinical mastitis. Our data demonstrate that BUE cells are highly susceptible to BHV4. Ten to
hundred times less BHV4 is detectable in BUE cells than in MDBK cells, and in addition, BHV4 can
grow to much higher titres in BUE cells than in MDBK cells. Our findings are in agreement with
those reported by Lin et al. (1997), although in their study bovine endothelialcells derived from carotid
arteries were used to examine the sensitivity of bovine endothelial cells to BHV4 by e.g. a plaque
formation assay. Data from both studies strongly suggest that bovine endothelial cells, derived from
umbilical cord or from carotid arteries, may be the cells of choice for the isolation of BHV4 from
clinical samples and to obtain high yields of BHV4.
Our findings further indicate that the BUE cells are also susceptible to: BHV1.1, BHV1.2., BHV2
and BHV5. However, MDBK cells are preferable above the BUE cells for the isolation of BHV1.1
and BHV1.2 from e.g. clinical specimens, and for the multiplication of these viruses, whereas, for the
isolation and multiplication of BHV5 both BUE cells and MDBK cells can be used. However, BUE
cells infected with BHV5 display cpe more rapidly than MDBK cells, which could alsobe a step in the
improvement in an early diagnosis of BHV5. Data on detection limits and growth curves of BHV2 in
BUE cells and Vero cells demonstrate that BUE cells are more susceptible to BHV2 than Vero cells.
Therefore, BUE cells appeared to be preferable above the commonly used Vero cells for the detection
of BHV2 in clinical samples, not only because of a slightly lower detection limit, but also because of a
marked earlier appearance of cpe. Growth curves showed that the replication rate of BHV2 was faster
in BUE cells than in Vero cells, and that BHV2 titres were higher in BUE cells than in Vero cells at
various times pi. Normally, BHV2 replicates in a variety of cells, e.g. foetal bovine kidney cells, but
the diagnosis of BHV2 infections by virus isolation can be unsuccessful (Farnsworth, 1995). Reasons
for false-negative cell culture results could be the application of disinfectants, or the examined lesions
are too old. On the other hand, the introduction of a susceptible BUE cell culture could be one of the
contributing factors to improve the diagnosis of BHV2 infections.
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In general, pseudocowpox virus is difficult to isolate from teat lesions. Virus isolation is sometimes
unsuccessful even though virus-like particles are observed in lesions. This study shows that the
susceptible BUE cell cultures could offer new opportunities in the diagnosis and isolation of
pseudocowpox virus from teat lesions above the commonly used, but more laborious, primary or
secondary cells.
Blunden et al. (1995), suggested that viral replication in the endothelium might be of importance in
the pathogenesis of viral diseases, or suggests a contributing factor of viruses in the initiation of vessel-
wall injuries, as suggested for cytomegalovirus in the initiation of atherogenesis (Melnick et al., 1993;
Nicholson and Hajjar, 1998). Others described a novel endotheliotropic herpesvirus in elephants with
a highly fatal hemorrhagic disease (Richman et al., 1999), and also the major role of a maternal
endothelial cell infection by equine herpesvirus 1 in the pathogenesis of equid abortion has been
discussed (Edington et al., 1991). Recently, Lin et al. (2000) reported that experimental infection of
rabbits with BHV4 enhances atherosclerosis processes. Further studies are needed to prove that
endothelial cells might be the target cells in vivo for e.g. other bovine herpesviruses, and whether
endothelial cells might act as latent reservoir cells for these viruses as reported for BHV4 (Lin et al.,
1999).
In conclusion, this study shows that the BUE cells are highly suitable for the isolation and growth of
BHV2, BHV4 and pseudocowpox virus. This BUE cell culture is easy to maintain, and all examined
viruses rapidly induce cpe. The use of BUE cell cultures might facilitate the diagnosis of above
mentioned bovine herpesviruses and pseudocowpox virus infections. For e.g. diagnostic purposes, the
susceptibility of BUE cells to more (bovine) viruses should be determined.
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Abstract
This study describes the evaluation of immunoperoxidase monolayer assays (IPMAs) for detection of
antibodies against bovine herpesvirus 4 (BHV4) DN-599 or BHV4 LVR140 in sera of cattle. We
compared the quality of these IPMAs with the quality of a BHV4 indirect enzyme-linked
immunosorbent assay (ELISA). In addition, a preliminary serological surveyon BHV4 antibodies was
carried out to estimate the seroprevalence of BHV4 in Dutch cattle at different ages. The specificities
of both BHV4 IPMAs were 1.00. The geometrical mean titers (detection limit) of the BHV4 IPMAs
were twice as high as that of the BHV4 indirect ELISA. In experimentally infected cattle, BHV4
antibodies were detectable by IPMAs 16 to 18 days post-infection, which was almost 2 weeks earlier
than in the indirect ELISA The reproducibility of the BHV4 DN-599 IPMA (κD-value: 0.92) and of
the BHV4 LVR140 IPMA (κD-value: 0.87) were good. For field sera the overall agreement between
the BHV4 indirect ELISA and the two BHV4 IPMAs, DN-599 and LVR140, was 95% and 96%,
respectively. The serological-survey study showed that the estimated seroprevalence of BHV4 in
Dutch cattle was 16-18%, and that the percentage of BHV4-positive animals varied by age category
(between 6% and 43%). In summary, the two BHV4 IPMA formats have several advantages that
make IPMA a useful alternative to the BHV4 indirect ELISA for detecting BHV4 antibodies in cattle.
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1. Introduction
Bovine herpesvirus 4 (BHV4), a group of virus strains belonging to the Gammaherpesvirinae (17), is
distributed worldwide, and BHV4 strains have been isolated from cattle with a variety of clinical
symptoms (8, 12, 14, 20, 23, 24). For antibody detection, a sensitive test is required because the
humoral immune response of cattle to BHV4 infections is characterized bya low neutralizingantibody
response, or even by absence of neutralizing antibodies (21). Other methods have been developed to
detect BHV4 antibodies in serum, such as complement fixation (9), indirect fluorescent-antibody test
(IFAT) (18), and indirect enzyme-linked immunosorbent assay (iELISA) (7). According to Guo et al.
(9), the complement fixation test was less sensitive than the iELISA for the detection of
immunoglobulin G (IgG) to BHV4. The IFAT and the iELISA are the most common tests to be used
for detection of BHV4 antibodies, but the IFAT is laborious, particularly if quantitative results are
required (7). Also cross-reactions between BHV4 and other herpesviruses have been recorded by
IFAT (11, 16). Edwards and Newman (7) described that the iELISA appeared to be as sensitive as the
IFAT, but these results were only based on sera collected from experimentally infected cattle. Until
now, no thorough validation of any BHV4 ELISA has been published. Because there is a need for an
easy test to detect BHV4 antibodies, we developed an immunoperoxidase monolayer assay (IPMA).
IPMAs have proven to be an easy method and a valuable tool for the diagnosis of several infectious
diseases (19), for instance it is a common method for the detection of antibodies against porcine
reproductive and respiratory syndrome virus in pigs (10).
The purpose of this study was to evaluate newly developed BHV4 IPMAs which are based on the
American BHV4 reference strain, DN-599 (13), and on LVR140, the Belgian BHV4 reference strain
(26), which belongs to the European Movar 33/63-like group (22). The results of the IPMAs were
compared with the results of a BHV4 iELISA. Data on the prevalence of BHV4 antibodies in Dutch
cattle are be presented.
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2. Materials and methods
2.1 BHV4 IPMA
2.1.1 Preparing BHV4 IPMA plates
Trypsinized embryonic bovine trachea cells (EBTr) were resuspended in Earle’s minimal essential
medium (EMEM) cell culture medium, containing 10% horse serum and 0.5% antibiotic mix
(antibiotic stock solution containing; 107 IU of penicillin G, 8.6 x 106 IU of streptomycin, 1%
kanamycin and 5 x 106 IU of nystatin per l liter aquadest), and seeded into wells of a 96-wells cell
culture plate (Greiner). Each well contained 100µl of an EBTr cell suspension of approximately 7.5 x
104 cells/ml. The plates were placed in a humidified incubator at 37°C with 5% CO2. After 3 to4 days,
when the monolayer was 100% confluent, the cell culture medium was discarded and the cells were
infected with 25µl (containing 102 50% tissue culture infective doses/ml) of the BHV4 DN-599 strain
(ATCC VR631) or the BHV4 LVR 140 strain (kindly provided by E. Thiry). After 1 hour at 37°C
(5% CO2), a volume of 75µl EMEM (containing 2% horse serum and 0.5% antibiotic mix) was added
to each well. When cytopathogic effect started to appear the incubation was stopped. The virus-cell
culture medium was discarded and a volume of 150 µl of 4% formaldehyde in phosphate-buffered-
saline (PBS) was added to the wells for 10 minutes at 18 to 25°C. The fluid was poured off, and again
a volume of 150 µl of 4% formaldehyde in PBS (fixative) was added to the wells. Plates were sealed
and stored at 4°C.
2.1.2 Performance BHV4 IPMA
Prior to use, the fixative was removed and the plates were washed once with 100 µl/well of a 2%
Triton X-100 solution (Sigma) in PBS. To reduce nonspecific reactions, the plates were first incubated
with a volume of 100 µl of 2% Triton X-100 in PBS for 60 minutes at 37°C. After the Triton X-100
solution was discarded, plates were incubated with 75 µl of PBS (containing 10% horse serum)/well
for 60 minutes at 37°C. Serum test samples were diluted 1:20 in IPMA buffer (38.5 g of NaCl, 2%
Tween-80, 0.1%NaN3 and 10% horse serum per 1 liter of PBS). After the pre-incubation, the PBS-
horse serum solution was discarded and a volume of 75 µl of the 1:20 pre-diluted serum sample were
added to the wells and incubated at 37°C for 1 h. The plates were washed six times in wash solution
(PBS, containing 1% Tween-80 [Merck]). A volume of 75 µl of the conjugate solution was added to
the wells (1:200 dilution of horseradish peroxidase labeled rabbit anti-bovine immunoglobulin
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[Dakopatt] in IPMA buffer [without NaN3]), and incubated at 37°C for 1 h. The plates were washed
five times as described above, and 75µl of substrate-chromogen (H2O2/3-amino-9-ethylcarbazole) was
added and incubated at 18 to 25°C for 30 min. Without stopping the reaction, the results were read
under a light microscope by at least two persons, independently from each other. The serum samples
were retested if the interpretations of the two persons were not the same. Positive reactions were
characterized by an intense red-brown staining of mainly the nucleus of the EBTr cell, indicating
binding of antibodies to BHV4 DN-599 or BHV4 LVR 140 antigens (Fig. 1). The results were
interpreted as either negative (a titer of < 20) or positive (a titer of ≥20).
A B
Fig. 1. (A) BHV4 IPMA positive staining reactions, which are characterized byred-brown staining mainlyof
the nuclei of BHV4 infected EBTr cells, indicate the binding of serum antibodies to BHV4 antigens. (B)
Negative reactions are characterized by the absence of color.
2.2 BHV4 iELISA
De BHV4 iELISA (BIO-X, Brussels, Belgium) was performed as described by the manufacturer; it
follows the principle of an iELISA. Briefly, the odd wells (antigen wells) of the ELISA microplate are
coated with a BHV4 LVR 140-cell suspension lysate, while the even wells (control wells) are coated
with a lysate of cell suspension. Volumes of 100 µl (each) of 1:100 diluted serum samples, including
the positive reference serum sample of the kit, were added to the antigen and the control well and
incubated at 18 to 25°C for 1 h. The plates were washed six times, and a volume of 100 µl of
conjugate (horseradish peroxidase-labeled anti-bovine IgG1 monoclonal antibody) was added toeach
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wells. Plates were incubated at 18 to 25°C for 1 h, and washed again (six times). After the washing, a
volume of 100 µl of the substrate-chromogen (H2O2-tetramethylbenzidine) was added to each well.
After 10 min the color reaction was stopped by the addition of 50 µl of 1M phosphoric acid. The
optical density (OD) value was determined by an ELISA plate reader at 450 nm. The interpretation of
the results was as follows: the OD value of the control well was subtracted from the OD value of the
antigen well. The net OD value was compared with the net OD value of the positive reference serum
sample by dividing the net OD value of the serum sample by the net OD value of the positive
reference serum sample. Finally, this value was multiplied with the coefficient of the iELISA batch, as
noted for each BHV4 iELISA batch. Serum samples with values < 0.2 were classified as negative, and
serum samples with values ≥0.2 were classified as positive for BHV4 antibodies.
2.3 Controls
To guarantee the quality of the performed tests, control serum samples were incorporated into ELISA
test plates and into each IPMA test run. Therefore a strong positive, a dilution of positive (weak-
positive) and a negative serum sample were used (15). The BHV4-positive serum samples were kindly
provided by E. Thiry and by G. Czaplicki (Belgium), while the negative control was provided by E.
VanOpdenbosch (Belgium). The results of test runs were accepted if the controls were correct.
2.4 Specificity
The specificities of the BHV4 tests were determined by testing monospecific serum samples
containing high antibody levels directed against BHV1 (number of serum samples; [n] = 5), BHV2 (n
= 1), bovine respiratory syncytial virus (n = 3), parainfluenza virus type 3 (n = 3), bovine leukemia
virus (n = 2), bovine immunodeficiency virus (n = 2), bovine viral diarrhea virus (n = 3), rotavirus (n =
4), and coronavirus (n = 4). The specificities of the BHV4 IPMA's and the BHV4 iELISA were also
determined by testing 69 individual serum samples collected from 69 specified-pathogen-free (SPF)
cattle (cattle born by caesarean section, held in isolation stables, and raised colostrum free).
2.5 Detection limit
For the determination of the detection limits for both BHV4 IPMAs, and the BHV4 iELISA, the
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following sera were used; the positive bovine BHV4 antiserum of the Central Veterinary Laboratory
(Weybridge, England), one serum sample collected from one experimentally infected SPF calf (4797),
and randomly chosen positive serum samples of cattle from the field study (n = 8). The sera were
titrated in serial twofold dilutions, starting at a dilution of 1:20. The detection limit was defined as the
reciprocal of the highest dilution giving a positive reaction.
2.6 Experimental infection
Two SPF calves (4797 and 4798), 3 weeks of age, were intranasally inoculated with 10 ml of 106.5
50% tissue culture infective doses of BHV4 DN-599 (ATCC VR631; bovine viral diarrhea virus and
Mycoplasma free)/ml. Pre- and post-inoculation serum samples were collected and tested for BHV4
antibodies. The serum samples were tested in the BHV4 IPMAs and the BHV4 iELISA in a 1:20
dilution. Positive serum samples were titrated in serial twofold dilutions, starting at a dilution of 1:20.
2.7 Reproducibility
The reproducibility of the BHV4 tests was calculated from the results of duplicate tests by use of the
Kappa test (2). Kappa (κD) was defined as the quotient of the observed proportion of agreement
beyond chance and the maximal proportion of agreement. Therefore, serum samples (n = 150) of six
randomly chosen BHV4-positive herds of the field study were tested twice on twodifferent occasions,
at least 2 months apart, using new IPMA reagents and ELISA kits with different lot numbers.
2.8 Field sera
Field sera were used to compare the newly developed BHV4 IPMAs with the iELISA and to estimate
the BHV4 seroprevalence in Dutch cattle. For that purpose, a total amount of 750 serum samples were
collected at random from 30 randomly chosen Dutch herds (25 serum samples per herd). These herds
had participated in a field study for BHV1 marker vaccine efficacy (3). The date of birth of each
animal was recorded to estimate the BHV4 seroprevalence in Dutch cattle at different ages.
2.9 Statistical analyses and data processing
Statistical analysis was performed on the data in Table 1 using the Friedman nonparametric two-way
analysis of variance test, followed by the Wilcoxon signed-rank test (one-sided test) for pairwise
comparison of both IPMAs with the iELISA. The data were processed with Statistix for Windows,
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version 2.0.
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3. Results
3.1 Evaluation of the BHV4 IPMAs
3.1.1 Specificity
No positive reactions were observed in the BHV4 IPMAs and the BHV4 iELISA with the
monospecific serum samples containing high antibody levels directed against BHV1, BHV2, bovine
respiratory syncytial virus, parainfluenza virus type 3, bovine leukemia virus, bovine
immunodeficiency virus, bovine viral diarrhea virus, rotavirus and coronavirus. In addition, all 69
serum samples collected from the SPF cattle reacted negative in the three BHV4 tests, indicating test
specificities of 100%.
3.1.2 Detection limit
The geometrical mean titers (reciprocal of the mean logarithmic titers) of the BHV4 DN-599 IPMA,
the BHV4 LVR 140 IPMA, and the BHV4 iELISA were 640, 686, and 343, respectively. Hence, the
detection limits of both BHV4 IPMAs were twice as high as that of the BHV4 iELISA (Table 1).
Statistical analyses by the Friedman test showed that the differences in BHV4 antibody titers in both
BHV4 IPMAs and those in the BH0V4 iELISA were statistically significant (P value, 0.048). The one-
sided P value, calculated by the Wilcoxon signed-rank test, was 0.031 for BHV4 DN-599
3.2 Experimentally infected cattle
The BHV4 IPMAs first demonstrated a BHV4 antibody response around 16 to 18 days after
experimental infection; the iELISA first demonstrated a response around 30 days after experimental
infection (Table 2). In the commercial BHV4 iELISA, serum samples of experimentally infected cattle
were screened for BHV4 antibodies in a 1:20 dilution, instead of a 1:100 dilution. For the screeningof
serum samples for BHV4 antibodies, a 1:100 serum dilution has been recommended by the
manufacturer. At this dilution, no BHV4 antibody responses were detectable at day 37 (calf 4797), or
even at day 44 (calf 4798), post-infection.
3.3 Reproducibility
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The reproducibilities of the BHV4 tests were good. The overall agreement of duplicate test results
were as follows: BHV4 DN-599 IPMA, 0.96 [(83⊕ + 62θ)/150], BHV4 LVR 140, 0.94 [(75⊕ +
66θ)/150]; and BHV4 iELISA, 0.97 [(87⊕ + 59θ)/150]. Based on these results the κD-values of the
BHV4 tests were as follows: DN-599 IPMA, 0.92; BHV4 LVR 140 IPMA, 0.87; and BHV4 iELISA,
0.96.
Table 1. Titer of antibody against BHV4 in sera of cattle as determined in the BHV4 IPMAs and the BHV4
iELISA (n = 10)
BHV4 antibody titer
Serum
BHV4 DN-599 BHV4 LVR 140 BHV4 LVR 140
IPMA IPMA iELISA
CVLa serum 320 320 320
4797 24/5 320 320 40
Herd A
Cow 1 640 640 320
Cow 2 1280 640 1280
Herd B
Cow 1 640 1280 640
Cow 2 640 1280 160
Herd C
Cow 1 640 640 160
Cow 2 1280 1280 1280
Herd D
Cow 1 640 320 320
Cow 2 640 1280 640
Geometric mean: 640 686 343
a CVL, Central Veterinary Laboratory
3.4 Field sera
Of the 750 field serum samples, 120 (16.0%), in the BHV4 DN-599 IPMA and 135 (18.0%) in the
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BHV4 LVR 140 IPMA scored positive for BHV4 antibodies, while in the BHV4 iELISA, 134
(17.9%) of the 750 field serum samples scored positive (Table 3). For field sera, the overall agreement
of the BHV4 DN-599 IPMA and the BHV4 LVR 140 IPMA with the BHV4 iELISA were 95% and
96%, respectively. The overall agreement between the BHV4 DN-599 IPMA and the BHV4 LVR 140
IPMA was 98% (n = 750).
Table 2. Antibody responses against BHV4 in experimentally infected calves as determined in the BHV4
IPMAs and the BHV4 iELISA.
BHV4 antibody titer
IPMA iELISA
Day
post-infection DN-599 LVR 140
4797a 4798 4797 4798 4797 4798
0 < 20 < 20 < 20 < 20 < 20 < 20
7 < 20 < 20 < 20 < 20 < 20 < 20
11 < 20 < 20 < 20 < 20 < 20 < 20
14 < 20 < 20 < 20 < 20 < 20 < 20
16 < 20 < 20 < 20 20 < 20 < 20
18 20 40 20 40 < 20 < 20
21 80 80 80 80 < 20 < 20
23 160 80 320 160 < 20 < 20
30 320 160 320 320 40 20
37 640 320 320 320 80 20
44 640 320 320 320 160 40
a Calf number
3.5 Serological survey
3.5.1 Dutch seroepidemiological field study
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Based on the results of the three BHV4 tests (Table 3), 16 to 18% of the 750 Dutch field sera tested
reacted positive for BHV4 antibodies. In 17 of the 30 herds examined (57%), BHV4 antibodies were
detected in the BHV4 IPMAs. The herd prevalence of BHV4 antibodies varied between 0 and 76%,
and within positive herds the seroprevalence of BHV4 antibodies varied by age category (Fig. 2).
Cattle 5 years old and older showed the highest BHV4 seroprevalence: 43% of the sera contained
antibodies to BHV4. The lowest level of BHV4 antibodies (6 to 7%) was found in the group of 0.5- to
2-year-old cattle. In young calves (between 0 and 6 months old) the BHV4 seroprevalence was 31%.
Figure 2 shows only the results of the BHV4 LVR 140 IPMA for BHV4 seroprevalence in Dutch
cattle at different ages; the same patterns were observed with the BHV4 DN-599 IPMA and the BHV4
iELISA.
Fig 2. BHV4 seroprevalence in Dutch cattle at different ages as assessed by the BHV4 LVR 140 IPMA
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4. Discussion
Our study shows that the BHV4 DN-599 and the BHV4 LVR 140 IPMAs can be used for the
screening of herds for BHV4 antibodies as an alternative to the BHV4 iELISA. Based on the
specificity, detection limit, results from early-infection sera collected from calves, and reproducibility,
the newly developed BHV4 IPMAs are reliable practical tests for the detection of BHV4 antibodies. In
this evaluation study, the BHV4 IPMA specificities (100%) are comparable with those of the BHV4
iELISA (100%). The data on the detection limits (analytical sensitivity) and the experimental infection
sera (diagnostic sensitivity) of both BHV4 IPMAs are even better than those of the BHV4 iELISA.
The geometrical mean antibody titers (detection limits) of the BHV4 IPMAs were twice as high as the
geometrical mean antibody titer of the BHV4 iELISA, and the differences between the BHV4
antibody titers of both BHV4 IPMAs and those of the BHV4 iELISA were statistically significant (P
value, <0.05). The BHV4 IPMAs were able to detect BHV4 antibody responses 16 to 18 days post-
experimental infection. Even when sera were tested in the commercial BHV4 iELISA in a 1:20
dilution, instead of a 1:100 dilution, no BHV4 antibody response was detectable within 30 days post-
infection.
Table 3. Concurrence of BHV4 IPMAs and BHV4 iELISA results for field sera (n = 750)
No. of samples
IPMA Resultsa BHV 4 BHV4 DN-599
iELISAb IPMAc
+ - + -
BHV4 DN-599 c + 107 13
- 27 603
BHV4 LVR 140 c + 119 16 120 15
- 15 600 0 615
a +, positive; - , negative ; b Titer of <100 was considered negative; titer of ≥100 was considered positive
c Titer of <20 was considered negative; titer ≥20 was considered positive
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One of the explanations for the inefficient detection of BHV4 antibodies could be that the commercial
BHV4 iELISA detects only bovine IgG1. The immunoglobulin-specific conjugate, used in the BHV4
IPMAs to detect antibodies in the bovine serum samples, is known to have affinity for all bovine
immunoglobulin subclasses (IgM, IgG1, IgG2, etc). The iELISA described by Edwards and Newman
(7) was based on the detection of bovine IgG (IgG1 and IgG2) and detected BHV4-specific antibodies
in experimentally infected calves 21 days after primary infection. The calves (infected with Movar
33/63) showed a response to the primary inoculation, which consisted mainly of IgG1. However, the
detection of IgG2 and IgM could have been underestimated due to competitive inhibition by high
levels of IgG1 (7). Although other parameters, e.g., buffer solutions and substrate, could also influence
the difference in sensitivity of IPMA versus iELISA, the choice of the anti-bovine Ig conjugate is
probably the most relevant factor.
The reproducibilities of the BHV4 DN-599 IPMA (κD value, 0.92) and the BHV4 iELISA (κD
value, 0.96) are good, while the reproducibility of the BHV4 LVR 140 is somewhat lower but still
acceptable (κD value, 0.87).
The seroepidemiological field study shows that the estimated BHV4 seroprevalence in Dutch cattle
is 16 to 18%. The BHV4 seroprevalences in cattle determined in countries surrounding the
Netherlands are comparable with those in Dutch cattle. In the Northern part of Belgium 15%, and in
Wallony (Belgium) 29%, of the cattle older than 1 year were BHV4 seropositive (24). In former West
Germany, the BHV4 seroprevalence in cattle was 18.4%, while 38% of the bulls used for artificial
insemination contained BHV4 antibodies (23). Young calves (< 6 months) had antibodies directed
against BHV4. These antibodies are probably of maternal origin and not the result of a BHV4
infection. According to VanOpdenbosch et al. (25), 38% of veal calves in Belgium (< 3 months) had
maternal antibodies against BHV4, and only 3% of the BHV4-negative veal calves seroconverted
within a period of 3 months. In this study, an increase in BHV4-seropositive animals was recorded
within the group of 2- to 3-year-old cattle. Hence, it is likely that most cattle become infected after
introduction in the dairy herd. Whether there is a relation between this finding and that of Czaplicki
and Thiry (4), who reported an association between BHV4 seropositivity and abortion in cows, is
unknown.
Although the group of BHV4 comprises a collection of antigenicallycloselyrelated isolates (1), and
no major antigenic differences between BHV4 isolates have been demonstrated by cross-serological
analysis with polyvalent antisera (5), the evaluation of the newly developed BHV4 IPMA was based
on two different BHV4 strains. The IPMAs were performed with the American BHV4 DN-599
reference strain, and the Belgian LVR 140 reference strain, which belongs to the European Movar
33/63-like group (22), because the use of monoclonal antibodies showed some differences in the
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antigenic patterns of BHV4 isolates (6), and BHV4 strains can be isolated in many countries all over
the world. Dubuisson et al. (6) confirmed the close antigenic relationships between BHV4 by
comparison of field isolates with BHV4 monoclonal antibodies, but some monoclonal antibodies
recognized all BHV4 isolates, while others allowed differentiation among them. Our data support the
finding that there could be some minor differences in the antigenic patterns of BHV4 isolates, because
the results, obtained with field sera, showed some slight differences between the BHV4 DN-599
IPMA and the BHV4 LVR 140 IPMA. Fifteen field serum samples reacted positive in the BHV4 LVR
140 IPMA, while these sera did not react in the BHV4 DN-599 IPMA. Thirteen of these 15 sera also
reacted positive in the BHV4 iELISA, in which the plates were coated with a BHV4 LVR 140-cell
suspension lysate. Differences in affinity of certain immunoglobulins of cattle for the different BHV4
strains could be an explanation, but another explanation could be the differences in antigenic
expression or differences in the exposure of certain BHV4 antigens. Probablythe antigenic expression
and antigen exposure of Dutch BHV4 strains are more related to BHV4 LVR 140 than to those of
BHV4 DN-599.
The BHV4 IPMA has several advantages compared to the BHV4 iELISA, e.g., this study shows
better analytical sensitivity results and the IPMA can be more easily adapted to the BHV4 strain of
choice (for example, the BHV4 strain which has been isolated in the area of interest) while the
commercial BHV4 iELISA is based on the use of BHV4 LVR 140. This study also shows that, in
comparison to the BHV4 iELISA, the BHV4 IPMA, which is based on the detection of all bovine
immunoglobulin subclasses, is the test of choice for the early detection of BHV4 antibodies in bovine
serum samples. A disadvantage of the IPMA is that it depends on subjective readings of test results
whereas the iELISA is more objective because of the use of automatic readers. IPMA test results need
to be interpreted by at least two trained persons to reduce the subjectivity of readings of test results (as
indicated in Materials and Methods).
In conclusion, the BHV4 IPMA is a reliable practical test for the screening of cattle for BHV4
antibodies, and it is a useful alternative to iELISA for detecting BHV4 antibodies in cattle.
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Abstract
A polymerase chain reaction (PCR) assay was developed to detect bovine herpesvirus 4 (BHV4)
glycoprotein B (gB) DNA, and nested-PCR assay was modified for the detection of BHV4 thymidine
kinase (TK) DNA in bovine milk samples. To identify false-negative PCR results, internal control
templates were constructed, added to milk samples, and co-amplified with viral DNA using the same
primers for both templates. Specificity, sensitivity, and reproducibility of the two PCR assays were
examined. In both PCR assays, all 31 BHV4 strains examined were scored positive, whereas 14
unrelated viruses scored negative. Sensitivity studies showed that two - ten copies of BHV4 DNA
were detectable by the gB-PCR, while one - three copies could be detected by the TK-PCR. For the
detection of BHV4 in milk samples, the gB-PCR amplification was found tobe ten-times, and the TK-
PCR was found to be 55-times more sensitive than virus isolation. BHV4 DNA was detected by gB-
PCR and TK-PCR in 93 and 95%, respectively, of 61 milk samples collected from cows infected
intramammarily with BHV4, while only 61% were positive by virus isolation. Four out of 48 cows
with clinical mastitis were positive for BHV4-gB and BHV4-TK DNA, whereas no BHV4 DNA was
detected in milk from control cows. Considerable agreement was seen between the results of the two
PCR assays, and both methods were considered as rapid and reliable tests for the screening of BHV4
DNA in bovine milk. The less laborious gB-PCR might be the recommended test of choice for
screening large amounts of milk samples for the presence of BHV4.
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1. Introduction
Bovine herpesvirus 4 (BHV4), a member of the Gammaherpesvirinae subfamily, has been isolated
from cows with various diseases all over the world. Recently, BHV4 has been isolated from milk
samples of cows with clinical mastitis, and not from milk samples of the matched control cows
(Wellenberg et al., 2000). More studies need to be carried out to clarify whether BHV4 might play a
role in the aetiology of bovine clinical mastitis. Therefore, a rapid, sensitive and reliable method is
required to screen large numbers of milk samples from cows with mastitis and their controls for the
presence of BHV4. A nested-PCR for the detection of thymidine kinase (TK) genomic sequences has
been described by Egyed et al. (1996). This assay has been shown to be suitable to study the in vivo
distribution of BHV4 in its host, but it has never been validated as diagnostic tool for the detection of
BHV4 DNA in milk samples, nor has this TK-PCR been used with the addition of an internal control
template. Internal control templates can be used to identify failures in DNA extractions, in PCR
amplifications, and allow semi-quantitative estimations of the amount of viralDNA (Van Engelenburg
et al., 1993). In this study, we report on the modification of the TK-PCR, and on the development of a
single PCR for the detection of BHV4 glycoprotein B (gB) DNA. Both PCR assays were validated for
the detection of BHV4 DNA in bovine milk samples. For that purpose, we tested milk samples from
cows infected intramammarily with BHV4, and from cows with clinical mastitis and from their
matched controls.
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2. Materials and methods
2.1 Cell cultures
Bovine umbilical cord endothelial (BUE) cells were used for BHV4 isolation and propagation
(Wellenberg et al., 2000). These cells were grown and maintained in Dulbecco’s minimal essential
medium (DMEM) (Gibco Laboratories, Life Technologies Inc., USA) supplemented with 10% fetal
bovine serum (Gibco Laboratories, Life Technologies Inc., USA), and 0.5% antibiotic mix (stockmix
contained: 10,000 IU penicillin, 11.25 mg streptomycin, 10 mg kanamycin and 5,000 IU nystatin per
ml). Other virus stocks were propagated in cell cultures of the Madin Darbybovine kidney, embryonic
bovine trachea, or bovine diploid lung cells (Van der Poel et al., 1996).
2.2 Virus strains
The American BHV4 DN-599 reference strain was obtained from the American Type Culture
Collection, Manassas, VA (Cat. No. VR 631). BHV4 Movar 33/63, the European reference strain, and
BHV4 LVR 140 were kindly provided by Dr. E. Thiry. In total, 28 other BHV4 strains, from various
European countries, and 14 viruses not belonging to the Gammaherpesvirinae, were used todetermine
the specificity of both PCR assays. The BHV4 strains were: five Dutch strains (including strain
Tolakker), two strains from Italy (strains 415 and 418), five strains from Hungary (strains 458, 461,
463, 488, and 497 were kindly provided by Dr. L. Egyed), nine strains from Belgium (strains
LVR260, AVR1478, 31788, BVR318, 99/3114, 99/2823, 00/2768, 00/2776, and 00/3847 were kindly
provided by Dr. P. Kerkhofs), and seven Bulgarian strains (strains Momchilgrad, Nikolovo, Svoboda,
Levski, Kazichene, Movar 90, and 453). BHV4 strain Tolakker, which was used for experimental
infection, was isolated from a Dutch cow with signs of clinical mastitis (Wellenberg et al., 2000).
Ovine herpesvirus 2 (OHV2 DNA from bovine lymphocytes) and virus stocks, containing>104 tissue
culture infective doses (TCID)50/ml, of bovine herpesviruses (BHV)1.1, BHV1.2, BHV2, BHV5
(N569), equine herpesvirus (EHV) 1, EHV4, suid herpesvirus 1 (SHV1), herpes simplex virus (HSV)
1, HSV2, (bovine) para-influenza 3 (PI-3) virus, bovine adenovirus 1, bovine viral diarrhoea virus
(BVDV-1) and bovine respiratory syncytial virus (BRSV) were also used to determine the specificity
of both PCR assays.
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2.3 BHV4 DNA cloning
BHV4 DNA was cloned to prepare internal control templates and to determine the number of the
DNA copies that can be detected by both PCR assays. Therefore, the gB-primers gB1 (5’-
CCCTTCTTTACCACCACCTACA-3’) and gB2 (5’-TGCCATAGCAGAGAAACAATGA-3’)
(Eurogentec, Belgium) and the TK-primers, 5’-GTTGGGCGTCCTGTATGGTAGC-3’ and 5’-
ATGTATGCCCAAAACTTATAATATGACCAG-3’ (Egyed et al., 1996), were used toamplifyparts
of the gB and the TK gene of BHV4 Movar 33/63. The amplification products were extracted from
agarose gels, and cloned into plasmid pCR 2.1 using the TA cloning kit (Invitrogen, USA). After
cloning, plasmids were purified using the WizardR Plus Minipreps DNA purification system
(Promega, USA). DNA concentrations were determined by comparison with known quantities of
DNA on agarose gels, and 10-fold dilutions of plasmids pCR 2.1 with inserts of BHV4-gB (pB34) or
BHV4-TK (pB19) (Fig. 1) were prepared in milk and stored at –20°C.
2.4 Construction and use of internal control templates for the gB-PCR and TK-PCR
The internal control templates were constructed by digestion of plasmid pB34 (gB) with restriction
enzyme SspI, and plasmid pB19 (TK) with restriction enzyme BsmI (Fig. 1). Both templates were
digested briefly with Bal31 exonuclease. After a ligase treatment, the resulting plasmids, containing
the shortened BHV4-gB insert (pB88) and the BHV4-TK insert (pB48), were cloned, isolated, and the
DNA concentration was determined. The resulting plasmids were used as internal control templates
and amplified under PCR conditions identical to those used to amplify BHV4 DNA. The internal
control products were distinguished from BHV4 viral DNA PCR products by agarose gel
electrophoresis.
2.5 DNA extraction
DNA extractions from defatted milk samples, and extractions from viruses used to examine the
specificity, were carried out by column chromatography using the QIAamp Blood and Tissue kit
(QIAGEN, Westburg, The Netherlands). For DNA extraction of defatted milk samples a volume of
1000 µl was used. Prior to DNA extraction, the defatted milk samples were centrifuged at 14,000 rpm
for 3 min. A volume of 800 µl was discarded and the cell pellet was resuspended in the remaining200
µl. Prior to DNA extraction, both internal control templates, plasmid pB88, and plasmid pB48, were
added to the defatted milk samples. For the DNA extraction of virus strains, 200 µl of virus stocks
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were used. Digestion with protease, DNA precipitation and elution of DNA was carried out according
to the description of the manufacturer. The DNA extraction products were stored at –20 °C.
2.6 gB and TK-PCR assays
For the amplification of BHV4-gB gene, primers gB1 and gB2 were used. The primers showed 100%
homology with the sense strand, on nucleotide positions –38 to –17 (gB1), and with the anti-sense
strand, on nucleotide positions 555 to 576 (gB2) of the BHV4-gB sequence published by Goltz et al.
(1994). Optimisation of the gB-PCR was performed for various PCR buffers, concentrations of
magnesium chloride, annealing temperatures, numbers of cycles, types of DNA polymerase, addition
of dimethylsulfoxide, glycerol, and primer concentrations. The optimised PCR assay conditions were
as follows: amplification of BHV4-gB DNA was performed by adding 5 µl of DNA extract in a final
volume of 50 µl containing, 1x PCR buffer minus magnesium chloride (Gibco BRL, Life
Technologies, USA), 5 mM dNTP-mix (containing 1.25 mM of each dATP, dCTP, dGTP, and
dTTP), 2 mM magnesium chloride (Roche), 2 U Ampli Taq Gold polymerase (Perkin Elmer/Applied
Biosystems, USA) and 30 pmol of primers gB1 and gB2. The amplification was performed on a
GeneAmp PCR System DNA Thermal cycler (Perkin Elmer Cetus, Norwalk, USA). The program
started with one step at 95 °C for 10 minutes, followed by 45 cycles of, 94°C for 60 sec, 58°C for 60
sec, and 72°C for 90 sec. The amplification was completed by an ultimate elongation step at 72°C for
7 min.
The amplification of BHV4-TK DNA templates was based on the nested TK-PCR as described by
Egyed et al. (1996), but with some modifications. DNA templates were amplified in the PCR mix as
described for the nested TK-PCR, but with 2 mM magnesium chloride (Roche), and 2 U Ampli Taq
Gold polymerase (Perkin Elmer/Applied Biosystems). A volume of 5 µl of PCR product of the first
PCR round was amplified further in a nested PCR round, using the same PCR mix as described for
the first round, but with the nested primers 3 and 4 (Egyed et al., 1996). In the first and the nested
PCR round, the following program was used to amplify BHV4-TK templates: one step at 95 °C for 10
minutes, followed by 30 cycles of 94°C for 60 sec, 60°C for 60 sec, and 72°C for 90 sec. The ampli-
fication was finalised by an ultimate elongation step at 72°C for 7 min. The amplification products
were stored at –20 °C. Eight microlitres of PCR products were analysed by horizontal agarose (1%)
gel electrophoresis. Gels were stained with 1 µg/ml ethidium bromide and photographed under UV
light.
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Fig 1. Construction of internal control templates for the gB-PCR and TK-PCR assays. (A) Schematic representation of the
BHV4 Movar 33/63 genome indicating the positions of the gB and TK genes and the cleavage positions of the restriction
enzymes SspI and BsmI (arrowheads). The Bal31 exonuclease digested segments in pB34 and pB19 are indicated as white
boxes that are removed in pB88 and pB48, respectively. During PCR, fragments of 377 bp and 167 bp (n-PCR product)
were amplified from pB88 and pB48, respectively. The positions of the primers are indicated by arrows. (B) The Bal31
exonuclease digested segments in pB34 and pB19 analysed on nucleotide level. The Bal31 cleaved nucleotides (lowercase)
are flanked on both sides by remaining nucleotides within the internal control templates (upper case) pB88 and pB48. (C)
PCR products obtained after amplification of pB34 (lane 2) and pB88 (lane 3) by gB-PCR, and pB19 (lane 5) and pB48
(lane 6) by TK-PCR after the first PCR round, and pB19 (lane 7) and pB48 (lane 8) by the nested TK-PCR. Lanes M, 100-
bp marker; lane 1, negative control gB-PCR; lane 4, negative control nested TK-PCR.
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2.7 Specificity of PCR products
The specificity of the gB-PCR and TK-PCR products was examined by evaluating their size, their
pattern after restriction enzyme analysis and by sequencing. For the digestion of gB-PCR products the
SspI restriction enzyme was used and for TK-PCR products the BsmI restriction enzyme.
Nucleotide sequences of BHV4-gB and BHV4-TK internal template constructs and the PCR
products were determined by the fluorescent dideoxy chain termination method using an automated
sequencer (model 373A; Applied Biosystems Inc., Foster City, USA).
2.8 Controls for PCR assays
In addition to the use of internal template controls, positive and negative controls were incorporated
into the total DNA extraction step, and into each step of the amplification, i.e. into the first (or single)
PCR round and into the nested (second) PCR round. A dilution, containing two TCID50 of BHV4
Movar 33/63 in milk, was incorporated as positive control into each test run. Also negative controls
(without DNA), consisting of PCR mix buffer and DNAse-free H2O, were incorporated into each
amplification step. Special care was taken to identify false-positive PCR results, and therefore, a
BHV4-free negative milk control (free of BHV4 and BHV4 antibodies) was added toeach set of 4 test
milk samples. The negative controls were processed together with the test samples, starting at DNA
extraction level. To avoid false-positive results, classical precautions for PCR were strictlyfollowed in
the laboratory (Kwok and Higuchi, 1989; Crespin et al., 1998).
2.9 Validation of the PCR assays
2.9.1 Specificity of the PCR assays
To determine the specificity of both PCR assays, DNA extracts were prepared from virus stocks (see
Section 2.2), and tested whether they were amplified by PCR with the selected primers.
2.9.2 Sensitivity of the PCR assays
Three methods were used to determine the sensitivity of both PCR assays. The sensitivity, defined as
the detection limit of the PCR assay, was first determined by an end-point titration assay using the
BHV4-gB and BHV4-TK internal control templates. Serial tenfold dilutions of plasmids pB88 and
pB48 in BHV4-free milk were used for DNA extraction, and the end-point dilution was determined.
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The amount of DNA copies in this dilution was considered to be the detection limit. The sensitivity
was also evaluated by preparing serial tenfold dilutions of the BHV4 reference strains DN599 (107.0
TCID50/ml) and Movar 33/63 (105.1 TCID50/ml) in milk. DNA extractions of these dilutions were
prepared with and without the addition of the internal control templates and amplified by both PCR
assays (see Section 3.5). The highest dilution giving a positive reaction was defined as the detection
limit. Thirdly, the sensitivity of both PCR assays was determined for BHV4 infected milksamples and
compared with virus isolation. Therefore, four milk samples from cows, intramammarily inoculated
with BHV4, were diluted in BHV4-free milk samples up to 10,000 times, and the internal control
templates were added to each dilution prior to DNA extraction. Detection limits of both PCR assays
were compared with the detection limits as determined by virus isolation. PCR assays and virus
isolations were performed in duplicate.
2.9.3 Reproducibility of the PCR assays
The reproducibility of both PCR assays was determined by analysing 24 selected milk samples, from
which BHV4 was isolated, of four cows experimentally infected with BHV4 strain Tolakker, and by
analysing 26 bovine milk samples from a case/control study shown tobe BHV4-free byvirus isolation.
All milk samples were examined twice by both PCR assays for BHV4 DNA by the same technician
on two different days. Internal control templates were added to the milk samples prior to DNA
extractions.
2.10 Virus isolation
Milk samples were defatted by centrifugation at 1500 x g for 10 min at 4°C, and stored at –70°C.
After thawing, a volume of 500 µl of de-fatted milk sample was examined for the presence of BHV4
by virus isolation on BUE cells using six- and 24-wells cell culture plates. One hour after inoculation,
the supernatant was replaced by new cell culture medium and the cell culture was incubated at 37°C
with 5% CO2. After 4 days of incubation, the virus/cell suspension was frozen at –70°C and passed
into a new six- or 24-wells cell culture plate with semi-confluent monolayers of BUE cells. Cells were
observed for cpe after an incubation period of 5 days at 37°C (5% CO2).
2.11 Bovine milk samples collected under experimental and field conditions
Bovine milk samples were collected from cows experimentally infected with BHV4 and from cows in
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a case/control study to compare both PCR assays as diagnostic tool in detecting BHV4 in milk with
virus isolation.
2.11.1 Experimental infection
Two quarters of four dairy cows each were inoculated intramammarily with BHV4 strain Tolakker.
On day 14 post-infection (pi.), the same two quarters of two out of four cows were inoculated with
Streptococcus uberis. Milk samples were collected from infected quarters between day 0 and day 28
pi., and stored at –70°C after collection. Prior to virus isolation and DNA extraction, milk samples
were thawed, and a volume of 2-5 ml of milk was defatted by centrifugation at 4°C (10 min at 1500 x
g). Internal control templates were added prior to DNA extraction. Lipid components in milk can
inhibit Taq polymerase which results in a failure to amplify low levels of viral DNA from native milk
samples (Hamprecht et al., 1998).
2.11.2 Field conditions
In a case/control study, milk samples were collected from Dutch dairy cows with clinical mastitis and
from matched control cows as described previously (Wellenberg et al., 2000). Milksamples have been
collected according to the recommendations of the National Mastitis Council (Harmon et al., 1990).
Samples for virus isolation and DNA extraction were stored directly at –70°C. Prior to virus isolation
and DNA extraction, milk samples were de-fatted as described above, and internal control templates
were added.
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3. Results
3.1 Construction of internal control templates
Internal control templates for the gB-PCR and the TK-PCR were constructed bydeleting238-bp of the
615-bp PCR product of BHV4-gB, and 93-bp of the 567-bp PCR product of BHV4-TK (Fig. 1). The
resulting plasmids, pB88 and pB48, were amplified under PCR conditions identical to those used for
the amplification of BHV4 viral DNA. After amplification of the internalcontrol template pB88 bythe
gB-PCR, a fragment of 377 bp was amplified. In the nested TK-PCR, the BHV4 viral DNA product
was 260 bp, whereas the internal control template product had a length of 167 bp.
Restriction enzyme analysis of PCR products showed that the internal control template fragments
were not cleaved by SspI and BsmI. gB-PCR products of BHV4 viral DNA were cleaved by SspI and
resulted in restriction enzyme digestion products of 441 bp and 174 bp, while BsmI cleaved TK-PCR
products from BHV4 viral DNA in restriction products of 171 bp and 89 bp (Fig. 2).
Fig 2. gB-PCR and TK-PCR amplification fragments of BHV4 DNA positive milk. Specificity of the PCR
products was checked by restriction enzymes SspI and BsmI. Lanes M, 100 bp marker; lane 1, negative milk
control BHV4-gB PCR; lane 2, BHV4-gB positive milk (PCR fragment of 615 bp); lane 3, BHV4-gB PCR
fragment cleaved by restriction enzyme SspI (restriction products of 441 and 174 bp); lane 4, BHV4-TK
positive milk (PCR fragment of 260 bp); lane 5, TK-PCR fragment cleaved by restriction enzyme BsmI
(restriction products of 171 and 89 bp); lane 6, negative milk control BHV4-TK PCR.
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3.2 Specificity of both PCR assays
Both PCR assays yielded fragments of the predicted size using DNA extracts from BHV4 strains DN-
599, Movar 33/63, and LVR 140, and from the other 28 BHV4 strains. The obtained PCR products
were cleaved into restriction products of the correct sizes by restriction enzymes SspI and BsmI.
No specific PCR products were obtained after amplification of DNA or RNA extracts from BHV1.1,
BHV1.2, BHV2, BHV5, OHV2, EHV1, EHV4, SHV1, HSV1, HSV2, PI3, bovine adenovirus 1,
BVDV, and BRSV. Only after the amplification of SHV1 DNA, weak PCR products were obtained in
the gB-PCR but the lengths of these two bands were approximately 200-bp and 480-bp, hence not of
the correct size.
Fig 3. The sensitivity of the gB-PCR, as determined by serial 10-fold dilutions of internal control template
DNA (plasmid pB88). Lanes M, 100-bp marker; lane 1, negative control (not spiked); lane 2, positive PCR
control Movar 33/63 (2 TCID50); lanes 3 – 8, serial 10-fold dilutions of internal control template plasmid pB88,
containing 20,000 – 0.2 copies/µl.
3.3 Sensitivity of the PCR assays
The estimated sensitivity of the gB-PCR, as determined with plasmid DNA of the gB gene (pB88),
was two - ten molecules (Fig. 3), whereas one – three molecules, as determined with plasmid pB48
containing DNA of the TK gene, was detected by the TK-PCR. In the TK-PCR, amplification
products were detectable of 10-fold dilutions of plasmid pB48 up to dilutions containingone molecule
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(data not shown). PCR assays, as performed on DNA extracts of 200 µl of serial dilutions of BHV4
strains DN599 and Movar 33/63 (infectious viruses without the addition of internal control templates)
showed that between 2 – 0.2 TCID50 were still detectable by gB-PCR, and 0.2 TCID50 by the TK-
PCR. The sensitivity of both PCR assays was also determined by serial 10-fold dilutions of four milk
samples obtained from cows after an intramammary inoculation with BHV4 (Fig. 4). Results of the
detection limits of both PCR assays and virus isolation are presented in Table 1. The gB-PCR was one
- ten times more sensitive in detecting low amounts of BHV4 in milk samples than virus isolation,
while the TK-PCR was 1 - 55 times more sensitive in detecting low amounts of BHV4 than virus
isolation.
Table 1. Comparison of the detection limits of the gB-PCR, the TK-PCR, and virus isolation by using serial
tenfold dilutions of milk from cows intramammarily inoculated with BHV4
Highest dilution positive for BHV4 Sensitivity ratio a
Milk sample BHV4-gB BHV4-TK Virus isolation BHV4-gB BHV4-TK
1 101 ,101 101 ,101 101 1 1
2 102 ,102 102 ,103 102 1 5
3 102 ,102 103 ,102 102 1 5
4 101 ,101 102 ,101 100 10 55
a: The sensitivity ratio is determined by dividing the detection limit of the PCR assay by that of the virus isolation method
3.4 Reproducibility
All 24 milk samples that were collected from cows infected experimentally with BHV4 were
positive for BHV4 DNA by both PCR assays, and the 26 milk samples of the control cows were
BHV4 DNA negative. All duplicate analyses, as obtained by the two PCR assays on a second
occasion, revealed the same results.
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Fig 4. Comparison of the sensitivity of the gB-PCR and the TK-PCR assays and virus isolation by serial tenfold dilutionof
milk sample 2, obtained from a cow intramammarily inoculated with BHV4, spiked with internal control templates pB88
and pB48. (A) Amplification products of the gB-PCR of viral DNA (615 bp) and internal control template (377 bp). (B)
Amplification products of the TK-PCR of viral DNA (260 bp) and internal control template (167 bp). For A and B: lanes
M, 100-bp marker; lane 1, negative milk control (not spiked); lane 2, positive PCR controlMovar33/63 (2 TCID50); lanes3
- 7, serial tenfold dilution (1 – 10,000 times) of milk sample 2. Above the lanes, the results of the virus isolation from each
dilutions of milk sample 2 are indicated.
3.5 Use of internal control templates
An essential requirement of an internal control template is that it is amplified with the same efficiency
as the viral template, and that the influences of the addition of internal control templates on the
sensitivity of the PCR assays are negligible. Therefore, the amount of internal control templates must
be as low as possible, but always detectable after addition to BHV4-free test samples prior to DNA
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extraction. Different amounts of copies of the internal control templates pB88 and pB48 were added to
native defatted milk prior to DNA extraction. After DNA extraction and amplification, the amount of
copies of each internal control template to be added to each test sample was calculated. In this study,
test samples were spiked, prior to DNA extraction, with 2.5 copies/µl of the internal control template
pB88 and six copies/µl of the internal control template pB48. This means that in each PCR run, 12.5
copies (5 µl x 2.5) of the internal control template pB88, and 30 copies (5 µl x 6) of the internal
control template pB48 were co-amplified with the viral DNA.
Fig 5. Determination of the detection limits of the gB-PCR and TK-PCR by amplification of serial tenfold dilution of
BHV4 DN-599 (stock: 107.0 TCID50/ml) and Movar 33/63 (stock: 105.1 TCID50/ml) DNA spiked with internal control
templates pB88 and pB48. (A) Amplification products of the gB-PCR of viral DNA (615 bp) and internal control template
(377 bp). (B) Amplification products of the TK-PCR of viral DNA (260 bp) and internal control template (167 bp). For A
and B: lanes M, 100-bp marker; lane 1, negative milk control (not spiked); lanes 2 - 4, 10-5 - 10-7 dilution of DN-599; lanes
5 - 7, 10-3 - 10-5 dilution of Movar 33/63.
To test the influence of the addition of internal template controls on the sensitivityof both PCR assays,
we added fixed amounts (as described above) of molecules of the internal template controls pB88 and
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pB48 to serial tenfold dilutions of the BHV4 reference strains Movar 33/63 and DN-599, and
compared the data on detection limits with those obtained without the addition (see Section 3.3.). For
both BHV4 reference strains, the detection limit of the gB-PCR was 2 TCID50, while 2 – 0.2 TCID50
was detected by the TK-PCR (Fig. 5).
3.6 Comparison of BHV4 detection in milk samples by PCR assays and virus isolation
3.6.1 Milk samples collected from cows inoculated intramammarily with BHV4
In total 61 milk samples were examined for BHV4 by PCR assays and by virus isolation. From 37 out
of 61 milk samples BHV4 was isolated. In all those 37 BHV4 positive milksamples, BHV4 DNA was
detectable by both PCR assays. From the 24 milk samples, in which no BHV4 was detected by virus
isolation, 21 were positive for BHV4-TK DNA and 20 for BHV4-gB DNA. In total, 7 randomly
selected PCR products, including 3 PCR products obtained from milk samples that were negative by
virus isolation, were examined by restriction enzyme analyses or sequence analysis for specificity.
After restriction analyses of gB-PCR and TK-PCR product by restriction enzymes SspI and BsmI,
respectively, the expected restriction fragments were obtained, confirming the specificity of the PCR
products. The sequences of PCR products were identical to parts of the BHV4-gB and the BHV4-TK
gene. After a TK-PCR on a DNA extract from one milk sample (collected on day 23 pi.), no PCR
product of the internal template control was detected, nor amplification products of the viral DNA
were observed. BHV4-gB DNA was detected in this milk sample by gB-PCR.
3.6.2 Milk samples from clinical mastitis and control cows
In total, milk samples from 48 clinical mastitis cases and 48 control cows were tested for BHV4 by
both PCR assays and by virus isolation. From milk samples of 4 out of 48 clinical mastitis cows,
BHV4 specific amplification products were obtained by both PCR assays (Table 2), whereas all
control cows were negative. In three clinical mastitis cases BHV4 was isolated from the milk, whereas
no BHV4 was isolated from their control cows (Wellenberg et al., 2000). In milk from two of these
three clinical mastitis cases, BHV4-gB and BHV4-TK DNA were detected. Statisticalanalyses, using
the Fisher’s exact test, demonstrated that BHV4-gB and BHV4-TK DNA were detected more
frequently in milk from cows with clinical mastitis than in control cows (P = 0.059).
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3.7 Comparison between the two BHV4 PCR assays in detecting BHV4 DNA in milk samples from
cows intramammarily inoculated with BHV4 and from the case- and control cows
In total, 61 milk samples from cows inoculated intramammarilywith BHV4 and 48 milksamples from
clinical mastitis cases and 48 milk samples from control cows were examined for BHV4 DNA by the
two PCR assays. BHV4-gB DNA was detected in 61 (57 (= 20 + 37) + 4 + 0) milk samples while
BHV4-TK DNA was detected in 62 (58 (= 21 + 37) + 4 + 0) of these 157 milk samples. Sixty milk
samples were scored positive by both PCR assays, while 94 milk samples were negative. The overall
agreement between the two PCR assays was 98% with a ΚD-value of 0.960.
Table 2. Detection of BHV4 in milk samples from clinical mastitis cases (n=48) and matched control
cows (n=48) from 10 herds by virus isolation, the gB-PCR and the nested TK-PCR
Herd Case / BHV4 BHV4 BHV4
control isolation -gB -TK
pairs (milk) (PCR) (nPCR)
per herd (M / C) (M / C) (M / C)
(M / C)a
1, 2, 4, 5 ,6, 7 30 / 30 - - / - - / -
3 3 /3 - 1 / - 1 / -
8 3 / 3 1 / - 1 / - 1 / -
9 5 / 5 1 / - - / - - / -
10 7 / 7 1 / - 2 / - 2 / -
Total: 48 / 48 3 / - 4 / - 4 / -
a M, mastitis cows; C, control cows
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4. Discussion
This study demonstrates that the newly developed gB-PCR and the adapted TK-PCR, can reliably be
used for the detection of BHV4 DNA in bovine milk samples. We have chosen to develop a PCR to
detect gB sequences because the gene for gB is one of the most conserved among the members of the
family of Herpesviridae. For most if not all members of the Herpesviridae, gB is essential for viral
infectivity (Little et al., 1981), and for BHV4, Lomonte et al. (1997) reported that gB is a major
component of the virion. These reports imply that the gB gene is probably present in allBHV4 strains.
For the development of a gB-PCR, the choice of primers was critical, because: (1) their nucleotide
sequence must be within a conserved region of the gB gene of BHV4 to detect all BHV4 variant
strains; and (2) on the other hand the primers must not react with regions of the gB genes of other
herpesviruses. The selected gB-primers, based on the oligonucleotide sequence of the gB gene as
published by Goltz et al. (1994), were shown to be specific as demonstrated by amplification of DNA
extracts from all 31 BHV4 strains by the gB-PCR, and the absence of specific amplification products
from other animal viruses and human herpesviruses.
The primers, selected for the amplification of regions of the BHV4-TK gene, have been shown to be
specific (Egyed et al., 1996), and we confirmed these findings. We chose to target also the BHV4 TK-
coding gene for PCR amplification, to detect BHV4 DNA in milk, for three reasons: (1) to evaluate
and compare the sensitivity of the gB-PCR with the sensitivity of the nested TK-PCR; (2) to confirm
the presence of BHV4 DNA in milk by a second PCR in case BHV4 DNA was detected by gB-PCR
(false-positive reactions may occur in PCR assays); and (3) to validate the TK-PCR that we adapted by
the addition of an internal control template and in the presence of milk as background. Prior to the
validation of the two PCR assays, internal control templates were constructed for each PCR. False-
negative PCR results can be traced by using an internal control (Van Engelenburg et al., 1993). Lipid
components in milk samples have been reported to inhibit Taq polymerase, which can lead to false-
negative PCR results (Hamprecht et al., 1998). In addition, milk collected from cows with clinical
mastitis show often abnormal morphology, high cell counts, and bacteria, and therefore may contain
inhibitors resulting in false-negative PCR results. The influence of these factors on the sensitivity of
PCR assays can be determined by the use of an internal control template. Although this control
competes with the BHV4 DNA template for e.g. primer binding and enzymes, it did hardly not
influence the detection of BHV4 DNA in milk samples. The sensitivities of both PCR assays, with or
without the addition of internal control templates, were comparable. The use of an internal control
template has certain advantages above the use of an extra PCR to check for quality of DNA extraction
and inhibition of amplification. An additional PCR, e.g. for the amplification of β-actin DNA, has to
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be performed for each test sample, and therefore this approach is more expensive, laborious, less
rapid, and more often other PCR conditions are used. Moreover, the extra PCR cannot give any semi-
quantitative indication. Boerner et al. (1999) described a PCR for the detection of BHV4-DNA in
combination with a PCR for the amplification of β-actin as test control, but their method seems less
useful for screening large numbers of samples by PCR than the use of an “internally controlled” PCR.
In the initial phase of this study the sensitivity, defined as detection limit, of the two PCR assays
was determined. Data on detection limits, as obtained by: (1) serial tenfold dilutions of purified BHV4
DNA plasmids; (2) serial tenfold dilutions of the two BHV4 reference strains DN-599 and Movar
33/63 in milk; and (3) serial tenfold dilutions of BHV4 infected milk, showed that both assays were
very sensitive. The sensitivity of the gB-PCR, as determined by the detection of low amounts of
BHV4 DNA copies, was somewhat lower than the sensitivity of the TK-PCR. Two - ten copies of
BHV4 DNA were detectable by the gB-PCR, while one - three copies of BHV4 DNA were detected
by the TK-PCR. Boerner et al. (1999) described a PCR for the detection of BHV4 DNA in bovine
tissue samples. This PCR, in combination with a Southern blot assay, detected six copies of BHV4
DNA.
This study also demonstrates that the two PCR assays are superior to virus isolation for detecting
BHV4 in bovine milk samples collected under experimental and field conditions. BHV4 DNA was
detected by gB-PCR and TK-PCR in 93% and 95%, respectively, of the milk samples collected from
cows infected intramammarily with BHV4, whereas only 61% were positive by virus isolation. The
presence of BHV4 DNA was confirmed by successful amplification of two different regions of the
viral genome, supporting the correctness of the PCR results. The fact that many milk samples, which
were positive in both PCR assays, were negative by virus isolation could be due to: (1) a low amount
of infectious virus (beneath the detection limit of the virus isolation method); (2) the presence of cell
toxic components produced by bacteria, e.g. Streptococcus uberis, which could influence with virus
isolation; and (3) the presence of non-infectious virus particles. A potential advantage of the PCR
assays over virus isolation is that BHV4 DNA can be detected in milk samples despite the presence of
BHV4 antibodies. BHV4 antibodies have been detected in milk samples of cows infected with BHV4
(unpublished observations). These considerations suggest that PCR assays will improve the diagnosis
of BHV4 in milk. Both PCR assays were also able to detect BHV4 DNA in milk samples containing
Streptococcus uberis and large amounts of cellular DNA (somatic cell count of > 1,000,000/ml). In
only one case, a milk sample collected on day 23 pi., the TK-PCR was probably inhibited by
components in the milk. No amplification products of the internal control template or any viral
templates were detectable.
The value of the two PCR assays, as diagnostic tools for detecting BHV4 in milk, was also
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corroborated in a case/control study. BHV4 DNA was detected in four out of 48 cows with clinical
mastitis and not in control cows. The data also demonstrate that BHV4 is more frequently detected in
mastitis cases than in control cows (P = 0.059). Taken together, these observations and the data
recently published by Wellenberg et al. (2000) indicate that BHV4 might playa role in bovine mastitis,
although more research on this subject is required. The use of one of the validated PCR assays for the
detection of BHV4 DNA in milk could facilitate these research programs. In onlyone occasion, BHV4
was detected in a milk sample by virus isolation while no BHV4 DNA was detected by both PCRs
(herd 9). We have tested this milk sample in triplicate for BHV4 DNA by both PCRs, and in only one
occasion BHV4-TK DNA was detected. Taking all PCR data together, this sample had tobe presented
as “negative” for BHV4 DNA. In addition, herpesvirus-like particles, which were further characterised
as BHV4, were detected in inoculated BUE cell cultures only after one passage, while no cpe was
observed in the BUE cells inoculated with this milk sample. Based on the data, obtained from virus
isolation and both PCRs, we may conclude that the amount of BHV4 in this milk sample was low, and
for both methods just around the limit of detection.
Data on the experimental infection and the case/control study, also demonstrate that the results of
the single gB-PCR were comparable to those obtained by the nested TK-PCR (overall agreement of
98%, and a high ΚD-value of 0.960). PCR has become an important diagnostic tool for veterinary
virologists, and a single PCR has several advantages above nested-PCR assays, e.g. less laborious, less
expensive, more rapid, and is less prone to contamination. For practical considerations, we
recommend the use of the single gB-PCR for the screening of milk samples for BHV4 DNA, although
the nested TK-PCR was slightly more sensitive.
In summary, the gB-PCR and the adapted TK-PCR are specific, sensitive, reproducible and rapid
PCR assays for the detection of BHV4-gB and BHV4-TK DNA in bovine milk samples. Both PCR
assays have several advantages above virus isolation for the screening of large numbers of bovine milk
samples to demonstrate the presence of BHV4.
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Abstract
This study describes the first isolation of bovine herpesvirus 4 (BHV4) from milk samples collected
from cows with clinical mastitis. Serum and milk samples were collected in 10 different herds from 58
dairy cows with clinical mastitis in the acute and the convalescent phase of the disease, and from 58
healthy matched control cows. Milk samples were examined for presence of viruses, using 4 different
types of cell cultures, and for bacterial pathogens. Bovine herpesvirus 4 was isolated, only in bovine
umbilical cord endothelial cells, from milk from 3 mastitis cows within 3 different herds, whereas no
virus was isolated from their matched control cows. Two of the 3 mastitis cows, from which BHV4
was isolated, developed antibodies against BHV4 concomitant with the infection, whereas none of
their matched controls did. In total, 16% of the mastitis cows and 10% of the controls developed
antibodies against BHV4. In one herd, 4 cattle developed BHV4 antibodies at the time mastitis
occurred, whereas no bacterial pathogens were isolated from the milk. Streptococcus uberis was also
isolated from the milk from 2 of the 3 cows from which BHV4 was isolated. This association between
BHV4 and Streptococcus uberis infections was statistically significant. The above findings strongly
suggest that BHV4 may play a direct or indirect role in causing bovine mastitis.
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Clinical mastitis has the largest economic impact on the dairy cattle industry. Despite intensive
bacteriological research, 20 to 35 per cent of clinical cases of bovine mastitis have an unknown
aetiology (Miltenburg and others 1996, Barkema and others 1998). Although virus infections have
occasionally been associated with bovine mastitis (Siegler and others 1984, Yoshikawa and others
1997), it is generally considered that viruses do not play a role in the aetiology of bovine mastitis
(Watts 1988, Radostits and others 1994). This study was undertaken to gain more insight into the
possible role of viruses in bovine clinical mastitis, due to the high percentage of unknown causes of
clinical mastitis.
In a case/control study, serum and milk samples were collected from 58 dairy cows with clinical
mastitis in 10 different Dutch herds at the acute (day 0) and the convalescent phase (day 21) of the
disease. Serum and milk samples were also taken from 58 healthy, matched control cows. The control
cows were from the same herd, did not show mastitis symptoms, were of the same age as the mastitis
cows and were in the same stage of lactation as the mastitis cows. Milk samples from the matched
control cows were collected on the same day from the same quarters as the affected quarters of the
corresponding clinical mastitis cases. The milk samples were collected as described by the National
Mastitis Council (Harmon and others 1990). Samples for virus isolation were stored directlyat –70°C,
while milk samples for the screening of bacterial agents were stored at 2 to 4°C, and usually cultured
within 24 hours. Blood samples were obtained from the median sacral vein of the tail, and centrifuged
at 2000 g for 10 minutes. Sera were stored at –20°C.
After sampling on day 0, cows with clinical mastitis were treated with antibiotics; the matched
controls were not treated. Convalescent samples were taken at least two weeks after the last antibiotic
medication. The number of lactating cows in the 10 different herds varied between 31 and 57, and the
number of case/control pairs between one to 22 per herd (Table 1). Milk samples were examined for
presence of viruses, using 4 different types of cell cultures: embryonic bovine trachea cells (EBTr; a
semipermanent cell line developed in the authors’ laboratory, ID-Lelystad); bovine epithelial udder
cells (including fibroblasts) (Schmid and others 1983); bovine umbilical cord endothelial (BUE) cells
(Van de Wiel and others 1989); and bovine alveolar lung macrophages obtained from specified-
pathogen-free (SPF) cattle (Schrijver and others 1995).
The milk samples were thawed, defatted by centrifugation at 1500 g for 10 minutes, and 0.5 ml of
the defatted milk was used for virus isolation. For the virus isolation on macrophages, 100 µl of
defatted milk samples was pipetted into the wells of a 96-wells cell culture plate, containing 3 to 5 x
104 cells per well. The inoculated cells were incubated for five to seven days at 37°C, with 5 per cent
carbon dioxide for the macrophages. After a freeze/thaw cycle, a second passage was performed.
During the first and the second passages, cell cultures were observed every day for cytopathogenic
effect (cpe). Four controls were included in each culture run. Two controls, containing 101 and 103
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median tissue culture infective dose (TCID50) of bovine herpesvirus 1 (BHV-1) per millilitre of milk,
served as positive controls. A milk sample without viruses and a plain cell culture control, served as
negative controls. After the second passage, a haemadsorption reaction, for the detection of, for
example, Orthomyxoviridae and Paramyxoviridae, was performed on EBTr cells with 0.2 per cent of
guinea pig erythrocytes, and incubated at 37°C for one hour. An EBTr cell culture inoculated with
parainfluenza type-3 virus was used as positive control. Electron microscopy (EM) was performed
after the second passages for all four cell types. A 400 mesh carbon-coated nickel grid with a collodion
film was floated on a drop of the inoculated cell cultures for five minutes, drained onto filter paper and
stained with 2 per cent phosphotungstic acid (pH 6.8). The grids were examined by transmission EM
after drying.
Serum samples collected from mastitis cows were examined for antibodies against BHV-1 by
ELISA (Kramps and others 1994), against bovine herpesvirus 2 (BHV-2) by a 24-hour virus
neutralisation test (Bushnell and Edwards 1988), against bovine herpesvirus 5 (BHV-4) by ELISA
(Wellenberg and others 1999), against bovine respiratory syncytial virus (BRSV) by ELISA
(Westenbrink and others 1985), against bovine viral diarrhoea virus (BVDV) by ELISA (Westenbrink
and others 1986), against bovine leukaemia virus (BLV) by ELISA (Pourquier, Montpellier, France),
and against adenovirus type-3 by ELISA (BIO-X). In case blocking percentages, ELISA coefficients or
optical density values indicated a significant increase in antibody titre, the serum samples were titrated
by serial two-fold dilution steps. The control cows were only examined for antibodies against BHV-4,
because only a few cows with clinical mastitis seroconverted (where seroconversion is defined as a
seronegative acute serum and a seropositive convalescent serum) against viruses other than
BHV-4. Serum samples containing antibodies against BHV-4, were titrated by serial two-fold dilution
steps. A four-fold (two dilution steps) higher antibody titre in convalescent serum compared with acute
serum is defined as a significant increase.
Bacteriological culture of milk samples was performed according to standards of the NationalMastitis
Council (Harmon and others 1990). Milk samples (0.01 ml) were inoculated on 6 per cent blood agar
plates (both aerobically and anaerobically), on TCT medium (Thallium sulphate, Crystal Violet,
Staphylococcus β-toxin; Merck) and on MacConkey number 3 agar (Oxoid). The plates were
incubated at 37°C and bacterial growth was evaluated after both 24 and 48 hours. Bacterial colonies
were identified as described by the National Mastitis Council. Bacteria were considered to be
pathogenic or non-pathogenic, on the basis of the description by Barkema and others (1998) which, in
some cases, depended on the number of colonies isolated.
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Table 1. Isolation of bovine herpesvirus 4 (BHV-4) and pathogenic bacteria from milk samples, including
BHV-4 antibodies in sera from clinical mastitis cases (n = 58) and control cows (n = 58) in 10 herds
Herd Case / BHV4 BHV4 Pathogenic bacteria in milk (day 0)
control isolation antibody
pairs (milk) at day 0
per herd (M / C)* (M / C) (M) (C)
1 1 - 1 / - Escherichia coli -
2 7 - 1 / 3 E. coli (x2), S. uberis (x2) -
3 3 - 3 / 1 - -
4 22 - 2 / 1 CNS (x2)**, E. coli (x2), -
S. aureus (x2),S. uberis (x3)
5 1 - - / - CNS -
6 1 - 1 / 1 - -
7 2 - 1 / - S. aureus, S. aureus
S. aureus + A. pyogenes
8 3 1 / - 1 / 1 S. uberis, S. dysgalactiae -
9 10 1 / - - / 1 E. coli, S. aureus (x2), S.aureus(x2)
E. coli + S. uberis,
CNS (x2), S. dysgalactiae,
S. uberis.
10 8 1 / - 2 / 4 A. pyogenes, C. bovis (x3)
C. bovis (x2), S. uberis.
Total 58 3 / - 12 / 12 31 6
*) M mastitis cows, C control cows,
**) CNS Coagulase-negative staphylococci.
No cpe was observed during the first and second passages in EBTr cell cultures, in bovine udder
epithelial cells, or macrophages that were inoculated with milk samples from the cows with clinical
mastitis. No virus particles were detectable in these cell cultures by EM. The haemadsorption reaction,
performed on EBTr cell cultures after the second passage, was negative for all these samples. The BUE
cell cultures inoculated with milk samples from the clinical mastitis cow 49 (day 0), and cow 400 (day
21) of herd 8 and herd 10, respectively, showed cpe six to seven days after inoculation. Herpesvirus
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particles were detected by EM in the BUE cell cultures inoculated with milk from cow 12 of herd 9
(day 0 and 21). No virus particles were detected in all the other milk samples from cows with clinical
mastitis and the matched control cows by virus isolation on BUE cells, or by EM. The results of virus
isolation on herd level and on an individual level are given in Tables 1 and 2, respectively. The three
virus isolates were characterised as herpesviruses by EM. The virus isolates and control BHV-4
reference strains DN-599 and LVR 140, were partly neutralised with monospecific antiserum against
BHV-4, and not with monospecific antisera against BHV-1 and BHV-2. In an immunoperoxidase
monolayer assay, the three virus isolates and the BHV-4 reference strains DN-599 and LVR 140
reacted with monoclonal antibody 123 which is directed against glycoprotein 1 of BHV-4 (Dubuisson
and others 1992), while BHV-1, BHV-2 and bovine herpesvirus 5 (BHV-5) did not react with
monoclonal antibody 123. Restriction enzyme analyses of DNA of the virus isolates, and the BHV-4
reference strains DN-599, Movar 33/63 and LVR 140, showed that the patterns of the virus isolates
were comparable to those of the BHV-4 reference strain Movar 33/63 (Fig 1). Statistical analysis,
using the sign test, indicated that BHV-4 was more frequently isolated from mastitis cows than from
controls (P = 0.125).
Fig 1. Restriction endonuclease analysis of viral DNA digested with EcoRI. Lane 1 bovine herpesvirus 4
(BHV-4) DN-599, Lane 2 BHV-4 Movar 33/63, Lane 3 BHV-4 LVR 140, Lane 4 BHV-4 strain from herd 8
(day 0), Lane 5 BHV-4 strain from herd 9 (day 0), Lane 6 BHV-4 strain from herd 9 (day 21), Lane 7 BHV-4
strain from herd 10 (day 21), M Marker. Molecular mass standards (in kb) are identified on the left.
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Table 2. Isolation of bovine herpesvirus 4 (BHV-4) and pathogenic bacteria from milk, and antibody
development against BHV-4 in sera from clinical mastitis cows and the matched control cows on an individual
level
BHV4
Herd Cow Case / Virus Antibody Pathogenic
control isolation development (serum) * bacteria in
from milk acute phase convalescent phase milk (day 0)
1 24 case - - - E. coli (sporadic)
control - - 800 C. bovis (day 21)
4 16 case - - 800 -
control - - - -
33 case - - 400 -
control - - 400 -
37 case - - 200 -
control - - 400 -
51 case - 100 400 -
control - - - -
54 case - 100 400 S. uberis (sporadic)
control - - - -
8 49 case + 100 400 S. uberis
control - - - -
52 case - - - S. dysgalactiae
control - 200 800 -
9 28 case - - 800 S. uberis and E. coli
control - - - -
22 case - - - S. aureus
control - - 200 S. aureus (day 21)
12 case + - - E. coli
control - - - -
10 275 case - - 100 A. pyogenes
control - 200 800 -
400 case + - 200 S. uberis
control - - - -
Antibody titres expressed as the reciprocal of the highest serum dilution giving a positive reaction; - Not detected, + Detected
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Two of the three cows from which BHV-4 was isolated, developed antibodies against BHV-4 (cow 49
and cow 400), while no antibodies against BHV-4 were detectable in cow 12 within 21 days. No
development in BHV-4 antibodies was detected in the three corresponding control cows of these three
cows (Table 2). In herd 4, which had a large number of clinical mastitis cases, even five cows with
clinical mastitis developed antibodies against BHV-4 at the time mastitis occurred. In total, 16 per cent
of the mastitis cows and 10 per cent of the controls developed antibodies against BHV-4. However,
development of antibodies against BHV-1, BRSV or adenovirus type 3 was detected in onlyfour cows
with clinical mastitis, but none of these viruses was isolated from the milk. In the sera of these four
cows, no antibodies against BHV-4 were detected. No development of antibodies was detected against
BHV-2, BVDV or BLV in the sera of all 58 cows with clinical mastitis.
Pathogenic bacteria were isolated in 31 (53 per cent) of the 58 milk samples from clinical mastitis
cows that were collected on day 0 (Table 1). Streptococcus uberis was also isolated from the milk
samples of cow 49 in herd 8 on day 0 (day 21; not determined), and cow 400 in herd 10 both on day 0
and 21 (Table 2). Escherichia coli was isolated from the milk of cow 12 (herd 9) on day 0 and day 21.
Fisher’s exact test showed that there was a significant positive association between BHV-4 isolation
and S. uberis isolation (P = 0.02).
This is the first report on the isolation of BHV-4 from milk from cows with clinical mastitis. Although,
BHV-4 DN-599 strains have been isolated from udder lesions from lactating dairy cows with
mammary pustular dermatitis (Reed and others 1977), and BHV-4 has been isolated from the cellular
fraction of a milk sample collected from a cow with chronic ulcerative mammary dermatitis (Cavirani
and others 1990), BHV-4 has never been identified as a possible cause of bovine mastitis. The three
cows from which BHV-4 was isolated did not show mammary dermatitis or teat lesions. BHV-4 DN-
599 strain was also recovered from milk samples after experimental inoculation via the teat channel,
showing that viral multiplication can occur after injection into the mammary gland (Osorio and Reed
1983).
The following findings further support a role of BHV-4 infection in bovine mastitis: in four of the 10
herds of this study there was an ongoing BHV-4 infection at the same time as clinical mastitis
occurred; in herd 4, where more than 50 per cent of the dairy cows showed clinical mastitis problems
per year, five (23 per cent) mastitis cows showed seroconversion or a significant increase in antibody
titre against BHV-4, compared with two (9 per cent) controls (Table 2); in four of the five mastitis
cows of this herd no pathogenic bacteria were isolated from milk, only a few colonies of S. uberis were
isolated from the milk of the fifth cow; of all 58 mastitis cows, 16 per cent developed antibodies
against BHV-4, and 10 per cent of the 58 control cows did so, but because subclinical mastitis was not
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included in the case population, the latter relatively high percentage might partially be explained bythe
fact that some control cows had subclinical mastitis. Support for this explanation is the finding that in
milk samples of two control cows that developed antibodies against BHV-4, Corynebacterium bovis
(herd 1) or Staphylococcus aureus (herd 9) were isolated, both on day 21 only (Table 2); in nine of the
10 herds studied, antibodies against BHV-4 were prevalent, whereas only 57 per cent of 30 randomly
chosen Dutch herds had antibodies against BHV-4 (Wellenberg and others 1999).
Whether BHV-4 may play a direct and/or indirect role in the pathogenesis of bovine mastitis
remains to be clarified. The finding that four cows develop antibodies against BHV-4 at the time of
clinical mastitis and that no pathogenic aerobic or anaerobic bacteria were isolated from these cows,
suggests BHV-4 as a primary cause. On the other hand, the concomitant isolation of BHV-4 and of S.
uberis or E. coli, both known to cause severe clinical mastitis (Barkema and others 1998), suggest that
BHV-4 infection of the udder may lead to a higher susceptibility for bacterial infections.
VanOpdenbosch and others (1984) reported that BHV-4 could induce immunosuppression favouring
the development of secondary infections in cattle. Infected splenic mononuclear cells and peripheral
blood leukocytes persistently infected with BHV-4 (Osorio and Reed 1983) could reduce the
phagocytic function of these cells. This enhances the possibility for bacterial infections to run a more
severe course which, in turn, may result in prolonged bacterial infections. On the other hand, cases of
clinical mastitis, that is, induced by S. uberis, could lead to reactivation of latent BHV-4 infection,
which in turn also may enhance the severity of mastitis cases.
The fact that this is the first report on the isolation of BHV-4 in milk samples from cows with
clinical mastitis may be explained by the use of BUE cells which are seldom used in bovine virology.
These cells appear to be much more susceptible to BHV-4 than other bovine cells, for example, several
BHV-4 strains reached 20- to 3000-fold higher titres in BUE cells than in EBTr cells (data not shown).
The susceptibility of endothelial cells to BHV-4 has recently been reported by Lin and others (1997).
In conclusion, these results demonstrate that BHV-4 may play a role in clinical mastitis in dairy
cows. Whether BHV-4 plays a primary or secondary role in the pathogenesis of bovine clinicalmastitis
needs to be elucidated. The authors are currently performing experimental infections with the BHV-4
isolate to attempt to reproduce bovine mastitis, and to fulfil Koch’s postulates.
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Abstract
A second case-control study was performed to investigate whether bovine herpesvirus 4 (BHV4) plays
a role in the aetiology of bovine mastitis. Serum and milk samples were collected in 16 different herds
from 54 dairy cows in the acute and convalescent phases of mastitis and from 54 healthy matched
control cows. Milk samples were examined for the presence of BHV4 bya BHV4 glycoprotein-B (gB)
PCR and by virus isolation, and for the presence of bacterial udder pathogens. The milk somatic cell
counts (SCC) were determined, and serum samples were screened for BHV4 antibodies. Bovine
herpesvirus 4 gB DNA was detected by PCR in 3 milk samples from 2 clinical mastitis cows. BHV4
was isolated on bovine umbilical cord endothelial cells from the same 3 milk samples, whereas no
BHV4 was detected by gB-PCR and virus isolation from their matched controlcows. One of the cows,
from which BHV4 was isolated, developed antibodies against BHV4 concomitant with the BHV4
infection, whereas no increase in BHV4 antibodies was detectable in the second cow within 21 days.
No BHV4 antibodies were detected in both matched control cows. Staphylococcus aureus and a few
colonies of Staphylococcus sp. were isolated from 2 out of 3 milk samples from which BHV4 was
isolated, whereas only BHV4 was isolated from the third milk sample (day 21). The somatic cell count
of this latter milk sample was 305.000 cells/ml.
This study confirmed the finding that BHV4 may play a role in the aetiology of bovine mastitis,
although, it probably does not play an important role as primary agent in the aetiology of bovine
clinical mastitis.
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1. Introduction
Bovine herpesvirus 4 (BHV4), a member of the subfamily of the Gammaherpesvirinae, has been
isolated from cows with various clinical signs, but also from apparently healthy cows (Thiry et al.,
1989). In a case-control study, BHV4 has been isolated from milk of cows with clinical mastitis, but
not from control cows (Wellenberg et al., 2000). A simultaneous intramammary and intranasal
inoculation of lactating cows with BHV4 resulted in subclinical mastitis in 2 out of 4 inoculated
lactating cows (Wellenberg et al., 2001a). Others, Zadoks et al. (2001), reported a positive association
between the BHV4 seropositivity of cows and the incidence of bovine mastitis caused by
Staphylococcus aureus, which may suggest that a BHV4 infection makes cows more susceptible for
mastitis especially when caused by Staphylococcus aureus. BHV4 has also been isolated from the
cellular fraction of milk from cows with antibodies against BHV4. Unfortunately, no data were
reported whether these milk samples were collected from cows with clinical or subclinical mastitis
(Donofrio et al., 2000).
We performed this second case-control study to get additional insight in the role of BHV4 in the
aetiology of bovine mastitis, and to examine whether results from the first case-control study could be
confirmed.
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2. Materials and methods
2.1 Design of the study and collection of samples
This second case/control study was started in 21 dairy herds with cows that suffered from clinical
mastitis. Clinical mastitis cases were defined as: abnormal morphology of the milk, painful udder,
swelling of the udder, or a combination of these signs. The farmer notified the local veterinarian when
observing these signs. At the first visit, the local veterinarian selected matched control cows in the
same herd that: (a) did not show signs of mastitis; (b) were of the same age; and (c) were in the same
stage of lactation as the mastitis cows. Samples were collected by the veterinarians and veterinary
technicians from dairy cows with clinical mastitis in the acute (day 0) and the convalescent phase of
the disease (day 21). At the same time, milk samples (from the same quarter as the affected quarter of
the corresponding case) were collected from their matched control cows. Milk samples were collected
according to the procedure described by the National Mastitis Council (Harmon et al., 1990).
In this study, from the 21 dairy herds, milk samples were collected from 90 cows with mastitis and
90 controls. Unfortunately, in 36 out of the 90 control cows an increased milk somatic cell counts
(SCC) of ≥250,000 was recorded on day 0 or on day 21, which is an indication of subclinical mastitis
(Dohoo and Leslie, 1991; Smith, 1996). These case-control pairs were not included in this study, and
thus milk from the remaining 54 cases and control cows on 16 herds were used for further
examination (Table 1).
Milk samples for BHV4-gB DNA detection and virus isolation were stored directly at –70 °C,
while milk samples for the screening of bacterial agents were stored at 2-4°C, and cultured within 24
hours. Milk samples used for the detection of SCC were also stored at 2-4°C, and the milk SCC was
determined within 24 hours. Blood samples were obtained from the median sacral vein of the tail, and
centrifuged at 1,500 x g for 10 minutes. Sera were stored at -20°C. After sampling on day 0, cows
with clinical mastitis were treated with antibiotics; the matched controls were not treated.
Convalescent blood and milk samples were taken by the local veterinarians 21 days ± 2 days after the
last antibiotic medication.
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2.2 Detection of BHV4
2.2.1 DNA extraction and BHV4-gB PCR
DNA extractions from defatted milk samples, and from inoculated cell cultures, were performed by
column chromatography using the QIAamp Blood and Tissue kit (QIAGEN, Westburg, The
Netherlands). For DNA extraction of defatted milk samples a total volume of 1000 µl was used per
cow. Prior to DNA extraction, the defatted milk samples were centrifuged at 14,000 rpm for 3 min. A
volume of 800 µl was discarded and the cell pellet was resuspended in the remaining 200 µl. Cell
lysis, digestion with protease, DNA precipitation and elution of DNA were performed according to the
description of the manufacturer. The DNA extraction products were stored at –20 °C. A gB-PCR
assay, which has proven to be a valuable tool in detecting BHV4-gB DNA in milk, was performed on
DNA extractions (Wellenberg et al., 2001b).
2.2.2 Virus isolation
Milk samples were thawed, defatted by centrifugation at 1,500 x g for 10 minutes, and a volume of 0.5
ml of the defatted milk was used for virus isolation. Bovine umbilical cord endothelial (BUE) cells
(Van de Wiel et al., 1989) were used for BHV4 isolation and propagation. BUE cells were grown and
maintained in Dulbecco’s minimal essential medium (DMEM) (Gibco Laboratories, Life
Technologies Inc., USA) supplemented with 10% normal calf serum (Gibco Laboratories, Life
Technologies Inc., USA), and 0.5% antibiotic mix (stock mix contained: 10,000 IU penicillin, 11.25
mg streptomycin, 10 mg kanamycin and 5,000 IU nystatin per ml). Normal bovine calf serum was
shown to be free of BHV4 antibodies. Cells were inoculated with 0.5 ml of defatted milk. Inoculated
cells were washed after an incubation of 1 hour at 37°C, and incubated for 5-7 days at 37°C (5%
CO2). After a freeze/thaw cycle a second passage was performed by inoculatingsemi-permanent BUE
cell cultures with 1 ml freeze/thawed virus/cell suspension. Inoculated cell cultures were incubated
again for 5-7 days at 37°C (5% CO2). During the first and the second passage, cell cultures were
observed for cytopathic effect (cpe). Cell cultures showing cpe were examined for the presence of
virus particles by electron microscopy (EM). The immunoperoxidase monolayer assay(IPMA) and the
gB-PCR were then performed on these cell cultures to identify BHV4. In each cell culture run, 5
controls were incorporated. Three controls, containing 101, 102and 103 TCID50 BHV4/mlmilk, served
as positive controls. A BHV4-free milk sample, and a non-inoculated cell culture, served as negative
controls.
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2.2.3 Electron microscopy
Electron microscopy was performed on BUE cell cultures showing cpe. Therefore, a 400 mesh carbon
coated nickel grid with a collodion film was floated on a drop of the inoculated cell cultures for 5
minutes, drained onto filter paper and stained with 2% phosphotungstic acid (pH 6.8). The grids were
examined by transmission electron microscopy after drying.
2.2.4 Immunoperoxidase monolayer assay
The IPMA, to identify BHV4, was basically performed as described before (Wellenberg et al., 1999).
Briefly, virus infected monolayers of BUE cells were washed with phosphate buffered salt solution,
dried for 45 minutes at 37°C, and fixed with 150 µl of 4% paraformaldehyde. After Triton X-100, and
10% horse serum pre-adsorption treatments, cells were incubated with a monospecific BHV4
antiserum. Plates were washed and incubated with a rabbit anti-bovine immunoglobulin-HRPO
conjugate (Dakopatts, Glostrup, Denmark). After staining with a chromogen/substrate solution
(AEC/H2O2), the results were read by light microscope. BHV4 DN-599 and non-inoculated BUE cells
served as positive and negative controls.
2.3 Somatic cell counts (SCC)
Somatic cells in quarter milk samples were counted by means of a Fossomatic (Foss Electric, Hillerφd,
Denmark). Mastitis was defined as subclinical in cases of quarter milk SCC of ≥250,000 cells/ml
(Dohoo and Leslie, 1991; Smith, 1996), without any visible abnormality of the milk or the udder.
Clinical mastitis cases showed increased milk SCC of ≥250,000 cells/ml and with visible abnormality
of the milk sample or the udder (International Dairy Federation, 1987).
2.4 BHV4 antibody detection
Serum samples were examined for antibodies against BHV4 by IPMA (Wellenberg et al., 1999). Sera
were screened in dilutions of 1:20, 1:40 and 1:200. Serum samples, showing possible increases of
BHV4 antibodies, were further titrated by serial 2-fold dilution steps starting at a dilution of 1:100. A
4-fold (2 dilution steps) higher antibody titre in convalescent serum than in acute serum was defined as
a significant increase.
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2.5 Bacterial analyses
Bacteriological culture of milk samples was performed based on standards of the National Mastitis
Council (Harmon et al., 1990). Briefly, milk samples (0.01 ml) were inoculated on 6% blood agar
plates (both aerobically and an-aerobically), on TCT medium (Thallium sulphate, Crystal Violet,
Staphylococcus β-toxin; Merck) and on MacConkey no. 3 agar (Oxoid, Basingstoke, UK). Plates were
incubated at 37° and bacterial growth was evaluated after 24 and after 48 hours. Bacterial colonies
were identified as described by the National Mastitis Council. A quarter was considered to have an
intramammary infection when ≥500 cfu/ml of minor udder pathogens were cultured from the milk, or
when ≥100 cfu/ml of a major udder pathogen was cultivated from a quarter with clinical signs of
mastitis (Lam et al., 1997; Barkema et al., 1999). If three or more bacterial species were cultivated
from a sample, the sample was considered to be contaminated.
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3. Results
In 3 milk samples, collected from mastitis cows, BHV4 was detected by gB-PCR and by virus
isolation, namely in milk collected on day 0 and in the convalescent milk sample from cow No. 6600,
and in a milk sample from cow No. 2789 on day 21 (Tables 1 and 2).
Table 1. Detection of BHV4 bygB-PCR and virus isolation from milk samples, and BHV4 antibodydetection
in sera from clinical mastitis cases (n=54) and matched control cows (n=54) in 16 herds
Herd Case / BHV4-gB BHV4 BHV4
control PCR isolation antibody
pairs (milk) (milk) at day 0
per herd (M / C)* (M / C) (M / C)
1 1 - ** - - / -
2 4 - - - / -
3 2 - - - / -
4 1 - - - / -
5 4 - - 2 / 2
6 2 - - - / -
7 2 - - - / 2
8 9 - - 3 / 4
9 1 - - - / -
10 6 - - - / -
11 3 - - 1 / 2
12 2 - - - / -
13 6 - - 4 / 4
14 2 1 / - 1 / - 2 / 1
15 2 - - - / 1
16 7 1 / - 1 / - 2 / 2
Totals 54 2 / - 2 / - 14 / 18
*): M = mastitis cows / C = control cows; **): - = Not detected
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The BUE cell cultures inoculated with milk samples from mastitis cows No. 6600, collected on day
21, showed cpe on day 6 post-inoculation (first passage), whereas the BUE cell cultures inoculated
with the other 2 milk samples showed cpe in the second passage. Electron microscopy revealed the
presence of virus particles, possessing the typical herpesvirus morphology, in cell cultures inoculated
with the milk sample of cow No. 6600 (day 21). The presence of BHV4 antigens and viral DNA in
cell cultures, inoculated with the 3 milk samples, was confirmed by IPMA and gB-PCR, respectively.
No BHV4 antigens or BHV4-gB DNA was detected in cell cultures, inoculated with milk from their
matched control cows. In addition, BHV4 was not detected in milk from the other controlcows bygB-
PCR or virus isolation.
BHV4 antibodies were detected in cows from 8 (50%) of the 16 examined herds. Both cows, from
which BHV4 was isolated, had BHV4 antibodies in their first collected blood sample. A significant
increase in BHV4 antibodies was detected in cow No. 2789 (Table 2), and no increase in BHV4
antibody titre was detectable in cow No. 6600 within 21 days. In addition, no BHV4 antibodies were
detected in the 2 corresponding control cows of these 2 mastitis cows (Table 2).
Seroconversion was detected in sera from 2 other control cows. These controlcows did not develop
clinical or subclinical mastitis and their SCC were <250,000 cells/ml (Table 2).
Pathogenic udder bacteria were isolated from 40 (74%) out of 54 milk samples collected from
mastitis cows on day 0 (data not shown). Staphylococcus aureus was isolated from the milk from cow
No. 6600 on day 0 (SCC of >1,000,000 cells/ml), whereas, no bacteria were isolated on day 21 (SCC
of 305,000 cells/ml) (Table 2). A few colonies of Staphylococcus sp. were isolated from the milk of
cow No. 2789 from which BHV4 was isolated too (the SCC was >1,000,000 cells/ml). No bacteria
were isolated from the milk of the matched control cows and the SCC in their milk samples were
<250,000 cells/ml.
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Table 2. Isolation of BHV4 and pathogenic bacteria from milk, antibodydevelopment against BHV4 in serum,
and quarter SCC in milk from clinical mastitis cows and their matched control cows presented on an individual
level
BHV4
Herd Cow Case / Virus Antibody Pathogenic Milk
control isolation development (serum) bacteria in SCC/ml
from milk (acute) (convalescent) milk (day 0) (x 1000)
8 1327 case -* - - - 3781
control - - 200 C. bovis (day 21) 32
14 2789 case - (day 0) 400 3200 S. dysgalactiae >1,000
+ (day 21) Staphylococcus sp. >1,000
(a few colonies)
control - - - - 203
15 1120 case - - - S. aureus 4990
control - - 200 S. aureus 4
16 6600 case + (day 0) 800 800 S. aureus >1,000
+ (day 21) - 305
control - - - - 3
* - Not detected
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4. Discussion
In this second case-control study, which was performed on other farms, in another region of the
Netherlands and 3-4 years later than the first case-control study, BHV4 was detected in milk from 2
(4%) out of 54 cows with clinical mastitis, and not from control cows. This finding agrees with one of
the findings of a previous study in which BHV4 was isolated from milk of 3 (5%) out of 58 cows with
clinical mastitis (Wellenberg et al., 2000). In addition, BHV4-gB DNA was detected in 4 (8%) out of
48 mastitis cows from the same case-control study (Wellenberg et al., 2001b).
Concomitant with the isolation of BHV4, an increase in BHV4 antibodies was detected in 1 of the 2
clinical mastitis cows. In the first case-control study, an increase of BHV4 antibodies was detected in 2
out of 3 clinical mastitis cows, from which BHV4 was isolated from the milk. These data support the
finding that there was an ongoing BHV4 infection at the same time as clinical mastitis occurred. On
the other hand, an increase of BHV4 antibodies was not only detected in 1 (2%) of the mastitis cows,
but also in 2 (4%) control cows without clinical or subclinical mastitis. This is in contrast to data
obtained from the first case-control study, in which more mastitis cows developed BHV4 antibodies
(16%) than controls (10%). Based on data of the first study, we concluded that the relatively high
percentage of controls, that developed BHV4 antibodies, might partially be explained by the fact that
some control cows developed subclinical mastitis, as the quarter milk SCC was not determined during
that study. However, the controls in the second case-control study, which developed antibodies against
BHV4, did not develop mastitis and their milk SCC stayed <250,000 cells/ml. This confirms that dairy
cows can undergo a BHV4 infection that is not associated with mastitis as was also evident from the
literature (Thiry et al., 1989; Egyed, 2000).
Another finding in the first case-control study that supported a possible role of BHV4 in bovine
clinical mastitis was that in 9 (90%) of the 10 herds studied, antibodies against BHV4 were prevalent,
whereas, only 57% of 30 randomly chosen Dutch herds had antibodies against BHV4 (Wellenberg et
al., 1999). In this study, in only 8 (50%) of the 16 examined herds antibodies against BHV4 were
detected. However, the number of BHV4 positive herds might have been higher in case more than 1 or
2 cows within one herd were examined for antibodies against BHV4 as was the case in 9 examined
herds.
In the first case-control study, BHV4 was isolated from milk in combination with known udder
pathogens, such as Streptococcus uberis and Escherichia coli. In the present study, in two of the three
cases BHV4 was accompanied again by bacteria, although other bacteria than noted in the first case-
control study. BHV4 was isolated from milk from cow No. 2789 (day 21) in combination with a few
colonies of Staphylococcus sp. (however no Staphylococcus aureus), and from milk of cow No. 6600
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in combination with the known udder pathogen Staphylococcus aureus (day 0). The presence of
known bacterial udder pathogens, besides the presence of BHV4 in milk, makes it even more difficult
to understand which primary role BHV4 plays in the aetiology of bovine clinical mastitis. In only one
occasion, BHV4 was isolated from milk (cow No. 6600; day 21) while no udder pathogens were
detected, and the quarter milk SCC was still increased (305,000 cells/ml).
In conclusion; both case-control studies, in which BHV4 and/or BHV4-gB DNA were detected in
milk of 4.5% of the 112 examined mastitis cows and never in milk from matched control cows,
support the hypothesis that BHV4 may play a role in the aetiology of bovine mastitis. Based on data
found in the 2 case-control studies and the experimental infection (Wellenberg et al., 2001a), we may
conclude that this agent does not play an important role as primary agent in the aetiology of bovine
clinical mastitis, although it could be involved in subclinical mastitis cases. The data of an
epidemiological study indicate that BHV4 may also play an indirect role in the aetiology of bovine
mastitis, because BHV4 seropositive cows have a higher susceptibility for mastitis especially when
caused by Staphylococcus aureus (Zadoks et al., 2001).
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Abstract
In this study we examined whether an experimental bovine herpesvirus 4 (BHV4) infection can induce
bovine mastitis, or can enhance bovine mastitis induced by Streptococcus uberis (S. uberis). Four
lactating cows were inoculated intramammarily and intranasallywith BHV4, and four lactatingcontrol
cows were mock-inoculated. After 14 days two of four cows from each group were inoculated
intramammarily with S. uberis. No clinical signs were recorded in cows inoculated only with BHV4,
and their milk samples showed no abnormal morphology, despite the fact that BHV4 replicated in
inoculated quarters. Somatic cell count increased significantly in milk from 3 of 6 BHV4 inoculated
quarters, compared to the non-inoculated quarters of the same cows (within-cow) and the quarters of
mock-inoculated cows (control group) on days 8, 9 and 11 post-inoculation (pi). BHV4 was isolated
from nasal swabs between days 2 and 9 post-inoculation (pi). Clinical mastitis was observed in all four
cows intramammarily inoculated with S. uberis. A preceding BHV4 infection did not exacerbate the
clinical mastitis induced by S. uberis. Streptococcus uberis infections appeared to trigger BHV4
replication. From one quarter of each of two cows inoculated with BHV4 and S. uberis, BHV4 was
isolated, and not from quarters inoculated with BHV4 only.
In conclusion, BHV4 did not induce bovine clinical mastitis after simultaneous intranasal and
intramammary inoculation. However, the BHV4 infection did induce subclinical mastitis in 50% of
the cows and the quarters.
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1. Introduction
Mastitis is a disease with large economic impact on dairy cattle industry (Miller and Dorn, 1990;
Schakenraad and Dijkhuizen, 1991). Bacteria and non-bacterial pathogens play a role in clinical
mastitis (Radostits et al., 1994; Watts, 1998). Despite intensive implementation of control programs,
still around 20-35% of clinical cases of bovine mastitis have an unknown etiology (Miltenburg et al.,
1996). The percentage of bacteriological culture-negative milk samples of both clinicaland subclinical
mastitis cases is still approximately 25% (Barkema et al., 1998). Recently, in a case-control study,
bovine herpesvirus 4 (BHV4) was isolated from milk samples collected from cows with clinical
mastitis, whereas no virus was isolated from matched controls (Wellenberg et al., 2000). Concomitant
development of BHV4 antibodies in cows supported the hypothesis that BHV4 may play a role in
mastitis in dairy cows. In the same study, a positive association was found between BHV4 isolation
and the isolation of S. uberis from milk samples.
This study was performed to examine whether: a) mastitis was induced after a simultaneous
intramammary and intranasal inoculation of lactating cows with BHV4; b) a preceding BHV4
infection exacerbated clinical mastitis induced by S. uberis; and c) a S. uberis infection triggered the
replication of BHV4.
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2. Materials and methods
2.1 Cell culture, virus and bacteria
A pestivirus-free and mycoplasma-free bovine umbilical cord endothelial (BUE) cell line was used for
virus isolation and multiplication (Van de Wiel et al., 1989). BUE cells were grown and maintained in
Dulbecco’s minimal essential medium (DMEM) (Gibco Laboratories, Life Technologies Inc., USA)
supplemented with 10% foetal bovine serum (Gibco Laboratories, Life Technologies Inc., USA), and
0.5% antibiotic mix (stock mix contained: 10,000 IU penicillin, 11.25 mg streptomycin, 10 mg
kanamycin and 5,000 IU nystatin per ml). The BHV4 strain Tolakker, which has been isolated from a
cow with clinical mastitis, was used for inoculation (Wellenberg et al., 2000). After isolation, this virus
was passaged once in BUE cells to obtain a virus stock. The stock virus batch, used for animal
inoculation, contained 107.3 median tissue culture infective doses (TCID50)/ml of BHV4 strain
Tolakker, and was free of other herpesviruses, pestiviruses, mycoplasmas, and bacteria. Streptococcus
uberis strain O140J has originally been isolated from a cow with mastitis, and was kindly provided by
P. Milner (Milner et al., 1996). Prior to inoculation, the S. uberis strain O140J was cultivated in Todd-
Hewitt broth for 24 hours at 37°C, and was found to be pure.
2.2 Animals and experimental design
Eight cows were selected from three different farms two weeks before the start of the study. Inclusion
criteria for selection were: a) no clinical or subclinical mastitis, (b) the same parity (first or second
parity), c) no history of Streptococcus (uberis) infections, d) first half of lactation, and e) no treatment
with antibiotics during the last month. In addition, milk samples from each udder quarter and blood
samples were collected from these eight cows to examine whether: (a) these cows contained no
antibodies against BHV4, (b) milk samples of the four quarters were free of udder pathogens, and c)
cows were BVDV-free. The eight cows were randomly allotted to a BHV4 and a control group. The
BHV4 and the control group were housed in two separate isolation units, and cows were tied
individually. Hygienic rules were strictly followed to prevent transmission of viruses and bacteria
between the two groups and from one cow to another. The four cows of the BHV4 group (B1, B2, B3
and B4) were inoculated intramammarily into the right forequarter (RF), and left hindquarter (LH)
with 107.3 TCID50 of the BHV4 strain Tolakker diluted in 20 ml of buffered phosphate salt solution
(PBS) per quarter (Table 1). The other two quarters (right hindquarter (RH), and left forequarter (LF))
were not inoculated and served as within-cow control quarters. Prior to each intramammary
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inoculation via the teat channel, teats were disinfected with alcohol. After each inoculation, using a
syringe with a short blunt ended needle, the udder was massaged to distribute the inoculum. The four
cows of the BHV4 group were also intranasally inoculated with one ml containing 107.3 TCID50 of
BHV4 per nostril, using a nozzle attached to a syringe to produce a spray. Cows of the control group
(C1, C2, C3, and C4) were mock-inoculated into the same two quarters as described above for the
BHV4 group with 20 ml BHV4-free BUE cell culture medium. The cows of the control group were
also intranasally inoculated as described for the BHV4 group with BHV4-free BUE cell culture
medium.
Fourteen days after the BHV4 inoculation, the RF and LH quarters of cows B1 and B4 from the
BHV4 group, and of cows C1 and C2 from the control group, were inoculated intramammarily with
800 colony-forming-units (cfu) of S. uberis strain O140J in 20 ml of PBS. Prior to inoculation, teats
were disinfected with alcohol and after inoculation the udder was massaged to distribute the
bacterium. All inoculations were performed after the morning milking between 10.00 and 12.00 a.m.
The cows were milked twice daily using a quarter milking device. During this study, cows were not
treated with antibiotics, except cow C4 that was treated with Duoprim (intramuscularly) and
Delvomast (LH) daily on days 9 – 17 pi.
Table 1. Inoculation scheme of cows inoculated with BHV4, BUE cell culture, or Streptococcus uberis.
Intranasally Intramammarily into quarters RF and LH with:
Cow BHV4 BUE* BHV4 BUE* S. uberis
(day 0) (day 0) (day 0) (day 0) (day 14)
B1 + -** + - +
B2 + - + - -
B3 + - + - -
B4 + - + - +
C1 - + - + +
C2 - + - + +
C3 - + - + -
C4 - + - + -
BUE*: BUE cell culture; -**: not inoculated
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2.3 Collection of samples
A volume of 50 ml of milk from each quarter of each cow was collected daily just before the a.m.
milking of the cows. Milk samples were collected according to the procedure described by the
National Mastitis Council (Harmon et al., 1990), and transported immediately to the laboratory,
homogenised and divided for storage. Milk samples for virus isolation were directly stored at –70°C.
Milk samples used for the determination of somatic cell counts (SCC), bacterial isolation, and
antibody detection, were immediately stored at –20°C. Weekly, blood samples were obtained from the
vena jugularis, centrifuged at 2000 x g for 10 minutes, and sera were stored at –20°C. Daily, blood
samples were collected in tubes containing EDTA starting on day –2 till day 28 pi for white blood cell
counts and for blood cell differentiation.
Daily, nasal swabs for BHV4 isolation and titration were collected, processed and stored directlyat
–70°C, as described by Kaashoek et al. (1994). All collected milk, nasal secretions, and serum samples
were stored in duplicate.
2.4 Clinical signs and morphology of the milk
Clinical signs and rectal temperatures were recorded daily in the morning. Udders were palpated for
signs of infection (swollen or painful). The morphology of the milk samples was examined daily.
Therefore, the first streams of milk secretion were discarded, and the foremilkwas checked for colour,
clots, and morphology.
2.5 Assays of samples
2.5.1 Somatic cell count (SCC)
Somatic cells in daily quarter milk samples were counted by means of a Fossomatic (Foss Electric,
Hillerφd, Denmark). Subclinical mastitis was defined high quarter milk SCC of ≥250,000 cells/ml
(Dohoo and Leslie, 1991; Smith, 1996), without any visible abnormality of the milk or the udder
(International Dairy Federation, 1987).
2.5.2 White blood cell counts and differentiation
The white blood cell (WBC) counts were determined using an automated cell counter (Sysmex F-800,
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Charles Goffin, The Netherlands). Each day, thin blood films were prepared from venous blood
collected in tubes containing EDTA. The slides were stained by using the May-Grunwald-Giemsa
staining method (Merck KGaA, Darmstadt, Germany), and the WBC were differentiated by typing
100 cells.
2.5.3 BHV4 isolation
In order to isolate virus, milk samples were thawed and defatted by centrifugation at 1500 x g for 10
minutes. A volume of 0.2 ml of the defatted milk was added to 0.3 ml of DMEM and pipetted on a
semi-confluent monolayer of BUE cells in 24-wells cell culture plates. Virus isolation was further
performed as described earlier (Wellenberg et al., 2000). Cell cultures were observed daily for
cytopathic effect (cpe). After a freeze/thaw cycle, a second passage was performed by inoculating the
virus/cell suspensions on semi-confluent monolayers of BUE cells. BUE cell cultures were incubated
again for 7 days at 37°C (5% CO2). In each test run, 5 controls were incorporated. Three controls,
containing 10, 100 and 1000 TCID50 BHV4/ml milk, served as positive controls. A BHV4-free milk
sample and a non-inoculated BUE cell culture control, served as negative controls.
The BHV4 titre was determined in milk samples from two arbitrarily chosen cows B1 (RF) and B3
(LH) on days 1, 3, 5, 7, 9 and 10 or 11 pi, and in BHV4 positive milk samples obtained after S. uberis
inoculation (Table 2). Virus titration was performed by preparing serial ten-fold dilution steps in
DMEM (10-1 – 10-8). A volume of 200 µl of each dilution, plus 300 µl of DMEM, was inoculated in
12-fold on BUE cells cultivated in 24-wells cell culture plates. Plates were incubated as described
above. After a freeze/thaw cycle, a second passage on BUE cells was performed, and cells were
examined for the appearance of cpe after an incubation period of 7 days at 37°C (5% CO2).
Isolation and titration of BHV4 from nasal secretions was performed on BUE cells using 96-wells cell
culture plates. For BHV4 isolation, BUE cells in suspensions of 150 µl were inoculated with 50 µl of
thawed nasal swab suspension and cells were examined for cpe after an incubation for 7 days at 37°C
(5% CO2). For virus titration, serial ten-fold dilutions of nasal swab suspensions were prepared in
DMEM (100 – 10-4). Each dilution was inoculated in 8-fold on BUE cells as described above and
incubated at 37°C (5% CO2). Plates for virus titration were examined after 7 days for the appearance
of cpe. In each virus titration assay, the endpoint titres were expressed as log10 TCID50/ml byusing the
method of Reed and Muench.
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2.5.4 BHV4 antibodies
Serum and pooled milk samples from all four quarters, in dilutions of 1:20 and 1:5, respectively, were
screened for antibodies against BHV4 by immunoperoxidase monolayer assay(IPMA) (Wellenberget
al., 1999). Samples, containing antibodies against BHV4, were titrated in serial twofold dilutions,
starting at a dilution of 1:20 (serum) or 1:5 (milk). The titre of the test sample was taken as the
reciprocal of the highest dilution giving a positive reaction.
2.5.5 Bacterial isolation
Bacteriological culturing of milk samples was performed based on standards of the IDF (International
Dairy Federation, 1984). Briefly, milk samples (0.025 ml) were inoculated on Oxiod Blood Agar Base
No 2, containing 5% blood and 0.1% aesculin. Plates were incubated at 37°C, and bacterial growth
was evaluated after 24 and after 48 hours. Bacterial colonies were identified, and bacteria were
considered to be pathogenic or non-pathogenic. A quarter was considered to have an intramammary
infection when ≥500 cfu/ml of the same udder pathogen was cultured from two out of three
consecutive milk samples, or when ≥100 cfu/ml of a bacterial species was cultivated from a quarter
with clinical signs of mastitis (Barkema et al., 1999). If three or more bacterial species were cultivated
from a sample, the sample was considered to be contaminated.
2.6 Statistical analysis
To approximate the normal distribution, a natural logarithmic transformation of the SCC was used
(Shook, 1982). Statistical analysis was used to compare the natural logarithm of SCC between quarters
inoculated with BHV4, control quarters of the same cow of the BHV4 group (within-cow controls),
quarters of the control cows inoculated with BUE cell culture, and quarters of the control cows that
were not inoculated. The following linear mixed model was used:
Yi, j, k(i, j) = m + Ci + CQi, j + tk(i, j) + ei, j, k(i, j)
where Yi, j, k(i, j) is the average natural logarithm of SCC of quarter j (j=1…4) of cow i (i=1…8) under
the assigned treatment k; m is the overall mean; Ci is the random effect of cow i; CQi, j is the random
effect of quarter j within cow i; tk(i, j) is the fixed effect of the treatment k and finally ei, j, k(i, j) is residual
error. The treatment effect has a factorial structure, since it consists of combinations of an
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intramammary inoculation (“+” or “-“) and inoculum (BHV4 or BUE cell culture). Estimation of the
parameters in the model is done by restricted maximum likelihood (REML) and the Wald-test is
applied to assess significance of effects. All statistical calculations were performed with Genstat
(1993). Statistical significance was declared at p < 0.05.
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3. Results
3.1 Clinical signs
3.1.1 Days 0-14 pi
Within the period of 0 – 14 days pi, clinical signs of mastitis or rectal temperatures >39.5°C were
recorded neither in the four cows of the BHV4 group nor in cows C1 and C2 of the control group. No
changes in udder health or morphology of the milk, collected from BHV4-inoculated quarters, BUE
cell culture inoculated quarters, and non-inoculated quarters were recorded in these six cows.
Cow C4 of the control group showed an increase in rectal temperatures (> 39.5°C) for 6 days, starting
at day 9 pi. Swelling of the udder, and changes in the morphology of the milk from all four quarters
from cow C4 were recorded starting at day 9 pi. This was also observed for the LF quarter from cow
C3 starting on day 2 pi. No clinical signs or increase of rectal temperature were further recorded for
cow C3, and no changes in the morphology of the milk, collected from the three remaining quarters
were recorded. Gram negative bacteria (Klebsiella sp.) were isolated from the milk of these clinical
mastitis cases. Therefore, all data of all four quarters from cow C4, that were obtained after day 8 pi,
and all data of the LF quarter from control cow C3 were excluded from statistical analysis.
3.1.2 Days 15-28 pi
After the intramammary inoculation of cows B1 and B4 (BHV4 group) and C1 and C2 (controlgroup)
with S. uberis on day 14 pi, increased rectal temperatures (> 39.5°C) were recorded for all four cows
starting between days 16 and 19 pi. Thereafter, rectal temperatures varied between 38.2 and 41.6°C
(Table 2). The morphology of the milk from S. uberis inoculated quarters altered and clots were
observed initially between days 15 and 20 pi. Changes in the morphology of the milk, in combination
with painful and swollen quarters, were recorded for all S. uberis inoculated quarters up to day 28 pi.
No changes in the morphology were observed in milk from non-S. uberis inoculated quarters of these
four cows. There were no marked differences in rectal temperatures or the morphology of the milk
from quarters inoculated with BHV4 and S. uberis (cows B1 and B4) compared to those of the two
cows that were inoculated with S. uberis only (C1 and C2) (Table 2).
Between days 15 - 28 pi., cows B2 and B3 (cows from the BHV4 group but not inoculated
intramammarily with S. uberis) and control cow C3 (except for quarter LF) showed no clinical signs,
increase of rectal temperatures, painful or swollen udders or any changes in the morphology of the
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milk.
3.2 Somatic cell count
3.2.1 Days 0-14 pi
Prior to the inoculation of BHV4, SCC in milk from two quarters (LH from cow B1 and RF from B4)
was >250,000 cells/ml, and therefore, SCC of these two quarters was not used for statistical analysis.
In 3 of the 6 remaining BHV4 inoculated quarters, the SCC in milk increased above 250,000 cells/ml
(cows B3 (RF and LH) and B4 (LH)), and reached levels up to 981,000 cells/ml. No increased SCC
was recorded in the quarters of cows B1 (RF) and B2 (RF and LH). An increase in SCC was recorded
between days 6 - 14 pi (Figure 1).
Fig 1. Mean SCC in milk from BHV4 inoculated quarters (n = 6), non-BHV4 inoculated quarters (within cow-
controls) (n = 8), BUE cell culture inoculated quarters (n = 6, plus data from cow C4 up to day9 pi), and non-
inoculated quarters (n = 5, plus data from cow C4 up to day 9 pi). SCC in milk from quarters inoculated with
BHV4 were significantlyhigher than the SCC in milk from the other quarters on day8, 9 and 11 pi (*: p <0.1,
**: p < 0.05, and ***: p < 0.01)
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No SCC >250,000 cells/ml was recorded in milk samples collected from the eight non-BHV4
inoculated quarters of four cows of the BHV4 group (within-cow controls), from the two quarters (RF
and LH) from cows C1, C2, C3 and C4 (up to day 9 pi) of the control group that were inoculated with
BUE cell culture suspension, and from the two non-inoculated quarters of these four cows of the
control group (except for the LF quarter of cow C3 as indicated in paragraph 3.1). In only one
occasion, day 12 pi, SCC in milk from quarter LH from cow C1 was >250,000 cells/ml (360,000
cells/ml).
Table 2. Rectal temperatures, morphology of the milk, SCC and peripheral WBC from cows inoculated
intramammarily with S. uberis, preceded by a BHV4 infection (day 0), or with S. uberis only (day 14 pi).
Response of (BHV4 +) S. uberis S. uberis
infected cows
Cow: B1 B4 C1 C2
Rectal temperature
First day temperature >39.5°C 5* 5 4 2
No of days >39.5°C (n = …) 4* 4 7 5
Morphology of the milk
First day clots in the milk 1 5 3 2
No days of abnormal milk (n =…) 13 6 12 12
Somatic cell counts
First day of >250.000/ml 2 2 2 2
No days >250.000/ml (n = …) 12 13 13 13
Peripheral WBC
First day of changes in WBC count 4 5 3 5
No days that the amount of
band form neutrophils >2 (n = …) 6 1 6 3
*: days after S. uberis inoculation (S. uberis inoculated on day 14 pi).
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On days 8, 9 and 11 pi, SCC in milk from quarters inoculated with BHV4 was significantly higher
than: a) SCC in milk from the non-BHV4 inoculated quarters from the same cows (within-cow
controls); b) SCC in milk from quarters inoculated with BUE cell culture (control group), and; c) SCC
in milk from non-inoculated quarters of the control group (Figure 1). The differences between the SCC
in milk from; a) the non-BHV4 inoculated quarters from cows of the BHV4 group; b) the quarters
inoculated with BUE cell culture (control group); and c) the non-inoculated quarters of the control
group, were not significant.
3.2.2 Days 15-28 pi.
The SCC in milk from the RF and LH quarters from cows C1, C2, B1 (RF), and B4 (LH) that were
inoculated with S. uberis on day 14 pi (n=6), started to increase above 250,000 cells/ml around day16
pi (Table 2), and reached levels above 1,000,000 cells/ml. The morphology of the milk changed
between days 15 and 20 pi (Table 2). The SCC in milk from the two non-S. uberis inoculated quarters
LF and RH of the same four cows (n = 8) stayed below 250,000 cells/ml. In only two occasions, the
SCC increased above 250,000 cells/ml, namely, for the non-inoculated LF quarter of cow B4 on days
23 and 24 pi (341,000 and 376,000 cells/ml, respectively). However, no BHV4, S. uberis or other
bacteria were isolated from the milk of this quarter.
3.3 WBC counts and differentiation of WBC
No effects on WBC counts were recorded in blood from the four cows inoculated with BHV4 and the
control cows C1 and C2 up to day 14 pi, and no shift was recorded in the peripheral differential WBC
of these cows. WBC counts started to decrease between days 17 - 19 pi, 3 – 5 days after the
inoculation with S. uberis, and WBC counts of 1.3 – 2.4 x 109/l were recorded in all four cows
between days 19 – 22 pi. In blood smears of all four cows that were inoculated with S. uberis, a shift
in the peripheral differential WBC was detectable. An increase of band form neutrophils, up to10% of
the WBC, was recorded in blood smears. In all four cows the WBC counts started to increase again to
normal values (5 – 10 x 109/l) after day 22 pi. No differences in WBC counts, or in the number of
band form neutrophils in blood smears were recorded in cows B1 and B4 compared to those in the two
cows that were inoculated with S. uberis only (C1 and C2) (Table 2). No effects on WBC counts were
recorded in blood from cows B2 and B3 of the BHV4 group, which were not inoculated with S.
uberis, and no shift was recorded in the peripheral differential WBC of these cows up to day 28 pi.
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3.4 BHV4 isolation.
BHV4 was isolated from all eight BHV4 inoculated quarters (RF and LH) from day 1 pi up to days 9 -
14 pi, and the titres in milk samples from cows B1 and B3 varied between 101.3 and 102.9
TCID50/ml (Table 3). BHV4 was isolated neither from milk samples from the two non-inoculated
quarters RH and LF of these cows (within-cow controls), nor from all four quarters from the cows of
the control group. After the intramammary inoculation with S. uberis, BHV4 was isolated from milk
collected from the RF quarter from cows B1 and B4 on several days between days 22 and 27 pi;
BHV4 titres varied between 101.2 and 103.1 TCID50/ml (Table 3). BHV4 was not isolated from milk
samples from cows B2 and B3 that were inoculated intramammarily with BHV4, but not with S.
uberis.
BHV4 was isolated from nasal swabs from all four cows of the BHV4 group between days 2 and 9
pi. The peak titres varied between 102.9 and 103.9 TCID50/ml (Figure 2). No BHV4 was isolated from
nasal swabs after the intramammary S. uberis inoculation.
Fig 2. BHV4 titres in nasal secretions from cows intranasally inoculated with BHV4.
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Table 3. Isolation of BHV4 from milk and BHV4 titres in milk from cows inoculated with BHV4.
Days pi. BHV4 isolation (log10 TCID50/ml)
Cow: B1 B2 B3 B4
RF LH RF LH RF LH RF LH
0 -* - - -
1 + (2.1)** + + + + + (1.8) + +
2 + + + + + + + +
3 + (1.4) + + + + + (2.4) + +
4 + + + + + + + +
5 + (1.4) + + + + + (2.0) + +
6 + + + + + + + +
7 + (1.8) + + + + + (2.9) + +
8 + + + + + + + +
9 + (1.6) + + + + + (1.5) + +
10 + (1.3) - + + + + + -
11 - - + + + + (1.3) + -
12 - - + + + + - -
13 - - + + + - - -
14 - - + - - - + -
15 - - - - - - - -
16 - 19 - - - - - - - -
20 - - - - - - - -
21 - - - - - - - -
22 + (1.2) - - - - - - -
23 + (2.3) - - - - - - -
24 + (3.1) - - - - - - -
25 + (3.0) - - - - - - -
26 + (2.4) - - - - - + (1.3) -
27 - - - - - - + (1.9) -
28 - - - - - - - -
-
* : no BHV4 isolated
( ) ** : BHV4 titre
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3.5 BHV4 antibody responses
In all four cows of the BHV4 group, serum antibodies against BHV4 were first detected on day 14 pi
(Table 4), and reached levels between 320 and 2560 on day 28 pi. In milk samples of the four cows of
the BHV4 group, antibodies against BHV4 were detectable around day 12 pi, and BHV4 antibody
titres increased up to 160. In sera and milk samples of the four cows of the control group no BHV4
antibodies were detected.
Table 4. BHV4 antibody titres in serum and milk from cows inoculated intramammarilyand intranasallywith
BHV4
Days pi. BHV4 antibody titres
Cow: B1 B2 B3 B4
serum milk serum milk serum milk serum milk
0 < 20 < 5 < 20 < 5 < 20 < 5 < 20 < 5
7 < 20 < 5 < 20 < 5 < 20 < 5 < 20 < 5
10 -* < 5 - < 5 - < 5 - < 5
12 - < 5 - 20 - 10 - 10
14 40 5 80 40 40 20 20 20
16 - 20 - 80 - 80 - 20
18 - 20 - 80 - 80 - 20
20 - 20 - 80 - 160 - 20
21 80 - 320 - 320 - 80 -
22 - 20 - 80 - 160 - 80
24 - 40 - 80 - 80 - 160
26 - 80 - 80 - 160 - 160
28 320 160 1280 80 2560 160 320 160
-
*: not determined
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3.6 Isolation of bacteria on days 0-14 pi
No pathogenic bacteria were isolated from milk samples collected from the quarters of the four cows
of the BHV4 group, from the control cows C1, C2, from the remaining quarters RF, RH and LH from
control cow C3, and from the four quarters of control cow C4 up to day 9 pi.
3.6.1 Isolation of bacteria on days 15-28 pi
Streptococcus uberis was isolated from all inoculated quarters of cows C1, C2, B1, and B4 (LH;
intermittent) (Table 2), whereas no S. uberis was isolated from the non-S. uberis inoculated quarters of
these cows. No pathogenic bacteria were isolated from the quarters of cows B2 and B3 that were
inoculated with BHV4 only (day 0), or from the remaining quarters RF, RH and LH from controlcow
C3.
Chapter 7
120
4. Discussion
In this study, a simultaneous intramammary and intranasal inoculation of lactating cows with BHV4
did not lead to clinical mastitis. However, subclinical mastitis was induced, as evidenced by BHV4
replication in all BHV4-inoculated quarters, by the increased SCC of≥250,000/ml in 2 of 4 cows and
in 3 of 6 BHV4-inoculated quarters, and by the absence of such an increase in SCC in controls.
General phenomena, such as differences in susceptibility or genetic background of individual cows,
might explain why the BHV4 infection induced an increase of SCC in only 50% of the inoculated
quarters. The increase in SCC in BHV4 inoculated quarters was not the result of an intramammary
infection by bacteria, as evidenced by the absence of udder pathogens in milk during the first 14 days
pi.
We have chosen to use two routes of inoculation to enhance the possibility of inducing clinical
mastitis. However, a disadvantage of this approach is that a possible interference of the BHV4
infection, that was induced after the intranasal inoculation, on the intramammary BHV4 infection
cannot be excluded. But, based on the facts that: 1) BHV4 was only isolated from the inoculated
quarters and not from the non-inoculated quarters of the same cows; and 2) an increase in SCC was
only detected in milk from BHV4 inoculated quarters, it is likely that the induced subclinical mastitis
was primarily the result of the intramammary BHV4 infection.
The SCC is an indicator of subclinical mastitis, and the major factor affecting SCC is infection of the
mammary gland (International Dairy Federation, 1987; Dohoo and Leslie, 1991; Harmon, 1994).
Inflammation of the mammary gland by udder pathogens often results in an increase of SCC >106 /ml
within 1 or 2 days post-infection (Paape et al., 1981), as was the case in all four cows intramammarily
inoculated with S. uberis. However, the SCC in milk from the BHV4 inoculated quarters did not
increase before day 6 pi. The reason for this difference in increase in SCC may be that different
defence mechanisms are involved in bacterial and viral infections of the mammary gland. In bacterial
udder infections, innate immunity, also known as non-specific responsiveness, is the predominant
defense during the early stages of infection (Harmon, 1994; Sordillo et al., 1997). In the earlystages of
infection, neutrophils, and the migration of neutrophils from the blood into the udder, which occurs by
chemotaxis, play a major role in host defence against environmental (coliform) mastitis in cows
(Kremer et al., 1990). We may speculate that the increase of SCC in milk from BHV4 inoculated
quarters was the result of cytotoxic responses against BHV4 infected cells mediated by other defense
mechanisms, i.e. the occurrence of the late cytokine cascade (including the production of interferon-γ),
the development of cell-mediated immunity and the more specific antibody dependent cell-mediated
cytotoxicity (ADCC), as reported for BHV1 (Rouse et al., 1976; Campos et al., 1994). Interferon-γ
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plays an important role in the generation of non-MHC-restricted cytotoxic reponses (Campos et al.,
1989), and it can activate macrophages to kill virus infected cells, as reported for BHV1 (Babiuket al.,
1996). The peak activities of these cell-mediated immune responses occurred 7-10 days pi (Campos et
al., 1994).
Unlike BHV4, experimental intramammary inoculation of bovine herpesvirus 1 (Greig and
Bannister, 1965; Corner et al., 1967; Straub and Kielwein, 1966), foot-and-mouth disease virus
(Burrows et al., 1971; Blackwell and Yilma, 1981), and parainfluenza 3 virus (Kawakami et al., 1966)
have been found to induce clinical mastitis. Increased temperatures, swollen udders, and changes in
the morphology of the milk were reported for all three virus infections. In addition, an increase of SCC
was recorded after the BHV1 and PI3 inoculation, and an intramammary inoculation with BHV1 and
foot-and-mouth disease virus also resulted in reduced milk yields.
For cases of subclinical mastitis, bovine leukaemia virus has been detected in mammary tissue of
affected cows (Yoshikawa et al., 1997). But, there is no clear evidence that this virus plays a role in the
aetiology of bovine subclinical mastitis, and no experimental studies have been reported to examine
whether this virus was able to induce bovine subclinical or clinical mastitis. Consequently, to our
knowledge this is the first report on a virus that induces bovine subclinical mastitis after experimental
inoculation.
In the preceding study (Wellenberg et al., 2000), BHV4 was isolated from milk from cows with
clinical mastitis in combination with udder pathogens, especially S. uberis, a major udder pathogen
(Thomas et al., 1994). To study whether BHV4 might play an indirect role in the aetiology of bovine
clinical mastitis, we examined whether a preceding BHV4 infection would exacerbate bovine clinical
mastitis induced by S. uberis. Based on data of clinical signs, morphology of the milk, SCC, and
peripheral WBCs, we conclude that a preceding BHV4 infection did not exacerbate bovine clinical
mastitis induced by S. uberis.
After the S. uberis inoculation, BHV4 was isolated from milk from two of four quarters inoculated
with BHV4 and S. uberis, whereas no BHV4 was isolated from milk from four quarters that were
inoculated with BHV4 only. These data indicate that BHV4 remained present in the infected cow, and
that the S. uberis infection appeared to trigger replication of BHV4. Replication of latent BHV4 from
various tissues has been reported after dexamethasone treatment (Castrucci and others, 1987;
Dubuisson and others, 1989). Whether BHV4 persisted in latent form in cells of the mammary gland
or in peripheral blood leukocytes (Osorio and Reed, 1983; Lopez et al., 1996; Egyed and Bartha,
1998), or as infectious virus in milk cell fractions (Donofrio et al., 2000) was not examined. However,
this study demonstrates for the first time that bacteria, i.e. S. uberis, appear to trigger the replication of
BHV4. Which process triggered BHV4 replication during the S. uberis infection is unknown. In an
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experimental mastitis model, an increase in serum cortisol level has been detected shortly after
Escherichia coli infection (Shuster et al., 1993). An increase of serum cortisol levels or comparable
processes that activate BHV4 replication could be induced in S. uberis mastitis. More research is
warranted to define whether bacterial infections may trigger reactivation of latent BHV4 and which
processes are involved. After the S. uberis inoculation, BHV4 was only detected in milk and not in
nasal secretions. This suggests a local trigger on the replication of BHV4 that did not result in systemic
spread.
In conclusion, this study shows that a simultaneous intramammary and intranasal inoculation of
lactating cows with BHV4 did not induce clinical mastitis, but induced subclinical mastitis. In
addition, no exacerbation of a S. uberis infection by a preceding BHV4 infection was noted, and S.
uberis infections may have triggered BHV4 replication. This study indicates that it is unlikely that
BHV4 is a major clinical mastitis pathogen, but it may play a role in the aetiologyof bovine subclinical
mastitis.
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Abstract
In this study the susceptibility of bovine herpesvirus 4 (BHV4) to various antiviral agents was
evaluated. Brivudin inhibited the replication of BHV4 in bovine umbilical cord endothelialcells with a
50% effective concentration (EC50) value of 0.05 µg/ml. Cidofovir and ganciclovir also inhibited the
replication of BHV4, but with EC50-values of 0.2 – 0.8 µg/ml and 6.3 – 12.5 µg/ml, respectively.
Inhibitory activity on the replication of BHV4 was observed for foscarnet at a concentration of 100
µg/ml, whereas no inhibition of BHV4 replication was noted for acyclovir, adefovir, and penciclovir at
concentrations of ≤100 µg/ml. Brivudin and cidofovir, and to a lesser extent ganciclovir, may have
potential for the treatment of BHV4 infections.
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1. Introduction
Bovine herpesvirus 4 (BHV4), one of the members of the Gammaherpesvirinae subfamily, has been
isolated from cows with various diseases e.g. mammary pustular dermatitis (Reed et al., 1977).
Recently, BHV4 has been isolated from milk samples of cows with clinicalmastitis, and not from milk
samples of control cows (Wellenberg et al., 2000). Following a simultaneous intramammary and
intranasal inoculation of lactating cows with BHV4, replication of BHV4 in the mammary gland and
an increase in milk somatic cell counts were noted (Wellenberg et al., 2001). Zadoks et al. (submitted)
reported an association between BHV4 seropositivity and the occurrence of bovine mastitis caused by
Staphylococcus aureus. These reports suggest that BHV4 plays a role in the aetiology of bovine
mastitis. A compound that would specifically inhibit the replication of BHV4 may have potential for
the treatment of BHV4 infections.
The susceptibility of murine gammaherpesvirus 68 (MHV-68), another member of the subfamily
of the Gammaherpesvirinae, to antiviral agents has been reported by Sunil-Chandra et al. (1994a;
1994b), and Neyts and De Clercq (1998). There have been no reports on the susceptibilityof BHV4 to
antiviral agents. Such knowledge may be of interest for the treatment of BHV4 infections, and also
provide deeper insight into the mode of replication of this virus. Therefore, we examined the
susceptibility of BHV4 to selected compounds with proven anti-herpesvirus activity.
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2. Materials and methods
2.1 Virus and cells
The Dutch BHV4 strain Tolakker has been isolated from a cow with signs of clinical mastitis
(Wellenberg et al., 2000). Bovine umbilical cord endothelial (BUE) cells were used for BHV4
propagation. BUE cells were grown and maintained in Dulbecco’s minimal essential medium
(DMEM) (Gibco Laboratories, Life Technologies Inc., USA) supplemented with 2% foetal bovine
serum (Gibco Laboratories, Life Technologies Inc., USA). The following antiviral agents were used;
penciclovir (PCV), ganciclovir (DHPG), acyclovir (ACV), cidofovir (HPMPC), adefovir (PMEA),
foscarnet (PFA), and brivudin (BVDU). Antiviral activity was studied on semi-confluent monolayers
of BUE cells grown in 96-well cell culture plates (Costar). Cells were inoculated with BHV4 at a
multiplicity of infection (m.o.i.) of 0.1. Following an adsorption period at 37°C for 2 hours, BUE cell
cultures were washed with phosphate buffered saline solution (PBS).
2.2 Antiviral agents
Serial two-fold dilutions of each antiviral agent, ranging from 0,05 µg/ml to 100 µg/ml, were prepared
in Earle’s minimal essential medium (EMEM + 2% normal calf serum) using dummy plates. A
volume of 100 µl of each dilution was added in duplicate to the washed BUE cell cultures, and cell
cultures were incubated at 37°C for 7 days (5% CO2). Each serial dilution of the antiviral agents was
checked for BUE cell toxicity by adding a volume of 100 µl of each dilution (in duplicate) to semi-
confluent monolayers of BUE cells that had not been inoculated with BHV4. For each antiviral agent,
also a cell control and a virus-growth control was incorporated into each cell culture plate. Therefore,
non-infected semi-confluent monolayers of BUE cells, with the addition of 100 µl EMEM (+ 2%
normal calf serum), but without the antiviral agents, were used as cell control. Semi-confluent
monolayers of BUE cells that were infected with BHV4 (m.o.i. = 0.1) were used as virus-growth
control. The virus-growth control was incubated and washed as described above. After the wash
procedure 100 µl EMEM (+ 2% normal calf serum), but without the antiviral agents, was added to the
wells. BUE cell toxicity, cell and virus-growth controls, were incubated for 7 days at 37°C (5% CO2).
The appearance and degree of cytopathic effects (cpe) in each well was recorded microscopically at
day 7 post-infection. The EC50-value was calculated on the concentration that inhibited virus-induced
cpe formation by 50%, and the complete inhibition (CI) of BHV4 replication was recorded in case no
cpe was observed.
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3. Results and discussion
The in vitro activities of the selected antiviral agents on the replication of BHV4 in BUE cell cultures
are presented in Table 1. Complete inhibition of virus-induced cpe formation was observed in BHV4
infected BUE cells treated with BVDU at concentrations of ≥0.05 µg/ml (EC50-value: 0.05 µg/ml),
with HPMPC at concentrations of ≥1.6 – 3.2 µg/ml (EC50-values: 0.2 – 0.8 µg/ml), and with DHPG at
concentrations of ≥25 µg/ml (EC50-values: 6.3 – 12.5 µg/ml). A limited inhibition of virus-induced cpe
formation was observed in BHV4 infected BUE cells treated with PFA at a concentration of 100
µg/ml, and no inhibition was observed with ACV, PMEA or PCV. Complete destruction of the BUE
cell monolayers (100% cpe) was observed in all wells used for virus-growth control, and no cpe was
observed in all BUE cell control wells.
Table 1. Inhibitory effects of selected anti-herpesvirus agents on the in vitro replication of BHV4 (strain
Tolakker).
Antiviral agent EC50a CIb MTCc
(µg/ml) (µg/ml) (µg/ml)
BVDU 0.05 ≥ 0.05 > 100
HPMPC 0.2 – 0.8 ≥ 1.6 – 3.2 > 100
DHPG 6.3 – 12.5 ≥ 25 > 100
PFA 100 > 100 > 100
ACV > 100 > 100 > 100
PCV > 100 > 100 > 100
PMEA > 100 > 100 > 100
a : concentration of antiviral agent required to reduce BHV4-induced cpe formation by 50%
b : concentration of antiviral agent required for complete inhibition of BHV4-induced cpe formation
c : minimal toxic concentration (concentration required to alter morphology of BUE cells)
BVDU, ACV, PCV and DHPG all depend on a virus-encoded thymidine kinase (TK) for activation.
However, in this study only BVDU and DHPG inhibited BHV4 replication. Compared to MHV-68,
BHV4 seems to be more susceptible to BVDU, whereas both viruses are equally susceptible to
DHPG. HPMPC, which does not depend on the viral TK for activation, but probably on the DNA
polymerisation process, proved to be a potent inhibitor of the replication of BHV4. Two other
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gammaherpesviruses, i.e. MHV-68 and Epstein-Barr virus, proved also to be susceptible to HPMPC.
Another acyclic nucleoside phosphonate, namely adefovir (PMEA), which has potent anti-retrovirus
and anti-herpesvirus activities (Naesens et al., 1997) was devoid of anti-BHV4 activity.
In conclusion, this study provides information on the susceptibility of BHV4 to a selection of anti-
herpesvirus agents. This information offers opportunities for designing strategies to inhibit BHV4
replication in e.g. the mammary gland or to treat pustular dermatitis.
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Abstract
This review deals with the role of viruses in the aetiology of bovine mastitis. Bovine herpesvirus 1,
bovine herpesvirus 4, foot-and-mouth disease virus, and parainfluenza 3 virus have been isolated from
milk from cows with clinical mastitis. Intramammary inoculations of bovine herpesvirus 1 or
parainfluenza 3 virus induced clinical mastitis, while an intramammary inoculation of foot-and-mouth
disease virus resulted in necrosis of the mammary gland. Subclinical mastitis has been induced after a
simultaneous intramammary and intranasal inoculation of lactating cows with bovine herpesvirus 4.
Bovine leukaemia virus has been detected in mammary tissue of cows with subclinical mastitis, but
whether this virus was able to induce bovine mastitis has not been reported.
Bovine herpesvirus 2, vaccinia, cowpox, pseudocowpox, vesicular stomatitis, foot-and-mouth disease
viruses, and bovine papillomaviruses can play an indirect role in the aetiology of bovine mastitis.
These viruses can induce teat lesions, for instance in the ductus papillaris, which result in a reduction
of the natural defence mechanisms of the udder and indirectly in bovine mastitis due to bacterial
pathogens. Bovine herpesvirus 1, bovine viral diarrhoea virus, bovine immunodeficiency virus, and
bovine leukaemia virus infections may play an indirect role in bovine mastitis, due to their
immunosuppressive properties.
We conclude that viral infections can play a direct or indirect role in the aetiology of bovine
mastitis; therefore their importance in the aetiology of bovine mastitis and their economical impact
needs further attention.
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1. Introduction
Bovine mastitis is a highly prevalent disease in dairy cattle, and one of the most important diseases
affecting the world’s dairy industry; it places a heavy economic burden on milk producers all over the
world (Miller and Dorn, 1990; Schakenraad and Dijkhuizen, 1990; Miller et al., 1993; Bennett et al.,
1999). Worldwide, annual losses due to mastitis have been estimated to be approximately 35 billion
US dollar. In the US, the annual costs of mastitis have been estimated to be 1.5 – 2.0 billion US dollar,
while losses of milk productions, due to subclinical mastitis, and higher cow replacements costs
associated with high somatic cell counts were estimated at 960 million US dollar (Wells et al., 1998).
Each case of clinical mastitis in the US and California costs approximately 107 and 200 US dollars,
respectively (Miller et al., 1993). In Scottish dairy herds, facing high bulk-tank somatic cell count, the
average annual costs of subclinical mastitis was 100 Pound Sterling/cow (Yalcin et al., 1999), while in
the UK and the Netherlands, the annual average revenue losses were calculated to be 42–84 Pound
Sterling/cow (Esslemont and Peeler, 1993) and approximately 130 Dutch Guilders/cow (Schakenraad
and Dijkhuizen, 1990).
Mastitis is defined as an inflammatory reaction of the parenchyma of the mammary gland that can
be of an infectious, traumatic or toxic nature (International Diary Federation, 1987). Mastitis is
characterized by physical, chemical and usually bacteriologicalchanges in the milkand bypathological
changes in the glandular udder tissue. The diagnosis of mastitis is based on clinical signs, e.g. swelling
of the udder, tender to the touch, fever, and depression. In many cases a reduced milk production can
be observed. Because of the large number of subclinical mastitis cases, the diagnosis of mastitis can
also depend on indirect tests which in turn depends on e.g. the leukocyte numbers in the milk
(Radostits et al., 1994).
Bovine mastitis is generally considered to be of infectious nature leading to inflammation of one or
more quarters of the mammary gland and it is often affecting not only the individual animal but the
whole herd or at least several animals within the herd. If left untreated, the condition can lead to
deterioration of animal welfare resulting in culling of affected cows, or even death.
Mastitis-causing pathogens include bacteria and non-bacterial pathogens, like mycoplasms, fungi,
yeasts, and chlamydia (Watts, 1988, Radostits et al., 1994). These pathogens infect the udder generally
through the ductus papillaris, which is the only opening of the udder to the outside world.
Despite intensive aetiological research, still around 20-35% of clinical cases of bovine mastitis have an
unknown aetiology (Miltenburg et al., 1996; Wedderkopp, 1997). Miltenburg et al. (1996) found a
28% negative rate in 1045 cases of clinical mastitis, and Wedderkopp (1997) did not note pathogens in
35% of 6809 milk quarters in 3783 cows suffering from clinical mastitis. The percentage of culture-
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negative samples of both clinical and subclinical mastitis cases in the Netherlands has recently been
determined to be approximately 25% (Barkema et al., 1998). An explanation for these high
percentages of culture-negative samples might be a low concentration of udder pathogens, e.g.
Escherichia coli. Other pathogens such as mycoplasma, yeasts and moulds are difficult to cultivate.
But these agents cannot be the explanation for all culture negative milk samples from mastitis cows,
because these agents are no common udder pathogens (Pfützner, 1994; Wendt, 1994). Due to the high
percentages of unknown causes of mastitis, it is obvious to study the role of viruses in the aetiologyof
bovine mastitis. This in spite of the fact that viruses are generally considered not to play an important
role. Watts (1988), for example, identified 137 microbial species as causative agents of bovine
mastitis, including agents involved in its pathogenesis. However, viruses were not included.
The reasons for this negligence could be manifold. Historically, mastitis research has concentrated
on bacterial pathogens. In case of viral infections, signs of mastitis may not have been recognised
because other clinical signs were more prominent. Subclinical mastitis cases are often not diagnosed
and consequently their aetiology is not investigated. This may cause an underestimation of virus
infections involved in bovine subclinical mastitis. Another reason might be that lactating cows are
seldom used in viral pathogenesis studies. In, e.g. most BHV1 pathogenesis studies, young calves are
used due to economic aspects. A disadvantages thereof is that it does not yield any indication as to
whether BHV1 can be involved in the aetiology of bovine mastitis. In addition, milk samples from
mastitis cows are often not properly collected, treated and stored for virological research, as this
requires special care. The laboratory diagnosis of viral mastitis is laborious and expensive. Diagnostic
tools, e.g. susceptible cells, for the detection of viruses are often not optimally used. These arguments
might explain why it is difficult to estimate the importancy of viral infection on the aetiologyof bovine
mastitis and their economical impact. It also explains the low number of viral mastitis reports, and it
may explain why the last brief review on viral infections of the bovine mammary gland has been
published 30 years ago (Afshar and Bannister, 1970). This review paper aims to make an inventoryof
the updated evidence that demonstrate whether viral infections are associated in a direct or indirect
way with bovine mastitis (Table 1).
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Table 1. Viral infections and their association with bovine mastitis
Virus Natural Experimental Indirect by Epide-
cases reproduction teat lesions miological
studies
Virus isolation IM route a Natural route
Bovine herpesvirus 1 + + D b
Bovine herpesvirus 4 + c + +
Foot-and-mouth disease virus + + + +
Parainfluenza 3 virus + +
Bovine leukaemia virus + d + / -
Bovine herpesvirus 2 +
Cowpox virus +
Pseudocowpox virus +
Vesicular stomatitis virus +
Bovine papillomaviruses +
Bovine viral diarrhoea virus +
Bovine immunodeficiency virus D b
Rinderpest virus D b
Bovine enterovirus +
IM a: intramammary
D b: data are considered to be insufficient for association
+ c: virus isolation from cases and not from matched controls
+ d: no virus isolated but viral particles detected by electron microscopy
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2. Viral infections and bovine clinical mastitis
Bovine herpesvirus (BHV) 1 (Gourlay et al., 1974; Roberts et al., 1974), BHV4 (Wellenberg et al.,
2000), foot-and-mouth disease virus (Burrows et al., 1971), and parainfluenza 3 virus (Kawakami et
al., 1966a and 1966b) have been detected in milk from cows with clinical mastitis. However, the
detection of virus in milk from cows with mastitis obviously does not prove that these agents are the
cause of mastitis, or that they are involved in an indirect way.
2.1 Bovine herpesvirus 1
Bovine herpesvirus 1, a member of the Alphaherpesvirinae subfamily within the Herpesviridae
family, causes infectious bovine rhinotracheitis (IBR), infectious pustular vulvovaginitis (IPV) and
infectious pustular balanoposthitis. In 1974, BHV1 was isolated from a cow with mastitis in the USA.
Although, bacterial culture was negative and only BHV1 was isolated from the milk, the evidence that
the virus caused the mastitis was, at most, circumstantial as the milk sample was collected three days
after vaccination with a live IBR-vaccine (Roberts et al., 1974). In France, BHV1 was isolated from
milk samples from cows with mastitis in combination with Mycoplasma agalactiae (Espinasse et al.,
1974; Gourlay et al., 1974). BHV1 was also isolated from one of the milk samples obtained from one
out of 96 cows with mastitis (Bilge, 1998). Besides the isolation of BHV1 in milk, the virus was also
isolated from vesicular lesions on the udder and on the teats of a cow. Thus, BHV1 was associated
with cutaneous lesions of the bovine udder, however it was difficult to ascertain whether the lesions
were primarily caused by the BHV1 infection (Guy et al., 1984).
A possible role of BHV1 in the aetiology of bovine mastitis, without or in combination with bovine
viral diarrhoea virus (BVDV), was also suggested by Siegler et al. (1984), who described a high
incidence of mastitis cases in a number of herds with BHV1 and BVDV infected cows.
Bacteriological examination of bovine milk samples in a number of herds suffering from mastitis
revealed no udder pathogens, while others suffered from mastitis induced by e.g. staphylococci and
streptococci. Immunisation of cows in the affected herds with IBR/IPV vaccine, without or in
combination with mucosal disease/BVD vaccine, resulted in an effective control of their mastitis
problems, including the herds suffering from mastitis induced by e.g. staphylococci and streptococci.
Any clear evidence that BHV1 or BVDV were involved in these mastitis cases was not presented, as
no attempts were made to isolate BHV1 or BVDV from milk of affected cows, and no data were
presented about unvaccinated control cows within the same herds.
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Bovine herpesvirus 1 has been shown to replicate in the bovine mammary gland and to induce
signs of clinical mastitis after an intramammary inoculation (Greig and Bannister, 1965; Straub and
Kielwein, 1966; Corner et al., 1967). An intramammary inoculation of one youngheifer with a BHV1-
IBR or a BHV1-IPV strain induced swollen quarters, hard and tender to the touch (Greig and
Bannister, 1965). A strong reduction in milk yield was recorded, and milk samples showed abnormal
morphology, with clots and blood, after the intramammary inoculation of cows with the BHV1-IBR
strain. Virus was first isolated from infected quarters on day 2 post-inoculation (pi) which continued
up to day 10-15 pi. The virus reached titres up to 106 – 107 TCID50/ml. No virus was detected in the
milk from the two uninoculated control quarters. Clinically, the experimental mastitis produced bythe
BHV1-IBR strain was similar to that induced by the BHV1-IPV strain. Dilution series further
demonstrated that about 103 TCID50 BHV1/ml was required to produce infection of the mammary
gland by the intramammary route (Greig and Bannister, 1965). In another study, an intramammary
inoculation with BHV1-IPV resulted in clinical mastitis as evidenced by an increase in body
temperature, decreased appetite, painful and swollen udders, and a strong reduction of the milk yield.
It was possible to isolate the virus from the milk of inoculated quarters until day 11 pi (Straub and
Kielwein, 1966).
Experimental BHV1 infections of the mammary gland resulted in necrosis of the alveolar epithelial
layer, infiltration and accumulation of polymorphic and mononuclear cells, and inclusion bodies in the
nuclei of epithelial cells (Corner et al., 1967).
The above mentioned studies demonstrate that BHV1 has been isolated from natural cases of
mastitis and that the bovine udder is susceptible to BHV1. However, its impact on bovine mastitis
cases in general is unclear. In view of the ubiquitous character of this virus, the number of reported
mastitis cases in which BHV1 played a role is probably low. Bovine herpesvirus 1 was not isolated
from milk of any of the 58 natural clinical mastitis cases from 10 herds examined virologically by
Wellenberg et al. (2000). BHV1 is probably not a major primary udder pathogen.
2.2 Bovine herpesvirus 4
Bovine herpesvirus 4, a rhadinovirus and member of the Gammaherpesvirinae subfamily within the
Herpesviridae family, has been isolated from cows with various clinical signs, including mammary
pustular dermatitis (Reed et al., 1977), and chronic ulcerative mammary dermatitis (Cavirani et al.,
1990). Recently, BHV4 has been isolated from 3 milk samples of 3 (5%) out of 58 cows with clinical
mastitis, and not from the 58 matched control cows. Two of the three cows from which BHV4 was
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isolated developed antibodies against BHV4, while no increase in antibodies against BHV4 were
detectable in the third cow within 21 days. A possible role of BHV4 in bovine mastitis was further
supported by the fact that in 4 of the 10 herds examined there was an ongoing BHV4 infection at the
same time as mastitis occurred (Wellenberg et al., 2000). In a second case-control study, a part of the
gene coding for BHV4-glycoprotein B was detected by PCR (Wellenberg et al, 2001) in milksamples
from 2 (4%) out of 54 mastitis cows. From the same milk samples, BHV4 was isolated on bovine
umbilical cord endothelial cells, a cell type highly susceptible to bovine herpesviruses (Wellenberg et
al., submitted). A significant increase in BHV4 antibody titres was detected in one of these two
mastitis cows at the same time as mastitis occurred. No BHV4 was detected in milk from their
matched control cows by gB-PCR or virus isolation. In both case-control studies, the presence of
BHV4 was in most cases accompanied by bacterial udder pathogens, e.g. Staphylococcus aureus and
Streptococcus uberis. An experimental study, performed to further investigate the role of BHV4 in
bovine mastitis, showed that a simultaneous intramammary and intranasal inoculation of lactating
cows with BHV4 did not result in clinical mastitis. However, subclinical mastitis was induced in 2 out
of 4 inoculated lactating cows (Wellenberg et al., in press). A significant increase of SCC was
recorded in milk from 50% of the BHV4 inoculated quarters on days 8, 9 and 11 pi, compared to the
non-inoculated quarters of the same cows (within-cow controls) and the quarters of the mock-
inoculated cows. Virus was isolated from milk samples of inoculated quarters only; from day 1 pi to
days 9 - 14 pi. A Streptococcus uberis infection appeared to trigger BHV4 replication in cows infected
2 weeks before with BHV4. Bovine herpesvirus 4 was isolated from the milk from 2 out of 4 quarters
after an intramammary Streptococcus uberis inoculation.
During an epidemiological study, a positive association between the presence of BHV4 antibodies
in cows and the incidence of bovine mastitis caused by Staphylococcus aureus was recorded (Zadoks
et al., submitted). This finding suggests that a previous BHV4 infection promotes the development of
mastitis especially caused by Staphylococcus aureus. BHV4 has also been isolated from the cellular
fraction of milk samples from cows with antibodies against BHV4. Unfortunately, no clinical data
were reported on mastitis in these cows (Donofrio et al., 2000).
All above mentioned studies strongly suggest a role for BHV4 in bovine mastitis. Although, BHV4
probably does not appear to play an important role as primary udder pathogen in the aetiology of
clinical mastitis, it may play a role in subclinical mastitis cases, or in an indirect way. More research is
warranted to establish a possible indirect role of BHV4 infections in bovine mastitis, e.g. as a result of
immunosuppression. The virus can infect cells involved in the immune system, e.g. mononuclear
blood cells (macrophages), and recently, a possible role of BHV4 has been postulated byplayinga role
in damaging vascular tissues (Lin et al., 2000). In addition, bovine endothelial cell cultures are highly
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susceptible to BHV4.
2.3 Foot-and-mouth disease virus
Foot-and-mouth disease (FMD) virus, a member of the Aphthovirus genus within the family of the
Picornaviridae, in general causes an infection whereby the virus is widespread through various tissues
and organs of the host. Although, a primary infection of the mammary gland is unlikely to be a
common occurrence in the pathogenesis of FMD, the virus can also replicate in the secretoryepithelial
cells of the mammary gland. Many researchers have isolated FMD virus from milk of FMD affected
cows (Burrows, 1968; Ray et al. 1989; Fuchs, 1994), and also teat and udder lesions have been
reported in FMD-affected cattle during an outbreak with an Asia-1 serotype (Firoozi et al., 1974).
The results of experimental inoculations of the udder show that it is a highly susceptible organ that
is capable of producing large amounts of virus. Evidence for the replication of FMD virus in the
mammary glands, as a result of a systemic infection, was found in cattle that were infected by
(simulated field-type) contact exposure to FMD virus infected animals (Blackwell et al., 1983).
Infection of FMD virus by the oronasal route also resulted in virus replication in secretory epithelial
cells of the alveoli of the udder (Blackwell and Yilma, 1981), and in progressive temporal necrosis in
the alveoli. Clumps of necrotic secretory epithelial cells and detached membrane-limited structures
(cellular debris) were observed within the alveolar lumen and in the milk (Blackwell et al., 1983).
During experimental infection, an increase of leukocytes was not recorded up today17 pi. This means
that FMD virus infections of the bovine udder result in necrosis of the alveolar epithelial cells, but this
occurs without a strong increase in leukocytes as observed for most bacterial udder infections. So,
FMD virus is not the cause of a viral clinical mastitis as such, but secondary bacterial infections may
result in clinical mastitis. The necrosis process is probably responsible for the observed decrease in
milk yield (Blackwell and Wool, 1986).
Replication of FMD virus in the mammary gland has also been reported after cows were exposed
to the virus either by aerosol, by a combination of intramammary-intravenous inoculation (Blackwell
and Yilma, 1981), or after an intramammary inoculation via the ductus papillaris (Burrows et al.,
1971). After intramammary inoculation, affected quarters became swollen and tender to the touch. The
milk showed abnormal morphology (with clots), and a drop in the milk yield of approximately 60%
was recorded. The FMD virus multiplied rapidly and virus titers of >107plaque formingunits/mlwere
recorded within 8-32 hours pi. Dissemination of the virus from the mammary gland was recorded by
virus isolation from milk within 4-24 hours pi. The ability of FMD virus to persist in the mammary
tissue was confirmed by the intermittent recovery of the virus from cows up to day 51 pi, which
indicates virus multiplication in the udders of immune cows (Burrows et al., 1971).
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Based on reports of natural mastitis cases and experimental infections, we mayconclude that the udder
is a highly susceptible organ for FMD. Infection of the secretory epithelial cells of the mammarygland
will usually be the result of a systemic infection, because a primary infection of the mammarygland by
this virus is unlikely to be a common occurrence. Mastitis associated with FMD virus is assumed tobe
due to secondary bacterial infections.
2.4 Parainfluenza 3 virus
In 1966, parainfluenza 3 (PI3) virus, a member within the Paramyxoviridae family, was recovered
from Japanese cattle with acute respiratory illness from nasal secretions, and also from milk
(Kawakami et al., 1966a). On one of the examined farms, the virus was recovered from milk in 14 of
58 cows (24%). The cows from which PI3 virus was recovered from the milk did not show signs of
clinical mastitis, but an increased milk SCC was recorded in many milk samples.
Parainfluenza 3 virus was also isolated from quarter milk from one cow of the same farm with
typical aseptic mastitis. An intramammary inoculation of PI3 virus resulted in respiratory signs and
other signs e.g. fever, malaise, and losing condition, as observed in calves infected with the same PI3
virus by intravenous or intranasal inoculation. The affected udders developed swellingand induration.
The milk showed a color change, an increased pH and increased numbers of glandular epithelialcells,
neutrophils, lymphocytes and monocytes. Virus was excreted in high titers (up to 107 TCID50/ 0.1 ml)
in milk from inoculated quarters up to day 10 pi. The histological examination revealed that the major
change was an interstitial inflammation, consistent of large lymphoid cells (Kawakami et al., 1966b).
Both studies indicate that the mammary gland is highly susceptible to PI3 virus, and that in naturally
PI3 virus infected cows udder infections may also occur. In some cases the infection may result in
overt clinical mastitis. These findings await confirmation.
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3. Viral infections and bovine subclinical mastitis
A possible role of viruses in bovine subclinical mastitis has been suggested before (Fuchs, 1994).
Subclinical mastitis occurs frequently, and may lead to high economical losses due to reduced milk
yields, and to penalties because of too high bulk-tank somatic-cell counts. Losses resulting from both
clinical and subclinical mastitis may amount to 20% of the potential production (Beck et al., 1992). In
practice, subclinical mastitis cases are often not detected rapidly, or may even not be recognized bythe
farmer.
3.1 Bovine leukaemia virus
Bovine leukaemia virus (BLV), belonging to the Deltaretrovirus genus and member of the family of
Retroviridae (Pringle 1999), causes enzootic bovine leukosis. It preferentially infects lymphocytes of
the B-lineage in cattle. Recently, BLV particles have been detected by electron microscopy around
lymphocytes in the mammary tissue of BLV antibody positive cows affected by subclinical mastitis
(Yoshikawa et al., 1997). No macroscopical lesions were detected in the mammary glands of the 6
cows examined, but histological lesions were found in some lobules of the mammary gland, i.e. an
infiltration of lymphocytes, plasma cells, and neutrophils into alveoli and interlobular connective
tissue. The alveoli also contained numerous macrophages and desquamated alveolar lining cells. No
information was recorded about the milk SCC, the presence of bacterial udder pathogens or milk
yields. Consequently, whether this virus was the causative agent in this “subclinical” mastitis case is
unknown.
A possible association of BLV infections and mastitis in dairy cows has been investigated on
individual and on herd level, however with contradictory results. A positive association has been
reported by Milojevic et al. (1991) and Rusov et al. (1994), who reported that the occurrence of
mastitis and increased cell counts are more often recorded in cows with enzootic leukosis than in
healthy cows. A significant association between BLV seropositivity and higher milk SCC has also
been recorded for older cows (Jacobs et al., 1995). According to Emanuelson et al. (1992), the risk for
infectious diseases seemed to be greater among BLV-infected herds than among non-BLV infected
herds. In this study a positive association between BLV antibody positive bulk milk and bovine
mastitis, and also for bulk SCC, was recorded. However, no data were presented on the differences in
management on the herd level, which is an important factor in bovine mastitis prevalence.
In the above mentioned studies a possible association of BLV infections and mastitis in dairycows
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is noted, but this is not the case in all studies performed. In one of these studies, 226 adult dairy cows
were examined for BLV infection and mastitis, but no statistically significant association was found
between the BLV infection and mastitis (Fetrow and Ferrer, 1982). Of the cows positive for BLV-
infection, 22.7% had bacteriological cultures positive for mastitis, whereas in the group of BLV-
infection negative cows 23.2% suffered from bacteriological mastitis pathogens. Scott et al. (1991)
reported that the number of subclinical mastitis cases in BLV positive cows was even lower than that
in BLV negative cows. In this study, the number of Staphylococcus sp. and Micrococcus sp., isolated
from milk from 50 BLV-positive cows, was significantly lower than that in 35 BLV-seronegative
cows. In a matched case-control study, to assess the risk of clinical mastitis in BLV-infected cows, the
BLV-infected cows did not produce less milk, or did not develop mastitis more often than did
noninfected cows (P> 0.05) (Huber et al., 1981).
Also studies on milk yields, which also might be an indication for the presence of subclinical
mastitis cases within herds, on BLV positive herds showed contradictory results. Heald et al. (1992)
could not find a significant association between milk yield, somatic cell counts and BLV-
seropositivity. One of the reasons why results on studies on herd level are not in agreement is that
many studies did not use a proper study design. None of the studies performed on individual or herd
level clarify the role of BLV in the aetiology of bovine subclinical mastitis. No experimental studies
have been reported to investigate whether BLV is able to induce subclinical or clinicalbovine mastitis.
Such experiments are necessary to gain more insight into the role of BLV in the aetiology of bovine
mastitis.
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4. Viral infections and their indirect role in bovine mastitis
Can viral infections play an indirect role in the pathogenesis of bovine mastitis? Damage of teat and
ductus papillaris (as natural barrier) and immunosuppression may lead to a higher susceptibility for
bacterial mastitis cases, and bacterial infections may run a more severe course.
4.1 Teat lesions
Bovine herpes mammillitis virus (BHV2), vaccinia, cowpox, pseudocowpox, FMD viruses, and to a
lesser extent vesicular stomatitis virus can cause a local dermatitis, often with ulcerations in the ductus
papillaris, leading to secondary bacterial infections in the sinus lactiferus and the corresponding
mammary gland (Turner et al, 1976; Francis, 1984; Scott and Holliman, 1984).
4.1.1 Bovine herpesvirus 2
Bovine mammillitis is an acute viral disease of cattle caused by BHV2 (Martin et al., 1966), a virus of
the genus Simplexvirus and member of the Alphaherpesvirinae subfamily within the Herpesviridae
family. Bovine herpesvirus 2 often infects young heifers and young cows at first parity or in the first
lactation period. The infection may be subclinical or relatively mild (Turner et al., 1976; Letchworth
and LaDue, 1982; Scott and Holliman, 1984), but it can also be very severe causing extensive painful
ulcerations on one or more teats and udders (Scott and Holliman, 1984). Lesions can range from
vesicles and ulcerations of large (up to 10 cm wide) areas of teat skin to single small (2-3 cm wide)
plaques of oedema. Severe BHV2 infections may also result in damage of the ductus papillaris. The
functions of the keratin in the ductus papillaris, with its fatty acids and proteins, and the macrophages,
lymphocytes and plasma cells in the ductus papillaris and the sinus lactiferus may be impaired due to
this BHV2 infection (Paape et al., 1985; Senft and Neudecker, 1991). This may enhance the
susceptibility of the mammary gland for bacterial mastitis (Martin et al., 1969; Letchworth and LaDue,
1982; Scott and Holliman, 1984; Gourreau et al., 1989).
BHV2 has also been isolated from milk from cows with ulcera on teats (Martin et al., 1969), but
leakage from these lesions was probably the cause of the presence of BHV2 in the examined milk
samples. Turner et al. (1976) recorded mastitis cases in cows with BHV2 infection. These cows had
ulcera in the ductus papillaris, and therefore its function was impaired. Chronic mastitis was observed
in cows with udder ulcera up to the ductus papillaris. These reports suggest that BHV2 may induce
mastitis due to damage of the mechanical defence of the udder. Mastitis indirectly due to BHV2
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infections (Letchworth and LaDue,1982: Scott and Holliman, 1984) mostly affect a few cows within a
herd, but also percentages of 22% have been recorded for BHV2 affected cows that developed mastitis
(Martin et al., 1969). Under experimental conditions, an intradermal and intravenous inoculation of a
30-month-old heifer with BHV2 resulted in several clinical signs e.g. mammilitis. However, in this
study mastitis has not been recorded and the mammary gland has not been examined for
histopathological lesions (Tabbaa et al., 1987).
In conclusion, BHV2 infections can result in damage of the natural defence mechanisms of the
udder, which results in a higher susceptibility to bacterial mastitis.
4.1.2 Vaccinia virus and cowpox virus
Infections with vaccinia virus and cowpox virus, both belonging to the genus Orthopoxvirus within the
subfamily Chordopoxvirinae of the Poxviridae family, do not occur anymore or are very rare,
respectively (Mayr and Czerny, 1990). Clinical signs are comparable to those described for BHV2
infections. As a result of teat lesions, mastitis may occur on the same way as it occurs after a BHV2
infection. After an intramammary inoculation with vaccinia virus, the virus that has been used for
smallpox vaccination, an inflammatory reaction in the bovine mammary gland was produced
(Easterday et al., 1959). The intramammary inoculation of the mammary glands via the ductus
papillaris of 6 cows with vaccinia virus (strain IHD) induced systemic signs e.g. elevated body
temperatures, and udder swelling in 5 of the 6 cows inoculated. Lesions appeared on the ends of all
vaccinia virus inoculated teats, and progressed from a papule to a vesicle to a scab. The SCC increased
up to >500.000/ml, and vaccinia virus was isolated from the milk of 4 out of 4 lactating cows up to 9
days pi (Easterday et al., 1959). Natural cases of bovine mastitis, in which vaccinia virus was
involved, are unknown.
Outbreaks of cowpox virus are extremely rare. The virus enters through teat skin injuries and
several stages of lesion development can be observed. Erythematous areas appear on the teat and can
change into raised papule and ruptures with pitted centers. Lesions spread rapidly throughout the herd.
Healing occurs within two to three weeks although secondary bacterial infections maydelayresolution
(Francis, 1984). During a cowpox virus infection in India of cows and buffalo’s some animals suffered
from mastitis (Sambyal et al., 1983). Most of the affected cows showed teat lesions, and udder
pathogens like Staphylococcus aureus and Klebsiella spp. were isolated from the milk of affected
cows. The role of cowpox virus in this case of mastitis was not clear, but the teat lesions, induced by
cowpox virus, might have resulted in secondary bacterial mastitis. The above mentioned studies
indicate that cowpox virus may play a role in bovine mastitis, but the incidence is probably very low.
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4.1.3 Pseudocowpox virus
The pseudocowpox virus belongs to the genus Parapoxvirus within the subfamily Chordopoxvirinae
of the Poxviridae family. Only one report was found concerning the isolation of a poxvirus from milk
(Dawson et al., 1968). The virus was isolated from a pooled milk sample and typed as a virus from the
paravaccinia subgroup, but no lesions suggestive of pseudocowpox were recorded, neither was clinical
or subclinical mastitis. An intramammary inoculation of one lactating cow with this strain did not
result in systemic disturbance, swelling or induration of the udder. Only a few small clots were
recorded in the milk on days 4 and 5 pi. No lesions developed on teats and on the udder. In milk from
one out of two inoculated quarters, the virus was isolated on only 24 hours pi, but clinical mastitis was
not noted (Dawson et al., 1968). No further reports on pseudocowpox virus and bovine mastitis were
found, despite the fact that this virus is ubiquitous and the infection induces comparable clinical signs
as reported for BHV2 infections (Gibbs, 1984). This suggests that, in addition to BHV2,
pseudocowpox virus may also induce mastitis due to damage of the mechanicaldefence mechanism of
the udder. The role of pseudocowpox virus in the aetiology of bovine mastitis is still an interestingarea
for research; this virus was detected in 5 out of 14 cases of bovine teat lesions in Dutch cattle
(Wellenberg, 2001, unpublished data).
4.1.4 Foot-and-mouth disease virus
FMD virus can play a secondary role in bovine mastitis in that FMD virus infection may result in
ductus papillaris lesions and therefore enhances bacterial infections as reported for an experimental
Arcanobacter pyogenes (A. pyogenes) udder infection (Saini et al., 1992). After an infection of
lactating cows with FMD virus, Arcanobacter pyogenes had been isolated from 15 quarters showing
purulent mastitis (Saini et al., 1992), while an intramammary inoculation of quarters with A. pyogenes
alone did produce only mild inflammatory reactions (Vecht et al., 1987). This suggests that the teat
epithelium of the quarters had already been damaged by FMD virus that supported the involvement of
A. pyogenes as the causative agent of purulent mastitis. The injury to teat epithelium was essential for
the establishment of infection (Seinhorst et al., 1991). Field studies also support a secondary role of
FMD in bovine mastitis. An increased incidence of bovine mastitis cases with secondary bacterial
pathogens has been reported after an infection with FMD virus (Ray et al., 1989; Seinhorst et al.,
1991).
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4.1.5 Vesicular stomatitis virus
Mastitis has been associated with some other virus diseases, but it has not been demonstrated that
these viruses were the primary invaders of the mammary gland. Strozzi and Ramos-Saco (1953)
reported teat lesions and associated mastitis in cases of vesicular stomatitis virus infections; a virus
belonging to the genus Vesiculovirus within the Rhabdoviridae family. An intramammaryinoculation
of 8 cows with vesicular stomatitis virus (New Jersey) did not induce udder swelling, but it resulted in
increased milk SCC of >500.000/ml in all 5 inoculated lactating cows. The virus was isolated from
milk from 4 out of 5 lactating cows. In 5 out of 8 cows elevated body temperatures were recorded. No
changes were recorded in the bacterial flora of any quarter inoculated with vesicular stomatitis virus
during this study (Easterday et al., 1959). Although vesicular stomatitis virus mayplaya role in bovine
mastitis, the incidence is probably very low as the number of reported mastitis cases in which vesicular
stomatitis virus has been involved is nil.
4.1.6 Bovine papillomaviruses
The bovine papillomaviruses belong to the genus Papillomavirus within the familyPapillomaviridae.
At least six types of bovine papillomavirus (BPV) have been recognised, and certain types can cause
fibropapillomas on teats (Olson, 1990). Fibropapillomas in the ductus papillaris due to bovine
papillomavirus may result in damage of the natural defence mechanisms of the udder and therefore in
a predisposition for mastitis (Francis, 1984). An ascending bacterial infection may result in mastitis
(William et al., 1992).
4.2 Immunosuppression
In addition to viruses that cause teat lesions, other viral infections may induce or enhance bovine
mastitis due to their immunosuppressive effects. Although, so far there is not any clear evidence for
this.
4.2.1 Bovine herpesvirus 1
Bovine herpesvirus 1 infections can impair the bovine immune system (Bielefeldt-Ohmann and
Babiuk, 1985; Straub, 1991; Nataraj et al., 1997; Saini et al., 1999; Koppers-Lalic et al., 2001). Based
on the immunosuppressive properties of BHV1, it has been proposed that the virus may play a
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secondary role in the aetiology of diseases caused by bacteria (Filion et al., 1983; Bielefeldt-Ohmann
and Babiuk, 1985; Hutchings et al., 1990), but whether and which secondary role BHV1 plays in the
aetiology of bovine mastitis is not clear. Epidemiological studies, to examine whether BHV1
seropositive animals are more prone to bovine mastitis than BHV1 seronegative animals, are
unknown. Hage et al. (1998) reported a significant drop in milk production, which might be an
indication for subclinical mastitis, during a subclinical BHV1 infection on a dairy herd. However, no
association was found between the BHV1 infection and mastitis, since the milk SCC was unaltered
and clinical mastitis was not observed.
4.2.2 Bovine viral diarrhoea virus (BVDV)
Another virus that causes immunosuppression is BVDV, a member of the Pestivirus genus, within the
family of the Flaviviridae (Roth et al., 1981; Bolin et al., 1985; Markham and Ramnaraine, 1985;
Welsh et al., 1995). Persistently infected animals show chronically impaired immunoresponses (Roth
and Bolin, 1986; Brownlie, 1989), and a delay in the onset of BRSV-specific IgG response and
reduced antibody titres has been noted in cattle infected concurrently with BVDV (Elvander, 1996).
These data indicate that BVDV may play an (indirect) role in the susceptibility of the animal to
secondary infections, or may enhance the possibility of secondary infections to run a more severe
course (Potgieter et al., 1984).
Studies on the immunosuppressive role of BVDV in relation to bovine mastitis are very scarce.
Siegler et al. (1984) reported an increased amount of mastitis cases in BVDV and BHV1 seropositive
herds, however which role BVDV played in these mastitis cases in unclear. Furthermore, a positive
association between BVDV and bovine mastitis, based on the BVDV antibody titres in bulk milk of
237 herds, has been reported. The number of mastitis cases increased in herds with an increased
BVDV antibody milk titre (Niskanen et al., 1995). In a retrospective longitudinal study, which was
conducted to examine whether the exposure of dairy herds to BVDV affected udder health, a 7%
increase was noted in the incidence rate of clinical mastitis in herds exposed to BVDV as compared
with non-BVDV exposed herds (Waage, 2000). A reduction in the milk yield was shown in cows that
seroconverted for BVDV antibodies, although no information was presented on mastitis (Moerman et
al., 1994). Further studies are warranted to clarify the role of BVDV in bovine mastitis. No
intramammary inoculation of cows with BVDV has been reported, and in addition there are noreports
on the isolation of BVDV from milk of cows with mastitis. However, BVDV genomic sequences can
be detected by PCR in milk and bulk milk samples (Radwan et al., 1995; Drew et al., 1999), but this is
likely to be caused by the presence of persistently infected cows in the herd, and consequentlydoes not
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mean that the virus is involved in a direct or indirect way in bovine mastitis cases.
4.2.3 Bovine leukaemia virus
An association of a virus infection with a higher susceptibility for bovine mastitis has also been
suggested for BLV. The primary target cells for BLV are cells of the B-lymphocyte lineage in cattle.
Infection of B-lymphocytes may influence the humoral immune responses, e.g. a reduction in plasma
IgM levels, and the cellular responses are very probably as well impaired in BLV-infected cattle
(Yamamoto et al., 1984; Meiron et al., 1985). These data suggest that the immune system of BLV
infected calves can be affected, although its effect on the incidence and the severity of bovine mastitis
cases is unclear.
4.2.4 Bovine immunodeficiency virus
Bovine immunodeficiency virus (BIV), a lentivirus within the Retroviridae family, was detected for
the first time in 1972. Although most infections run a subclinical course, BIV infections may also
result in clinical signs such as lymphadenopathy, lymphocytosis, lesions of the centralnervous system,
wasting and several secondary bacterial infections (Snider et al., 1996). Lymphoid depletion with a
reduction of the follicular development and depletion of B and T-cell compartments in lymph nodes
are observed in BIV infected animals. Secondary infections were often multiple such as, e.g. metritis
and mastitis (Snider et al., 1996). In this study, 24 (40%) out of 59 cows with a BIV infection showed
chronic mastitis. Necrotising udder tissue were recorded in combination with a few udder pathogens
like Escherichia coli.
The effect of co-infection with BLV and the influence of immunosuppression on the severity of
chronic bovine mastitis cases remains to be of interest for future investigations.
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5. Other viral infections, including non-bovine related virus infections, of the
bovine mammary gland
A few other viral infections have been associated with bovine mastitis. For example, mastitis, which
may be secondary, has been attributed to a systemic virus disease such as malignant catarrhal fever
(Beckman, et al., 1960). This report suggests that severe lesions in the mammary gland may account
for a decline in milk production and cracking of the epithelium of the teats. However, this is the only
report on any possible relation between malignant catarrhal fever and mastitis.
5.1 Rinderpest virus
The role of rinderpest virus, a Morbillivirus and one of the members of the Paramyxoviridae family,
in bovine mastitis has not been examined thoroughly. Infection of two swamp buffaloes with a
rinderpest virus, isolated from the spleen of an infected buffalo, resulted in clinical signs as fever,
depression and conjunctivitis, and vesicles appeared on lips and mammary gland (Tesprateep et al.,
1987). Natural primary or secondary cases of mastitis due to rinderpest virus infections have not been
reported.
5.2 Bovine enterovirus
Bovine enteroviruses are members of the genus Enterovirus in the Picornaviridae family. This virus
has been isolated from healthy cattle and cattle with enteric, respiratory and reproductive disease
problems (Knowles and Mann, 1990), but its role in mastitis is unknown. After an intramammary
inoculation of two cows with bovine enterovirus, an acute catarrhal mastitis with marked increased
milk SCC, and only mild clinical symptoms were recorded in both cows. The virus was isolated from
milk of inoculated quarters (Straub and Kielwein, 1965).
5.3 Non-bovine related viruses
Also non-bovine related viruses have been shown to replicate in the bovine mammary gland after
intramammary inoculation (reviewed by Afshar and Bannister, 1970). An inflammatoryreaction in the
bovine mammary gland was produced by infusion of the Newcastle disease virus (strain Roakin). The
intramammary inoculation of 3 cows, one of which did not lactate, with Newcastle disease virus
resulted in udder swelling and an increase in body temperature in one of the inoculated cows. An
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increase in milk SCC was recorded in the two inoculated lactating cows, and the milk also contained
virus on day 6 after inoculation, but not on day 9 (Easterday et al., 1959).
Mitchell et al. (1956) have demonstrated that influenza and NCD viruses will multiply when
inoculated into the mammary gland (Mitchell et al., 1956). No mention was made of anyinflammatory
processes. These studies show that non-bovine viruses are able to replicate in the bovine mammary
gland.
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6. Concluding remarks
This review shows that viruses can be involved, in a direct or indirect way in the aetiology of bovine
mastitis. In natural cases of mastitis, BHV1, BHV4, FMD and PI3 viruses have been isolated from
milk. In addition, experimental infections via the ductus papillaris clearly demonstrated that these
viruses replicated in the mammary gland tissue, followed by clinical mastitis in the cases of BHV1,
FMD virus and PI3 virus infections, and subclinical mastitis after a BHV4 infection. However, no
investigations have been performed to examine whether this route of infection is of importance in the
field. Because bacterial pathogens usually infect the udder through the ductus papillaris, it may be
expected that also viruses can infect the mammary gland tissue via this route after transmission by,
e.g. milking devices. Especially in cases when hygienic measures are not well taken. However, we
assume that BHV1, BHV4, FMD and PI3 viruses are mostly transmitted by direct contact and by
aerosols. That an experimental infection through the natural route leads to mastitis, has been shown
only for FMD (Table 1). However, in the Western world FMD virus induced bovine mastitis is not of
practical relevance because cattle infected with FMD virus will be destroyed immediately after the
diagnosis has been made. With regard to BHV1, BHV4, PI3 virus and BLV infections, the data in the
literature do not convincingly demonstrate that these viruses can playa primaryrole in causingmastitis
in the field.
It is likely that viruses that cause teat lesions (BHV2, cowpox, pseudocowpox, FMD, vesicular
stomatitis virus, and papillomaviruses), and thereby damaging the integrity of the bovine udder,
indirectly contribute to mastitis. The impact of these virus infections may be great within individual
herds but less within regions or districts of countries.
Although it is plausible that virus-induced immunosuppression underlies mastitis, there are nodata
that underpin this assumption. In addition, only very few well-designed epidemiological studies have
been performed to support a causal relationship between virus infections and mastitis.
Further research should be performed to firmly establish the importance of viral infections on
bovine mastitis in the field. Such research should certainly take into account that mastitis is a
multifactorial disease, consequently such studies are difficult todesign. Investigations should dealwith
well-designed case-control studies, more experimental viral infections whether or not in conjunction
with bacterial infections, and various epidemiological studies. Application of new more powerful
diagnostic tools, based on the detection of viral genomic sequences e.g. by (multiplex) PCR or micro-
array devices, offer new opportunities for a rapid simultaneous detection of most viruses involved in
bovine mastitis. In the future, these new screening methods may also provide a better insight in the
prevalence of viruses in milk from cows with mastitis.
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Summary
Mastitis is an often occurring disease in dairy cattle with an enormous economic impact for milk
producers worldwide. Despite intensive research, which is historically based on the detection of
bacterial udder pathogens, still around 20-35% of clinical cases of bovine mastitis have an unknown
aetiology. Due to the high number of unknown causes of clinical mastitis, studies were undertaken to
gain more insight into the role of viruses in this important disease. A case-control study was set up, in
which non-conventional cell types were used for virus isolation. We found that BHV4 may be
involved in the aetiology of bovine mastitis, because it was isolated from milk of 3 (5%) out of 58
cows with clinical mastitis and not from the 58 matched control cows. Concomitant with the isolation
of BHV4, an increase in antibody titre against BHV4 was noted in two of these three mastitis cows
from which BHV4 was isolated. Bovine herpesvirus 4 (BHV4), a member of the
Gammaherpesvirinae subfamily, has a worldwide distribution. It has been isolated from cows with
various clinical signs, but never from milk of mastitis cows before. Restriction enzyme analyses
studies showed that the first isolated BHV4 strain from milk of cows with clinical mastitis belonged to
the Movar 33/63 group. Because there was a lack of well-validated tests for the detection of BHV4,
BHV4 antibodies and BHV4 DNA when we began our investigations, new tests for the diagnosis of
BHV4 infections were developed and validated.
The replication of BHV4 is absent or slow in many routinely used cell types. Therefore non-
conventional cell types such as bovine udder epithelial cells, bovine umbilical cord endothelial cells
and bovine alveolar lung macrophages were additionally used for virus isolation. The use of the bovine
umbilical cord endothelial cells, a cell type seldom used in bovine virology, proved to be a good
choice. In the first case-control study, BHV4 was isolated only on this cell type and not on three other
cell types used. Susceptibility studies showed that BHV4 grew to much higher titres in bovine
umbilical cord endothelial cells than in the routinely used Madin Darby bovine kidney cells. The
bovine umbilical cord endothelial cell type was not only highly susceptible to BHV4, but it alsoproved
to be susceptible to other bovine herpesviruses, such as BHV2 and BHV5 (Chapter 2).
For the detection of BHV4 antibodies only one commercial indirect-ELISA was available. We
developed and evaluated an immunoperoxidase monolayer assay (IPMA) for the detection of
antibodies directed against BHV4. The newly developed BHV4 IPMAs were based on the detection of
antibodies against the American BHV4 reference strain DN-599 and on LVR 140, a reference strain
belonging to the European Movar 33/63-like group. After validation, the IPMA proved to be a reliable
test, and it was found more sensitive for the early detection of BHV4 antibodies than the indirect-
ELISA. In the IPMA, BHV4 antibodies were first detectable 16-18 days post infection and in the
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indirect-ELISA only after 30 days post-infection. In addition, a serological survey showed that the
estimated seroprevalence of BHV4 in Dutch cattle was 16-18% and that the percentage of BHV4
seropositive cattle varied by age category between 6 and 43% (Chapter 3).
A polymerase chain reaction for the detection of BHV4-glycoprotein-B (gB) DNA was developed
and validated, and a nested-PCR was modified to detect BHV4-thymidine kinase (TK) DNA in bovine
milk samples. Both methods proved to be rapid and reliable tests for the screening of BHV4 DNA in
milk (Chapter 4). In a second case-control study, using these newly developed diagnostic tools, BHV4
was detected again from mastitis cows only and not from matched controls (Chapter 6). BHV4 and
BHV4-gB DNA was detected in milk from 2 (4%) out of 54 cows with clinical mastitis, whereas no
BHV4 was detected by virus isolation and PCR in 54 matched controls. Also other results from the
second case-control study largely confirmed those from the first case-control study. An experimental
study was performed to examine whether a simultaneous intramammary and intranasal inoculation of
lactating cows with BHV4 induced clinical mastitis (Chapter 7). No clinical mastitis was noted in the
four inoculated lactating cows, but the somatic cell counts increased significantly in milkof 50% of the
BHV4 inoculated quarters, compared to the non-inoculated quarters of the same cows and quarters of
mock-inoculated cows (control group) on days 8, 9, and 11 post-inoculation. Another interesting
finding was that a bacterial infection, Streptococcus uberis infection, triggered BHV4 replication.
Replication of latent BHV4 from tissues has been reported after dexamethasone treatments, but it
has never been described that its replication may be triggered by a bacterial infection. This study also
showed that a preceding BHV4 infection did not exacerbate clinical mastitis induced by an
intramammary Streptococcus uberis inoculation.
The study on the susceptibility of BHV4 to various anti-viral agents showed that brivudin
effectively inhibited the in vitro replication of BHV4. These anti-viral agents offer opportunities for
designing strategies to inhibit BHV4 replication in cattle with e.g. mastitis. Cidofovir and ganciclovir
inhibited the replication to a lesser degree (Chapter 8).
Based on the studies performed, we conclude that BHV4 may play a role in the aetiology of bovine
mastitis, albeit likely a minor one in clinical mastitis. In both case-control studies, the presence of
BHV4 in milk was mostly accompanied by the presence of known udder pathogens, e.g.
Staphylococcus aureus and Streptococcus uberis, which makes it even more difficult to understand
the direct role of BHV4 in causing bovine clinical mastitis. It suggests rather a role in subclinical
mastitis and an indirect role for BHV4 in the aetiology of bovine mastitis. More research is warranted
to investigate its indirect role as a result of e.g. immunosuppression. BHV4 has a close relationship
with cells of the immune system, and it grows to high titres in endothelial cell cultures in vitro, but
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whether this virus has immunosuppressive properties is not completely clear.
Finally, based on the studies performed during this thesis and the review study on viral infections and
bovine mastitis (Chapter 9), we may conclude that viruses can play a direct or indirect role in the
aetiology of bovine mastitis.
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Samenvatting
Mastitis is één van de belangrijkste gezondheidsproblemen bij melkkoeien met enorme economische
gevolgen binnen de melkveehouderij. Ondanks intensieve onderzoeks- en bestrijdingsprogramma’s,
die voornamelijk gebaseerd zijn op de detectie en behandeling van bacteriële infectieziekten, is bij 20-
35% van het aantal klinische gevallen van mastitis de oorzaak nog steeds niet vast te stellen. Omdat de
rol van het virus bij klinische gevallen van mastitis niet geheel duidelijk was en van ondergeschikt
belang werd geacht, werd er ook niet veel onderzoek naar gedaan. Toch zou een deel van het aantal
onbekende mastitis gevallen een virale oorzaak kunnen hebben. Om de mogelijke rol van virussen bij
het ontstaan van bovine mastitis nader te onderzoeken werd een case-control studie uitgevoerd. In deze
eerste case-control studie werd gebruik gemaakt van non-conventionele cellen voor de isolatie van
virussen, gecombineerd met verschillende gevalideerde serologische testen voor het aantonen van een
antilichaamrespons.
Op basis van de resultaten van de case-control studie werd voor het eerst een relatie gelegd tussen
bovine herpesvirus 4 (BHV4) infecties en bovine mastitis. BHV4 werd bij 3 (5%) van de 58
onderzochte lacterende mastitis runderen aangetoond in de melk, en bij geen van de 58 controle
runderen. Gelijktijdig met de isolatie van BHV4 werd bij 2 van de drie mastitis runderen een
significante stijging van BHV4 antilichamen in serum aangetoond. Het aantal dat BHV4 vaker werd
geïsoleerd uit melk van mastitis runderen dan bij controle runderen was bijna statistisch significant
(P = 0.125).
Bovine herpesvirus 4 behoort tot de Gammaherpesvirinae, een subfamilie van de Herpesviridae
familie. Het virus is wijd verspreid, en kan geïsoleerd worden uit runderen met verschillende klinische
symptomen, maar een BHV4 infectie was nog nooit eerder geassocieerd met klinische mastitis.
Omdat het virus langzaam groeide op veel routinematig gebruikte cellijnen, er geen commerciële
gevalideerde test was om BHV4 antilichamen aan te tonen, en er geen geavanceerde moleculair-
biologische technieken bestonden voor de detectie van BHV4-DNA in melk, zijn we begonnen met
het opzetten en valideren van een aantal diagnostische methoden voor de detectie van BHV4 infecties.
In de eerste case-control studie werden verschillende cellen gebruikt voor de isolatie van virussen,
namelijk; bovine uier epitheelcellen, bovine navelstreng endotheelcellen, bovine alveolaire long
macrofagen en de routinematig gebruikte embryonale bovine tracheacellen. De non-conventionele
bovine navelstreng endotheelcel (BUEc) bleek uitermate geschikt te zijn voor de isolatie van BHV4. In
de eerste case-control studie werd BHV4 namelijk alleen geïsoleerd op BUEc en niet op de drie andere
celtypen. Op de BUEc werd een duidelijke verlaging van de detectielimiet en werden hogere BHV4
virustiters verkregen t.o.v. de routinematig gebruikte Madin Darby Bovine Kidney (MDBK) cellijn.
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De BUEc bleek niet alleen geschikt te zijn voor de isolatie van BHV4 maar deze cellen bleken ookerg
gevoelig te zijn voor andere bovine herpesvirussen, m.n. BHV2 en BHV5 (Hoofdstuk 2).
Voor het specifiek aantonen van BHV4 antilichamen in serum werd een immunoperoxidase test
(IPMA) ontwikkeld en gevalideerd. Deze IPMA was gebaseerd op de detectie van antilichamen
gericht tegen de Amerikaanse BHV4 referentiestam DN-599 en tegen LVR-140, een referentiestam
behorende tot de Europese Movar 33/63-groep. Na validatie bleek dat de IPMA een specifieke en
betrouwbare test was voor het aantonen van BHV4 antilichamen in serum. Het is een gevoeligere test
dan de indirecte-ELISA voor de vroege detectie van BHV4 antilichamen. De IPMA toonde BHV4
antilichamen aan op dag 16-18 na experimentele infectie en de indirecte-ELISA pas op dag 30. Een
pilot-studie werd uitgevoerd, omdat er geen data waren over de BHV4 seroprevalentie in het
Nederlandse rund. Op basis van deze pilot-studie werd de BHV4 seroprevalentie in runderen in
Nederland geschat op 16-18%. Ook bleek dat de BHV4 seroprevalentie varieerde per leeftijdscategorie
en wel van 6 – 43% (Hoofdstuk 3).
Om sneller en gevoeliger BHV4 aan te kunnen tonen in melk werd een polymerase ketting reactie
(PCR) opgezet en gevalideerd voor de detectie van BHV4-glycoprotein B (gB) DNA. Daarnaast werd
een bestaande nested-PCR voor de detectie van BHV4-thymidine kinase (TK) DNA gemodificeerd.
Beide PCR’s bleken snelle en betrouwbare testen te zijn voor het screenen van melkop BHV4; de gB-
PCR is een snellere. Deze test verdiende daarom de voorkeur boven de BHV4-TK PCR in ons verdere
onderzoek (Hoofdstuk 4).
In een tweede case-control studie, waarbij gebruik werd gemaakt van de nieuw ontwikkelde testen
voor het detecteren van BHV4 infecties, werd selectiever gekeken naar de rol van BHV4 in de
etiologie van bovine klinische mastitis. Wederom werd BHV4 alleen gedetecteerd in melk van
klinische mastitis runderen en niet in controle runderen. Bovine herpesvirus 4 en BHV4-gB DNA
werd gedetecteerd in melk van 2 (4%) van de 54 onderzochte mastitis runderen en niet in melk van de
54 controles (Hoofdstuk 6).
In een experimentele infectie, waarbij lacterende koeien gelijktijdig intramammair en intranasaal
geïnoculeerd werden met BHV4, werden geen klinische mastitis gevallen waargenomen, maar wel
werd in 50% van de geïnoculeerde kwartieren een verhoogd celgetal in de melk waargenomen, wat
een indicatie is voor subklinische mastitis. Op de dagen 8, 9, en 11 na infectie waren de celgetallen in
melk van BHV4-geïnoculeerde kwartieren significant hoger dan in melk van niet-geïnoculeerde
controlekwartieren van dezelfde koeien (within-cow controles), en de celgetallen in melk afkomstig
van mock-geïnoculeerde kwartieren van controle koeien (controle groep) (Hoofdstuk 7).
Vier van de 8 BHV4 geïnoculeerde kwartieren werden op dag 14 na de BHV4 inoculatie geïnfecteerd
met Streptococcus uberis om de invloed van een voorafgaande BHV4 infectie op de ernst van een
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klinische mastitis geïnduceerd door een S. uberis infectie te bestuderen. Hieruit bleek dat een
voorafgaande BHV4 infectie niet van invloed was op de ernst van een klinische mastitis geïnduceerd
door een S. uberis infectie. Wel kon op diverse dagen na de S. uberis inoculatie wederom BHV4
geïsoleerd worden uit de melk van twee van de vier kwartieren, terwijl vanaf dag 14 na de BHV4
infectie geen BHV4 meer kon worden geïsoleerd uit melk van kwartieren die alleen met BHV4 waren
geïnoculeerd. Dit duidt op een activatie van de BHV4 replicatie door S. uberis. Activatie van de
replicatie van BHV4 door bepaalde bacterien is nog nooit eerder beschreven, terwijl reactivatie van
latent BHV4 door een dexamethason-behandeling een bekend fenomeen is.
In hoofdstuk 8 werd onderzocht of enkele geselecteerde virale agentia de replicatie van BHV4 in
vitro kunnen remmen. Hieruit bleek dat brivudin (BVDU) de replicatie van BHV4 in BUE cellen
efficiënt remt tot concentraties van minimaal 0.05 µg/ml. Ook cidofovir en ganciclovir (DHPG)
remmen de replicatie van BHV4, maar dan bij hogere concentraties. Deze studie kan als uitgangspunt
dienen voor het ontwikkelen van geneesmiddelen om BHV4 infecties te behandelen.
Op basis van de twee case-control studies, de experimentele infectiestudie en de epidemiologische
studie (Zadoks et al., submitted) kunnen we concluderen dat BHV4 waarschijnlijk een rol speelt in de
etiologie van bovine mastitis. Het speelt geen (grote) rol als primair agens in klinische mastitis
gevallen, maar op basis van gegevens van de experimentele infectieproef kunnen we concluderen dat
het virus mogelijk wel een rol kan spelen als subklinische mastitis verwekker. Op basis van de
epidemiologie studie zijn er aanwijzingen dat BHV4 ook op een indirecte wijze betrokken kan zijn bij
bovine mastitis. Het virus kan o.a. macrofagen latent infecteren, en daarnaast groeit het virus goed in
endotheelcelcultures. Of dit de aanwijzingen zijn waarom BHV4 van indirecte invloed kan zijn op
bovine mastitis, en of BHV4 infecties kunnen leiden tot immuunsuppressie, zal nader onderzocht
moeten worden.
Het review artikel “Viral infections and bovine mastitis” geeft aan dat virussen een rol kunnen
spelen in de etiologie van bovine mastitis. Hoe groot deze invloed is zal nader onderzocht moeten
worden. In de praktijk zal wat vaker gedacht moeten worden aan een mogelijke virale oorzaak bij
mastitis gevallen met onbekende etiologie. De opkomst van micro-array technieken biedt hierbij
mogelijkheden tot verbetering.
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Dankwoord
Bij deze wil ik van de gelegenheid gebruik maken de mensen te bedanken voor hun hulp bij het tot
stand komen van dit proefschrift. Zonder de hulp en toewijding van velen was het zeker niet gelukt.
Professor dr. Jan van Oirschot wil ik als eerste bedanken omdat hij het onderzoek heeft begeleid.
Het enthousiasme waarmee Jan sprak over een mogelijke relatie van virussen, en later met name
BHV4, bij bovine mastitis spoorde anderen en mij aan om meer onderzoek te gaan doen in deze
richting. Mede dankzij het “Nieuwe Virussen project” werd het mogelijk dit onderzoek uit te voeren.
Jan, de manier waarom jij mensen stimuleert en motiveert is uniek. Op de momenten waarop ikdacht;
“Waar moet dit onderzoek naar toe?”, gaf je altijd weer aan dat er nog voldoende mogelijkheden
waren voor vervolg. Beste Jan, ik wil jou dan ook hartelijk bedanken voor jouw bijdrage aan het
onderzoek. Bedankt voor het geven van wetenschappelijke inzichten en de kritische beoordelingen van
de manuscripten. Ik heb hier veel van geleerd, ook al heb ik wel eens diep adem moeten halen en het
idee had dat op elke ‘ï’ twee puntjes moesten komen te staan. Toch gaf een goed en kritisch
beoordeeld manuscript daarna weinig problemen. Ik zal altijd op de “controles” blijven letten!!Jan ook
bedankt voor de gezellige uurtjes, want die waren er gelukkig ook nog.
Alle mede-auteurs, en met name Wim van der Poel en Herman Barkema, wil ik hartelijk danken.
Dank voor jullie inbreng en wetenschappelijke adviezen.
Zonder de medewerkers / collega’s van Zoogdier Virologie lab 6 was het onmogelijk geweest dit
proefschrift te schrijven. Bedankt voor jullie toewijding, en het onophoudelijk stellen van de vraag
”Wanneer promoveer je nu eens?”. Er bleef voor mij geen keus over. Ik moest wel, en het is er dan
toch nog van gekomen. Betty Verstraten wil ik graag bedanken voor haar inzet en het voeren van de
discussies om alle testen tot een goed einde te brengen. Je hebt er erg veel tijd in gestopt. Betty van
Gelderen, bedankt voor het uitvoeren van de testen die “mee moesten in de routine”, en die er altijd
weer tussendoor moesten. Bedankt dat de exportdiagnostiek voor een groot deel op jouw schouders
mocht rusten. Achteraf had ik het proefschrift misschien toch de titel ”Working at ZVee with the two
Bee’s” mee moeten geven. Jan Maissan, die met technische precisie vele testen heeft uitgevoerd en
waarbij ik de resultaten altijd kon vertrouwen. Uitstekend werk! Teun van der Vorst zag als analist
binnen het “Nieuwe Virussen project” het eerste cpe. Dit was het startsein om meer onderzoek te gaan
doen naar de rol van BHV4 bij bovine mastitis. Samen met Toon Pover werden vele monsters
verwerkt. Vele cellijnen moesten meerdere malen gepasseerd worden. Virus-typeringen, serologische
testen en vele andere testen werden door jullie uitgevoerd. We vergeten bij het schrijven van dit
proefschrift misschien wel eens dat deze taken er vaak tussendoor moesten, en dat er ook nog andere
taken waren waar we ons mee bezig hebben gehouden. Dank aan de andere collega’s binnen het
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voormalige ZV6 lab, Olga, Peter en Sonja, en de vele stagiaires die we nog op tijd hebben kunnen
bijsturen. Ik kijk terug op een mooie periode waarbij we een goed team vormden, die met veel plezier
veel heeft gepresteerd en veel dingen voor elkaar heeft gekregen. Nogmaals dank voor deze periode.
Verder wil ik alle mensen van vleugel 18 bedanken die in de afgelopen periode met mij moesten
samenwerken, of door dezelfde gang moesten lopen. Dank voor het “lenen” van de reagentia, de hulp
bij computerprogramma’s, het gebruik van vriezers, etc. Dank voor het verzamelen van de monsters,
zowel door de week als in het weekend (Klaas, Marieke en Henri). Binnen ZV moet ik eigenlijk
iedereen met naam en toenaam noemen, ook de personen die zijn vertrokken, maar dat wordt teveel.
Toch wil ik er eentje uitlichten. Frans, je weet dat ik graag de moleculaire diagnostiek wilde gaan
toepassen op ons “eigen” laboratorium. Hiervoor kwamen we toch vaak bij jou voor advies en ideeën.
Soms gaf je die met het idee van……. Toch is het altijd goed gekomen, en ik wil je hierbij dan ook
hartelijk danken voor de steun, de moleculaire begeleiding en de ruimte die we van jou gekregen
hebben om wat meer aan moleculaire diagnostiek te kunnen doen.
Medewerkers van de afdeling Dierverzorging en Biotechniek, dank voor het verzorgen van de
dieren tijdens de mastitis-proeven.
Ook nu weer heb ik met diverse mensen binnen de Gezondheidsdienst samen mogen werken. Als
ik wat nodig had was er altijd wel een helpende hand. Met name van Otlis Sampimon en Jan Sol heb
ik veel steun ontvangen bij het uitvoeren van het veldwerk. Zonder jullie (de Gezondheidsdienst)
hebben wij geen contacten met het veld.
I would gratefully acknowledge all colleagues, including our colleagues from the Facultyof Utrecht,
for providing me sera, virus strains, cells, monoclonals, etc. Without their assistance it was impossible
to perform research work on a certain level of quality.
Speciaal gaat mijn dank uit naar Hermien, voor haar liefde, hulp, steun en vertrouwen en nog veel
meer. Als er geen support van haar kant was om dit werk af te ronden, dan was het nooit gelukt. Zij
zorgde voor een “stabiel thuisfront”, en daardoor werd mij alle gelegenheid geboden om het af te
ronden. In een onstabiele situatie is het veel moeilijker om dit soort “klusjes” te klaren. Voor Ruud en
Tim, die weer eens niet op de computer konden, of dat ik weer eens niet mee kon. Jullie vrije uurtjes
die weer eens alleen doorgebracht moesten worden.
Dank aan familie en kennissen voor alle belangstelling, en met name dank aan mijn ouders. Jullie
hebben mij de gelegenheid geboden om te studeren. Hierbij werd door ma op de juiste momenten die
ondersteuning gegeven die bepalend bleek te zijn voor mijn levenspad. Pa, hartelijk dank voor het
geven van de financiële ondersteuning om de kosten van dit proefschrift te drukken.
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Ik heb een tevreden gevoel over het proefschrift, al denk ik niet altijd met even veel plezier terug aan
de afgelopen maanden. Ik heb vaak alle energie bij elkaar moeten rapen om toch maar weer uren
achter die ellendige computer te blijven zitten. Het is voorbij! Jongens, de computer is weer vrij.
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